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1 SUMMARY 
The remit of the Evidence Review Group (ERG) is to comment on the clinical and cost 
effectiveness evidence submitted to the National Institute for Health and Care Excellence 
(NICE) as part of the single technology appraisal (STA) process. Clinical and economic 
evidence has been submitted to NICE by Amgen Limited in support of the use of talimogene 
laherparepvec (Imlygic®) (hereafter referred to as T-VEC) to treat patients with non-visceral 
metastatic melanoma.  
1.1 Critique of the decision problem in the company’s submission 
The intervention specified in the NICE scope is T-VEC. It has been recognised by the 
European Medicines Agency (EMA) as a novel, first-in-class oncolytic immunotherapy 
treatment. The company estimates that, if recommended by NICE, 728 patients in England 
would be eligible for treatm nt with T-VEC in 2015. 
The population specified in the NICE scope is adults with stage IIIB to stage IV melanoma. A 
positive opinion for the granting of a marketing authorisation has been issued by the 
Committee for Medicinal Products for Human Use and is awaiting approval by the European 
Commission expected in xxxxxxxxxxxxx. It is anticipated that the licence will be for the 
treatment of adults with unresectable melanoma that is regionally or distantly metastatic 
(stage IIIB, stage IIIC and stage IV M1a) with no bone, brain, lung or other visceral disease. 
However, as T-VEC is administered by intralesional injection, its use will be restricted to 
patients whose melanoma is considered injectable, i.e. there must be cutaneous, 
subcutaneous, and/or nodal lesions that are visible, palpable or detectable by ultrasound 
guidance.  
The following comparators are specified in the NICE scope: ipilimumab, vemurafenib and 
dabrafenib. Unfortunately, none of these drugs has been studied in trials comprising only 
patients with non-visceral metastatic stage IIIB to stage IV M1a melanoma or in trials where 
these patients are a specified subgroup. Ipilimumab is considered by the company to be the 
primary comparator to T-VEC and vemurafenib and dabrafenib are not evaluated in the 
company submission (CS). However, with NICE’s recent recommendation that 
pembrolizumab should be made available through the NHS as a treatment for some patients 
with metastatic melanoma, the ERG considers that, in future, all patients who are currently 
offered first- or second-line treatment with ipilimumab will now be offered pembrolizumab (if 
they have not already received it).  
Clinical evidence is reported in the CS for all five outcomes specified in the NICE scope: 
overall survival (OS), progression-free survival (PFS), tumour response rate, adverse events 
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(AEs) of treatment and health-related quality of life (HRQoL). These are all outcomes that 
are commonly measured in metastatic melanoma drug trials. In addition, durable response 
rate (DRR) was also reported as the primary outcome in the OPTiM trial from which the 
majority of evidence for T-VEC is derived; DRR is a non-validated, albeit a clinically relevant, 
endpoint. The OPTiM trial reported time to treatment failure (TTF) instead of PFS since 
patients were permitted to continue to receive treatment despite showing evidence of 
disease progression with T-VEC. 
1.2 Summary of clinical effectiveness evidence submitted by the 
company 
Evidence for the relative efficacy of T-VEC was obtained from the OPTiM randomised 
controlled trial (RCT). Evidence from one Phase II non-RCT (Study 002/03) is also 
presented in the CS. 
In the open label OPTiM trial patients with stage IIIB to stage IV M1c disease were 
randomised in a 2:1 ratio to receive either T-VEC (n=295) or granulocyte macrophage 
colony-stimulating factor (GM-CSF) (n=141). The anticipated licence for T-VEC is based on 
clinical data from a post-hoc analysis of a subgroup of these patients (n=249), namely 
patients with injectable non-visceral metastatic melanoma (i.e. stage IIIB to stage IV M1a 
disease). Post-hoc analysis refers to those in which the hypotheses being tested are not 
specified before any examination of the data. The results for this subgroup (final data cut) 
are: 
 DRR by Endpoint Assessment Committee (EAC) assessment was higher in patients 
treated with T-VEC compared with GM-CSF (25.2% vs 1.2%; unadjusted odds ratio 
28.6; [95% CI: 3.9 to 211.5]; p<0.0001) 
 TTF by investigator assessment was longer in the T-VEC arm than in the GM-CSF 
arm (median 13.1 months vs 3.3 months; hazard ratio [HR]=0.28; [95% CI: 0.20 to 
0.40]; p<0.0001) 
 Overall tumour response rate by EAC assessment was higher in the T-VEC arm than 
in the GM-CSF arm (40.5% vs 2.3%, p<0.0001) 
 At the final OS analysis, median OS gain was 25.3 months for patients in the T-VEC 
arm vs patients in the GM-CSF arm (median 46.8 months vs 21.5 months, 
unstratified HR=0.56; [95% CI: 0.40 to 0.79]; p=0.0008). 
 
In patients with non-visceral metastatic disease treated with T-VEC, treatment-related Grade 
3 to 5 AEs and treatment-related serious AEs (SAEs) were reported by 14% and 6% of 
patients respectively, and treatment emergent AEs leading to discontinuation were reported 
by 9% of patients. In the overall trial population, the most common AEs reported by patients 
receiving T-VEC were flu-like symptoms (90%) and injection-site reactions (42%).  
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HRQoL data were collected as part of the OPTiM trial using the Functional Assessment of 
Cancer Therapy-Biologic Response Modifier (FACT-BRM) questionnaire. Results show that, 
for the patients with non-visceral metastatic melanoma, in six of the 11 measures that were 
used the differences identified between trial arms reached statistical significance and 
favoured T-VEC. 
Unlike the OPTiM trial, Study 002/03 did not include patients with stage IIIB melanoma and 
only included 23 patients with stage IIIC to stage IV M1a disease; an additional 27 patients 
had later stage disease. Relevant subgroup findings were not reported in the CS. 
Nevertheless, the company considers Study 002/03 provides supportive evidence for the 
effectiveness of T-VEC. 
Despite undertaking a broad literature search, only the OPTiM trial was identified as being 
relevant to the decision problem. Furthermore, none of the comparators identified in the 
NICE scope has been studied in trials comprising only patients with non-visceral metastatic 
melanoma or in trials were patients with non-visceral metastatic disease are a specified 
subgroup. Therefore it was not possible for the company to construct a complete network 
that would determine indirect estimates of the clinical effectiveness of the comparators listed 
in the NICE scope to be determined. Furthermore, the company did not attempt to estimate 
the clinical effectiveness of vemurafenib or dabrafenib but did explore a number of different 
ways to obtain evidence for the efficacy of ipilimumab in patients with non-visceral metastatic 
melanoma. After considerable investigation, the company concluded that two methods could 
be used, the modified Korn model (“best case” findings) and the two-step Korn model (“worst 
case” findings). Both methods aim to adjust baseline characteristics so that patients who had 
received ipilimumab in two previous trials were comparable to those in the OPTiM trial. 
Results using the modified Korn model suggest T-VEC to be superior to ipilimumab, whilst 
results using the two-step Korn model suggest that T-VEC is at least comparable to 
ipilimumab in patients with non-visceral metastatic melanoma. 
1.3 Summary of the ERG’s critique of clinical effectiveness evidence 
submitted 
The company’s literature searches did not identify any studies, in addition to the OPTiM trial 
or Study 002/03, which included T-VEC (or GM-CSF) as either an intervention or 
comparator. Nor did they reveal any studies which assessed the efficacy of ipilimumab, 
vemurafenib or dabrafenib in patients with non-visceral metastatic disease. The ERG is not 
aware of any additional RCTs or non-randomised studies, which should have been included 
as part of the evidence base. 
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Overall, the ERG considers that patients with non-visceral metastatic disease in the OPTiM 
trial are generally similar to the patients with stage IIIC to stage IV M1a disease likely to be 
considered for treatment with T-VEC in clinical practice in England.  
The ERG has concerns that the population considered in this STA is one that has been 
constructed following the results of a post-hoc analysis of data collected during the OPTiM 
trial. The ERG is particularly concerned that the disease trajectory of patients with stage III 
disease is likely to differ from that of those with stage IV M1a disease. Furthermore, the ERG 
considers that the OPTiM trial may be subject to bias due to limited blinding, a higher 
proportion of dropouts in the GM-CSF arm (particularly in the first few months of the trial), 
and the use of DRR as the primary endpoint. It is noted in the draft European Public 
Assessment Report (EPAR) that DRR is a new, clinically relevant, endpoint that is non-
validated and is potentially prone to bias. However, the ERG does not consider that the 
potential sources of bias fully explain the improvements in efficacy in the T-VEC arm 
compared with the GM-CSF arm. The ERG notes that a further uncertainty, raised by the US 
Food and Drug Administration (FDA), relates to the size of lesions. The results of an FDA 
post-hoc analysis of the overall intention-to-treat population (i.e. including those with stage 
IV M1b and stage IV M1c disease) suggest that patients who had very small lesions (<1 
cm2) were more likely to respond to T-VEC than were the overall population (10.1%). The 
ERG further notes that evidence for the effectiveness of T-VEC treatment is not presented 
by line of therapy in the subgroup of patients with non-visceral metastatic disease. 
Results from the OPTiM trial suggest that T-VEC’s safety profile compares favourably with 
those of the comparator treatments detailed in the NICE scope. The ERG, however, notes 
that there are limited data to support the long-term safety of treatment with T-VEC. 
Although HRQoL data collected as part of the OPTiM trial show that, in general, quality of life 
for patients receiving T-VEC was better than for those receiving GM-CSF, a substantial 
proportion of patients in the GM-CSF arm did not complete HRQoL assessments, 
suggesting that the HRQoL findings should be interpreted with caution. 
For reasons highlighted in Section 1.5, the ERG does not consider the ipilimumab survival 
estimates generated by the company, using either the modified Korn model or the two-step 
Korn model to be reliable. It is, therefore, impossible to determine the relative clinical 
effectiveness of T-VEC compared with any of the comparators listed in the NICE scope. 
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1.4 Summary of submitted cost effectiveness evidence 
To allow the cost effectiveness of T-VEC to be compared with that of ipilimumab, the 
company developed a de novo partitioned survival model. The model comprised three 
mutually exclusive health states: non-progressive disease, progressive disease and death. 
All patients entered the model in the non-progressive disease state. Variants of this model 
structure have been used in a number of previous STAs that have considered the cost 
effectiveness of treatments for patients with metastatic melanoma. The model has been 
developed in Microsoft Excel using a 1-week cycle length and the time horizon is set at 30 
years. As recommended by NICE, a discount rate of 3.5% has been used for both costs and 
outcomes; outcomes are measured in quality adjusted life years (QALYs). The model 
perspective is that of the UK NHS.  
PFS for patients receiving T-VEC was based on OPTiM trial data for TTF and published 
sources. For patients treated with ipilimumab, two different PFS models were developed, 
depending on whether data from two ipilimumab trials were adjusted for differences in 
baseline characteristics between these trials and the OPTiM trial by using the modified Korn 
algorithm or the two-step Korn algorithm.  
For patients receiving T-VEC, OS was modelled using a multi-phase approach that utilised 
both OPTiM trial data and published sources. The modelling of OS for patients treated with 
ipilimumab was a similar multi-phase approach, but with cut-points implemented at different 
times to those used to estimate OS for patients treated with T-VEC. Two different OS 
projections were developed for ipilimumab patients, depending on whether the modified Korn 
model or the two-step Korn model was used to adjust for differences in baseline 
characteristics between the two relevant ipilimumab trials and the OPTiM trial.  
Health state utility values from NICE TA321 (Dabrafenib for treating unresectable or 
metastatic BRAF V600 mutation positive melanoma) were used in the model. Disutility 
values associated with AEs were obtained from a proprietary study commissioned by the 
company. Resource use and costs were estimated based on information collected in the 
company’s resource utilisation study, published sources and the views of clinical experts.  
The company has proposed a Patient Access Scheme (PAS). This is currently undergoing 
consideration by the Patient Access Scheme Liaison Unit and so only the results based on 
the list prices of T-VEC are presented in the CS.  
For the comparison of T-VEC vs ipilimumab, implemented in the company model using the 
modified Korn model (or two-step Korn model), the company’s incremental cost-
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effectiveness ratio (ICER) per QALY gained was £1,458 (or £8,654). These figures were 
calculated using the full list price for ipilimumab. However, a confidential PAS means that 
ipilimumab is available to the NHS at an undisclosed price which is less than the list price. 
The company calculated ICERs per QALY gained for a range of discounts. Their results 
showed that in the analyses that used the modified Korn model (or two-step Korn model) to 
model the efficacy of ipilimumab the ICER remained below a threshold of £30,000 per QALY 
gained when a discount of 55% (or 10%) or less was assumed.  
The company carried out a range of deterministic sensitivity analyses. The results show that 
the most influential variables were the duration of treatment and the prices of the two drugs. 
A number of scenario analyses were carried out. The two that had the most influence 
(impact of increasing the ICER per QALY gained by more than £5,000) were varying T-VEC 
dosing and the assumptions concerning routine treatment for non-progressive disease. The 
results of the company’s probabilistic sensitivity analysis (PSA), using the list price, show 
that compared with ipilimumab implemented in the model using the modified Korn model (or 
two-step Korn model), the probability of T-VEC being cost effective is 98.39% (or 80.02%) at 
a threshold of £20,000 per QALY gained and 99.7% (or 81.83%) at a threshold of £30,000 
per QALY gained.  
1.5 Summary of the ERG’s critique of cost effectiveness evidence 
Following NICE’s recent recommendation for the use of pembrolizumab for the first- and 
second-line treatment of patients with metastatic melanoma, the ERG considers that 
clinicians’ first choice systemic treatment will shift away from ipilimumab towards 
pembrolizumab for all eligible patients. Hence, for patients with non-visceral metastatic 
melanoma, ipilimumab will only be the first choice comparator to T-VEC in the first- and 
second-line setting for a limited time period. 
Due to a lack of either direct or indirect trial evidence that would allow a comparison between 
the efficacy of T-VEC and ipilimumab, the company developed evidence for the efficacy of 
treatment with ipilimumab using data from two clinical trials. The ERG has serious concerns 
relating to the reliability of this synthesised comparator: 
1. Pooling ipilimumab data from the arms of two published clinical trials assumes that 
(a) dacarbazine and gp100 are both ineffective, (b) survival patterns are equivalent 
regardless of whether ipilimumab is administered as a first-line or as a subsequent 
line of therapy and (c) censoring occurs at a constant rate within each (arbitrary) 
time period. The ERG is not convinced that these assumptions can be substantiated 
2. The modified Korn model was used to correct for differences in patient characteristics 
between two ipilimumab trials and the OPTiM trial. The main reason why the ERG 
considers that this model is not appropriate is that it was developed and calibrated 
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using data from patients with predominantly stage IV M1b and stage IV M1c 
disease, whilst it is patients with stage IV M1a disease who mostly feature in the 
OPTiM trial. Furthermore, in the OPTiM trial 54.7% of T-VEC patients had stage IIIB, 
stage IIIC or stage IV M1a disease compared with less than 20% in the ipilimumab 
trials 
3. There is no information in the public domain relating to the way in which the original 
(published) Korn model has been modified or to the data used to calibrate the 
model. It is likely that the issues outlined in point 2 also hold for the modified Korn 
model. In addition, the modified Korn model includes an adjustment for elevated 
lactate dehydrogenase (LDH), which is not relevant for patients with stage IIIB, 
stage IIIC or stage IV M1a disease, but has the effect of reducing the size of the 
coefficients associated with other adjustment factors (and improving the relative 
efficacy of T-VEC) 
4. The effectiveness of ipilimumab may vary significantly by stage of disease. The 
company has attempted to correct for this case-mix imbalance by using the two-step 
Korn model, which is a further application of the modified Korn model. This 
additional adjustment is likely to mean that the problems previously described are 
further compounded 
5. The original Korn publication includes both PFS and OS models. The PFS model is 
quite different from the OS model. The ERG, therefore, concludes that the 
company’s use of the same modified Korn model for both OS and PFS is 
inappropriate.  
 
Within the company model, different methods are applied sequentially to estimate OS. A 
number of issues with this approach were identified by the ERG, including: 
1. OS data from the earlier, less mature, data cut of the OPTiM trial were used by the 
company 
2. The exponential trend used by the company to project OS for patients treated with T-
VEC deviates markedly from the final recorded OPTiM trial data 
3. For patients with stage I, stage II and stage III disease, the American Joint 
Committee on Cancer (AJCC) survival trends provide results from the date of 
diagnosis, whilst for patients with stage IV disease trends are recorded from the time 
of identification of first distant metastases. The relevance of these mixed AJCC 
adjusted mortality estimates is highly questionable 
4. The data on which the AJCC analyses were performed were gathered prior to the 
current era of novel immunological treatments and may be unrealistic as these 
newer treatments have significantly altered the prospects for many patients 
5. A sudden increase in the mortality rate after 270 weeks (62.1 months) is observed in 
the company model. The ERG considers that this effect is arbitrary and without any 
clinical justification 
6. After 10 years, UK life table mortality rates are applied within the company model 
without adjustment, other than for age and sex. This implies that the cohort of long-
term survivors is suddenly cured at this time point.  
 
Other model-related issues identified by the ERG include an error in the discounting 
calculation, poor choice of health state utility values, lack of use of a terminal state disutility, 
use of a half-cycle (rather than a mid-cycle) continuity correction and a PSA ICER 
calculation error. 
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 Results from the OPTiM trial show that the effectiveness of T-VEC is markedly 
improved in the subgroup of patients with stage IIIB to stage IV M1a disease when 
compared with the overall trial population (which includes patients with stage IV M1b 
and M1c disease) 
 Evidence from the OPTiM trial suggests that the safety profile of T-VEC compares 
favourably to the safety profile of the comparators listed in the NICE scope  
 The company has made thorough attempts to identify studies that include both a 
relevant treatment comparator to T-VEC and a relevant patient population.  
Cost effectiveness evidence 
 The company supported the appraisal process by providing the additional analyses 
requested by the ERG in a timely manner. 
1.6.2 Weaknesses and areas of uncertainty 
Clinical evidence 
 Following the very recent approval of pembrolizumab for the first- and second-line 
treatment of patients with metastatic malignant melanoma, clinicians’ first choice of 
systemic treatment for this population is likely to shift away from ipilimumab towards 
pembrolizumab 
 The efficacy data for the anticipated T-VEC licensed population (patients with non-
visceral metastatic melanoma) has been extracted from a post-hoc subgroup data 
analysis from the OPTiM trial 
 The OPTiM trial may be subject to bias due to limited blinding and a higher 
proportion of dropouts in the GM-CSF arm (particularly in the first few months of the 
trial) 
 The use of DRR as the primary endpoint in the OPTiM trial raises concerns as DRR 
is a new, albeit clinically relevant, endpoint which is non-validated and is potentially 
prone to bias 
 The results of an FDA post-hoc analysis suggest that patients who had very small 
lesions (<1 cm2) were more likely to respond to T-VEC than the overall population  
 Two areas where evidence relating to treatment with T-VEC is lacking are in relation 
to line of treatment and long-term safety 
 The relative clinical effectiveness of T-VEC compared with any treatment currently 
used in clinical practice is unknown. 
Cost effectiveness evidence 
 The ERG does not consider that the synthesised ipilimumab comparator is 
sufficiently reliable to support a valid assessment of the cost effectiveness of 
treatment with T-VEC vs ipilimumab 
 The methods employed by the company to project OS for patients receiving T-VEC 
lack face-validity. Key issues are that the projection: 
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o Diverges from OPTiM trial data 
o Shows a sudden increase in mortality at 270 weeks that is not supported by 
clinical evidence  
o Includes an inappropriate use of AJCC data  
o Is based on the assumption that all long-term survivors are cured at 10 years. 
1.7 Summary of exploratory and sensitivity analyses undertaken by the 
ERG 
The ERG has formulated alternative methods to projecting survival for patients with non-
visceral metastatic disease receiving T-VEC. However, due to the high degree of volatility 
exhibited in the model-generated results when the ERG amendments were implemented, 
and the serious problems identified relating to the construction of an ipilimumab comparator, 
the ERG does not consider that it is appropriate to present detailed alternative ICERs for this 
questionable comparison. However, it is possible to offer a broad indication of the relative 
significance of the issues identified: 
 The company base case analysis uses the list price for ipilimumab and the proposed 
list price for T-VEC. Thus the current PAS price for ipilimumab is not applied. Results 
from the company model suggest that the estimated cost effectiveness of T-VEC is 
substantially worsened when a lower ipilimumab PAS price is implemented 
 Taken separately, the ERG approach to estimating OS and PFS has contrary effects 
on estimated cost effectiveness: the revised OS estimate appears to improve the 
position of T-VEC, whereas the revised PFS estimate worsens it 
 All of the other model-related issues identified are considered individually and all 
have a very small impact on the position of T-VEC, generally increasing the size of 
the estimated ICER when T-VEC is compared with ipilimumab 
 When the PAS for ipilimumab is applied alongside the OS and PFS revised ERG 
estimates, the ICER per QALY gained is very severely increased far beyond the 
range normally considered acceptable by NICE 
 The cost effectiveness of T-VEC compared to ipilimumab varies from dominating 
(more effective at less cost in the modified Korn model) to being dominated (less 
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2 BACKGROUND  
2.1 Critique of the company’s description of the underlying health 
problem 
In Section 3.1 of the company’s submission (CS), the company presents a brief overview of 
melanoma. In Section 3.2 of the CS, the company describes the effects of the disease on 
patients, carers and society. Information about the life expectancy of patients with the 
disease is presented in Section 3.4 of the CS. Key points from these sections of the CS are 
reproduced (as bulleted items) by the Evidence Review Group (ERG) in Box 1. While the 
ERG considers that these key points appropriately summarise the underlying health 
problems relating to melanoma in general, it is important to note that the evidence presented 
in the CS relates to a subgroup of patients with injectable disease, defined by disease 
staging. 
Box 1 Summary of company’s description of underlying health problem 
Pathophysiology 
 Melanoma is a malignancy of pigment-producing cells in the skin called melanocytes 
 Superficial spreading melanoma, nodular melanoma, and lentigo maligna melanomas make up 
90% of all diagnosed malignant melanomas  
 Malignant melanoma is associated with high mortality due to the potential for: fast progression of 
disease; sudden relapse of disease; and a greater likelihood than other skin cancers to 
metastasise to distant hard to treat sites in the body 
 If melanoma is detected before cancer cells have reached the blood vessels that are deeper in 
the skin, it can usually be completely removed with surgery. However, melanoma is often not 
detected in its earliest stages because the patient may not notice or bring attention to the lesion, 
or the clinician may not detect the melanoma at an examination 
 The most common sites to which melanoma metastasises are lymph nodes, lung, liver, and brain, 
but it can metastasise to almost any organ and may affect many sites simultaneously 
 
Incidence and survival 
 Malignant melanoma is the fifth most common cancer in the UK with a total of 13,348 new cases 
diagnosed in 2011 (latest year available) 
 The incidence of melanoma in the UK has risen sharply in recent years  
 In the UK, malignant melanoma was responsible for 2,148 deaths in 2012 (latest year available) 
 Survival rates for malignant melanoma vary dramatically according to the stage of the disease at 
diagnosis 
 Although the treatment of malignant melanoma has progressed in recent years there is still a low 
5-year survival rate of 20% to 34% for patients with stage IIIC disease and 5% to 22% for stage 
IV disease 
 
Effects of disease on patients, carers and society 
 Overall survival (OS) differs by stage of metastatic disease; however, even patients with non-
visceral metastatic melanoma have a shorter median OS compared to patients with many other 
cancers 
 Malignant melanoma … [is] one of the leading causes of lost life years due to cancer 
 Melanoma can result in substantial impairment in health-related quality of life and psychological 
functioning 
 Melanoma poses a substantial economic burden to society 
 Lost productivity and travel costs incurred while receiving treatments further contribute to the 
societal burden of melanoma and can impact caregivers as well 
Source: CS, Sections 3.1, 3.2 and 3.4  
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Disease staging 
As stated in the CS, melanoma is considered advanced and described as metastatic disease 
if it has spread to surrounding lymph nodes (stage III) or to other parts of the body (stage 
IV). Malignant melanoma is classified in metastatic sub-stages, which encompass [either]: 
1. Unresectable stage III disease with regional skin and/or lymph node involvement 
(M0)  
or  
2. Distant metastatic disease (stage IV), to any site, with location either in: 
o skin (distant cutaneous or subcutaneous tissue) or distant lymph nodes (M1a) 
o lung (M1b) 
o any visceral organ and/or increased lactate dehydrogenase (LDH) levels in 
the serum, indicating aggressive tumour growth (stage IV M1c). 
 
Non-visceral metastatic disease (T-VEC licensed population) 
The evidence presented in the CS relates to a subgroup of patients with unresectable 
melanoma that is regionally or distantly metastatic (stage IIIB, stage IIIC, and stage IV M1a) 
with no bone, brain, lung or other visceral disease. This is the expected T-VEC licensed 
population and the population for which the technology (talimogene laherparepvec [T-VEC]) 
is being appraised. Throughout the CS, and hereafter in this ERG report, this specific type of 
melanoma is referred to as non-visceral metastatic disease. 
Patients with non-visceral metastatic disease make up a specific patient population that has 
rarely been studied in clinical trials. Hence there is little description of patients with this 
strictly defined disease type included in the CS. In the CS (page 29) it is stated that: “Overall 
survival (OS) differs by stage of metastatic disease” and, on page 36, that “…over 60% of 
patients with stage IIIB/C and stage IV M1a disease will eventually progress to visceral 
disease (stage IV M1b/c)”.1-3  
Confidential until published 
 
Talimogene laherparepvec for treating metastatic melanoma [ID508] 
Single Technology Appraisal: Evidence Review Group Report 
Page 20 of 134 
Injectable melanoma 
As T-VEC is administered only by intralesional injection, patients must have non-visceral 
metastatic disease as well as injectable melanoma. The company does not give any context 
regarding injectable disease in the CS. Injectable melanoma is however defined in the 
OPTiM trial4 in the CS (Table 4-4) as:  
 at least 1 injectable cutaneous, subcutaneous or nodal melanoma lesion ≥ 10mm in 
longest diameter or;  
 multiple injectable melanoma lesions which in aggregate have a longest diameter of 
≥ 10mm (draft European Public Assessment Report (EPAR),5 page 64). 
 
The ERG makes the following observations in relation to patients with injectable non-visceral 
metastatic melanoma: 
 Patients who are considered to have injectable disease are typically those for whom 
lesions locally recur relatively frequently over several years and for whom there 
comes the point where simply surgically removing lesions becomes no longer a 
feasible treatment option due to the number of lesions and frequency at which they 
appear (e.g. 2 to 3 times a year) i.e. patients will eventually develop unresectable 
melanoma 
 Such patients are typically those for whom it may be many years until their disease 
becomes visceral and hence have regionally or distantly metastatic (stage IIIB, stage 
IIIC, and stage IV M1a) disease with no bone, brain, lung or other visceral disease 
(metastatic non-visceral disease) 
 The ERG considers that patients for whom T-VEC is most likely to be appropriate are 
those with stage III disease, i.e. patients with regional inoperable disease with small 
volume and little or no distant metastases 
 Compared with patients who would not be considered to be eligible for injections, 
patients with exclusively injectable disease tend to have a better prognosis. 
B-Raf proto-oncogene, serine/threonine kinase mutation positive or negative disease 
In clinical practice, patients with metastatic melanoma are commonly tested for the presence 
of B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations since there are 
additional specific treatment options for patients who test BRAF mutation positive, namely 
BRAF inhibitors (see Section 2.2). It is estimated that 48% of patients with melanoma have 
BRAF mutation positive disease.6 T-VEC is considered to be a suitable treatment option for 
patients with or without BRAF mutations since injectable tumours may be BRAF mutation 
positive or BRAF mutation negative.   
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2.2 Critique of company’s overview of current service provision  
Aims of treatment for patients with non-visceral and visceral metastatic disease 
In Section 3.3 of the CS, the company presents an overview of current service provision for 
patients with metastatic melanoma and highlights the different aims of the therapies 
available to treat patients with non-visceral and visceral disease. While for both groups of 
patients the key aim is to improve long-term survival, for patients with non-visceral disease 
the primary goal of treatment is to maintain local and regional control and delay/prevent 
relapse or progression to visceral disease.7 The company also states (CS, page 30) that 
“…OS is correlated with both level and durability of response/complete response to 
treatment. Importantly, complete response [CR] (i.e. the disappearance of all signs of 
cancer) significantly correlates with long-term survival in melanoma”.8,9 
Treatment options for patients with metastatic melanoma prior to 2011 
The company observes that, historically, patients with metastatic disease have been treated 
with dacarbazine (DTIC) despite there being no clinically meaningful improvement in OS 
demonstrated by DTIC in randomised controlled trials (RCTs). British Association of 
Dermatologist guidelines for the management of cutaneous melanoma produced in 201010 
recommended the use of DTIC as palliative chemotherapy. These guidelines also noted that 
although high-dose interleukin-2 has not been evaluated in a randomised Phase III trial, a 
small minority of patients may experience durable CRs; hence the guidelines10 
recommended that patients with stage IV melanoma should be considered for entry to 
clinical trials for treatment with interleukin-2. 
Treatment options for patients with metastatic melanoma since 2011 
Since 2011, a number of drugs have been licensed for the treatment of patients with 
metastatic malignant melanoma including ipilimumab, vemurafenib, dabrafenib, trametinib, 
nivolumab, pembrolizumab and cobimetinib (in combination with vemurafenib). However, 
only four of these agents are currently recommended by the National Institute for Health and 
Care Excellence (NICE): ipilimumab,11,12 vemurafenib,13 dabrafenib14 and 
pembrolizumab.15,16 Ipilimumab and pembrolizumab and are immunotherapies whereas 
vemurafenib and dabrafenib are BRAF inhibitors.  
The company highlights that the NICE recommendations for treatment do not distinguish 
between sub-stages of metastatic melanoma. This is due in part to the design of the relevant 
clinical trials as they include a mix of patients in terms of disease stage. The company also 
states that the efficacy of the licensed treatments recommended by NICE is expected to be 
better in patients with non-visceral metastatic disease than in those with later stage disease; 
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however, the magnitude of the OS gain for patients with non-visceral metastatic disease is 
uncertain. Again, this uncertainty is due to the design of the relevant clinical trials. 
To illustrate, in Table 1 the ERG has summarised data on patients and disease stage from 
five trials17-22 of NICE recommended melanoma treatments alongside data from the OPTiM 
trial.4 Fewer than 20% of patients had non-visceral metastatic melanoma in all five of the 
trials17-22 of NICE recommended treatments compared with 57% of patients in the OPTiM 
trial.4 Subgroup analyses have been conducted by stage of disease in all but one21 of these 
trials. Importantly, the ERG notes that, with the exception of the OPTiM trial,4 none of the 
subgroup analyses conducted included the group of patients who are the focus of this 
appraisal, namely patients with non-visceral malignant melanoma (stage IIIB to stage IV M1a 
disease). 
The company notes that use of vemurafenib and dabrafenib is limited by the terms of their 
licences: patients must have BRAF mutation positive melanoma to be eligible for treatment 
with vemurafenib or dabrafenib. It is estimated that 48% of patients with melanoma have 
BRAF mutation positive disease.6 Furthermore, clinical advice received by the company is 
that BRAF inhibitors are likely to be reserved for patients with more rapidly progressing 
disease and high disease burden. In clinical trials BRAF inhibitors have demonstrated 
relatively high overall response rates (ORRs) but these responses appear to be of limited 
duration, perhaps due to the development of treatment resistance.23 In contrast, the 
company notes that ipilimumab has been shown to have a markedly more durable response. 
However, this marked benefit only exists for a small proportion of patients (whether BRAF 
mutation positive or wild type) who obtain a response. 
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Table 1 Proportion of patients by stage of disease and subgroup analyses conducted by 






Patients by disease 
stage (%) 
Disease stage subgroups 
included in subgroup analyses  
MDX010-20, 

























































IV M1b  
M1c 
IIIC, IV M1a and IV M1b combined 
BREAK-3, 
















III, IV M1a and IV M1b combined 
M1c 
KEYNOTE-002, 


















No subgroup analyses were 
conducted by disease stage 
KEYNOTE-006, 




















No subgroup analyses were 
conducted by disease stage 
OPTiM trial,  

























IIIB, IIIC and IV M1a combined 
GM-CSF= granulocyte-macrophage colony-stimulating factor 
*All trials were Phase III trials except KEYNOTE-002 which was a Phase II trial 
‡Further classification of disease stage was not provided 
 
Treatment pathway for patients with non-visceral metastatic disease prior to 
December 2015 
In Figure 3-2 of the CS, the company presents T-VEC as a potential alternative in clinical 
practice to all of the agents recently recommended by NICE for metastatic melanoma and for 
any line of treatment. The company argues: “…immunomodulators, such as ipilimumab, are 
the likely treatment options for patients with non-visceral metastatic disease (IIIB-IV M1a), 
for which T-VEC is indicated” (CS, page 34).  
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Furthermore, the company also highlights that all of the current treatment options can 
“…result in significant toxicity, which complicates treatment and affects quality of life for 
many patients already struggling with metastatic melanoma” (CS, page 37). Hence the 
company also argues: 
Clinical expert opinion suggests that for those patients with non-visceral metastatic 
disease and limited systemic disease, who would benefit from treatment to prevent 
progression to visceral disease, physicians may choose to adopt a wait and watch 
policy, because of the range of treatment limiting and potentially fatal immune-related 
adverse events associated with ipilimumab and the lack of less toxic alternatives 
treatment options. Therefore for patients with non-visceral disease and limited 
systemic disease, there remains an unmet need for effective therapies that provide a 
high complete response that is durable, a long term survival benefit, combined with 
an improved safety profile. (CS, page 37) 
The ERG considers that the ‘wait and watch’ policy described in the CS reflects relatively 
common practice for patients with very limited cutaneous or subcutaneous disease and for 
whom ongoing excisions are not feasible. These patients are likely to have stage III disease 
rather than stage IV M1a disease. For these patients, ipilimumab (and BRAF inhibitors) 
would be deemed less attractive than a ‘wait and watch policy’ due potential toxicity 
associated with the drug (ipilimumab or BRAF inhibitors). 
The ERG concurs with the company that, prior to December 2015, ipilimumab was the 
treatment of choice for the majority of patients with metastatic melanoma who were not 
suitable for a ‘wait and watch’ treatment. In particular, the ERG considers that the majority of 
patients with stage IV M1a disease would have been considered for treatment with 
ipilimumab.  
In addition, the ERG notes that there are alternative treatment choices for selected patients 
with non-visceral metastatic disease, including isolated limb perfusion or 
electrochemotherapy, both of which are standards in melanoma care delivered in the UK, 
may be considered as options for patients with non-visceral metastatic disease. Indeed, 
electrochemotherapy has been identified in NICE guidance (IPG446)24 as an option for this 
patient group. However, it is noted that the evidence base is limited:25 approximately 160 
patients from two RCTs,26,27 three non-randomised comparative studies28-30 and three case 
series.31-33 Expert advice to the ERG has also highlighted that there is a range of other 
intralesional therapeutics available to treat this patient population. 
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Expected treatment pathway for patients with non-visceral metastatic disease from 
December 2015 onwards 
Since the company presented its submission to NICE, pembrolizumab, another 
immunotherapy, has been recommended as a treatment option for patients with metastatic 
melanoma who have15 and who have not16  been previously treated with ipilimumab. The 
ERG considers that many patients with metastatic melanoma who have not been previously 
treated with ipilimumab will now be considered for treatment with pembrolizumab. This is 
particularly true for patients with stage IV M1a disease.  
The ERG also considers that the ‘wait and watch policy’ or a regional treatment such as 
isolated limb perfusion or a procedure such as electrochemotherapy remain potential 
treatment options, particularly for patients with stage III melanoma. Pembrolizumab is 
considered to be less toxic than ipilimumab (as it is associated with fewer Grade 3 to 5 
adverse effects and serious adverse effects compared with ipilimumab21). Therefore as 
clinicians are now able to offer pembrolizumab as a first-line treatment option, there are 
fewer patients likely to be considered for ‘wait and watch’ policy, a regional treatment such 
as isolated limb perfusion or a procedure such as electrochemotherapy than was the case 
prior to December 2015. 
There is a small group of patients with metastatic melanoma who would not be treated with 
immunotherapy. These include patients with autoimmune diseases such as rheumatoid 
arthritis and inflammatory diseases such as ulcerative colitis.  
Anticipated numbers of patients eligible for treatment with T-VEC 
Sections 3.4 and 6.2 of the CS present an overview of the anticipated numbers of patients 
expected to be eligible for treatment with T-VEC. The company considers that 1,424 patients 
have stage IIIB to stage IV M1a melanoma in 2015 (9% of all patients with melanoma) and 
T-VEC would be an eligible treatment option in England for around half of these, namely 728 
patients. The ERG notes that the estimated proportions (and definitions) of patients with 
stage III and stage IV melanoma have varied in recently conducted appraisals for NICE;11-16  
from 10% (1,190)11 to 20% (2,330)14 with stage III or stage IV disease (and similar estimates 
for stage IIIc to stage IV M1c disease: 10% [1,137],15,16 20% [1,993]13 or 21% [2,240]12). The 
ERG therefore considers that the numbers of eligible patients estimated in the CS appears 
to be a reasonable estimate. 
 
Confidential until published 
 
Talimogene laherparepvec for treating metastatic melanoma [ID508] 
Single Technology Appraisal: Evidence Review Group Report 
Page 26 of 134 
3 CRITIQUE OF COMPANY’S DEFINITION OF THE 
DECISION PROBLEM 
The decision problem described by the company in the CS is presented in Table 2. It relates 
to the final scope issued by NICE. Each parameter is discussed in more detail in the text 
following the table (Section 3.1 to Section 3.7). 
Table 2 NICE scope and company’s decision problem 
Parameter 
 
Final scope issued by NICE 
Decision problem addressed in the 
company’s submission 
Population Adults with stage IIIB to stage IV 
melanoma 
Adults with unresectable melanoma that is 
regionally or distantly metastatic with no bone, 
brain, lung or other visceral disease (disease 
stage IIIB to stage IV M1a) described within 
this submission as non-visceral metastatic 
disease 
Intervention T-VEC T-VEC 
Comparator (s) -Ipilimumab  
-Vemurafenib (for people with BRAF 
mutation positive disease) 
-Dabrafenib (for people with BRAF 
mutation positive disease) 
Ipilimumab is considered to be the primary 
comparator in the submission since BRAF 
inhibitors (vemurafenib and dabrafenib) are 
often reserved for those patients with rapidly 
progressing disease and high disease burden  
Outcomes -Overall survival  
-Progression-free survival 
-Time to treatment failure 
-Response rate 
-Adverse effects of treatment 
-Health-related quality of life 
- Overall survival  
-Progression-free survival* 
-Time to treatment failure* 
-Response rate (durable response rate and 
overall response rate) 
-Adverse effects of treatment 
-Health-related quality of life 
Economic 
analysis 
In accordance with the NICE Reference 
Case which stipulates: 
The cost effectiveness of treatments should 
be expressed in terms of incremental cost 
per QALY 
The time horizon for estimating clinical and 
cost effectiveness should be sufficiently 
long to reflect any differences in costs or 
outcomes between the technologies being 
compared 
Costs will be considered from an NHS and 
Personal Social Services perspective 
Cost effectiveness of treatments is expressed 
in terms of incremental cost per quality 
adjusted life year 
A lifetime time horizon reflecting any 
differences in costs or outcomes between the 
technologies being compared has been 
modelled 
Costs are considered from an NHS and 
Personal Social Services perspective 
Subgroups to be 
considered 
If the evidence allows, consideration will be 
given to subgroups based on volume of 
disease and distribution of disease 
The CS only includes patients from the pivotal 
OPTiM trial
4





BRAF=B-Raf proto-oncogene, serine/threonine kinase; CS=company submission; QALY=quality adjusted life year 
Source: CS, adapted from Table 1-1 
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Superseded – see 
erratum 
3.1 Population 
The population specified in the NICE scope is adults with stage IIIB to stage IV melanoma. 
T-VEC does not currently have a licence in Europe for patients with melanoma. However, a 
positive opinion for the granting of a marketing authorisation has been issued by the 
Committee for Medicinal Products for Human Use (CHMP)5 and is awaiting approval by the 
European Commission (expected in xxxxxxxxxxxx) for adults with unresectable melanoma 
that is regionally or distantly metastatic (stage IIIB, stage IIIC and stage IV M1a) with no 
bone, brain, lung or other visceral disease. These patients with non-visceral metastatic 
melanoma are referenced in the company’s description of the population in the decision 
problem. Therefore, the clinical evidence presented by the company is only applicable to a 
subgroup of the patients specified in the NICE scope.  
Importantly, but not explicitly stated in either the NICE scope or company’s decision problem 
or in the anticipated licence, as T-VEC is administered by intralesional injection, the patient 
population is further restricted to patient’s whose melanoma is considered injectable, i.e. 
there must be cutaneous, subcutaneous, and/or nodal lesions that are visible, palpable or 
detectable by ultrasound guidance. Patient experience of injectable treatments is not 
discussed in the CS. The ERG is not confident that all patients with injectable melanoma will 
be accepting of this type of treatment every 2 weeks over a long period of time. 
Just under three-quarters (73%) of patients with metastatic non-visceral disease are 
considered by the company to have injectable disease. The population in the OPTiM trial4 is 
therefore not directly comparable with patients in other trials for two reasons: (i) as noted by 
the ERG in Section 2.2 (Table 1), no other trial has conducted a subgroup analysis of 
patients with stage IIIB to stage IV M1a disease and (ii) only the OPTiM trial4 has included 
patients solely with injectable disease.       
3.2 Intervention 
The intervention specified in the CS and in the company’s decision problem statement is an 
oncolytic virus, T-VEC, derived from the herpes simplex virus type-1 (HSV-1) that has been 
modified to efficiently replicate within tumours and to produce the immune stimulatory protein 
granulocyte-macrophage colony-stimulating factor (GM-CSF). The aim of treatment is to 
boost the body’s immune system to protect itself from carcinogenesis and progression of 
cancer.34,35 
T-VEC has two complementary mechanisms of action in/on cancerous cells:36 (i) replication 
that causes cell rupture/lysis and death (intracellular or direct effect) (ii) post-lysis release of 
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tumour-derived antigens and GM-CSF, stimulating a systemic immune response from 
antigen-presenting cells (APCs) upon distant tumour sites (extracellular or indirect effect). 
Since T-VEC is a live virus, it would be administered in key centres of excellence with 
established oncology units. Staff need to be given specific training to be able to administer 
T-VEC. 
T-VEC is administered by intralesional injection into cutaneous, subcutaneous, and/or nodal 
lesions that are visible, palpable or detectable by ultrasound guidance. It is provided in single 
use 1mL vials. According to the draft Summary of Product Characteristics (SmPC),36 and as 
administered in the pivotal OPTiM trial,4 the total injection volume for each treatment visit 
should be up to a maximum of 4mL. The initial recommended dose is up to a maximum of 
4mL of T-VEC at a concentration of 106 (1 million) PFU/mL. The second dose, which is 
administered 3 weeks later, and then all subsequent doses, which are administered every 2 
weeks thereafter, should be administered up to a volume of 4mL at a concentration of 108 
(100 million) PFU/mL. The volume of T-VEC to be injected into each lesion is dependent on 
the size of the lesion, as described in Table 2 of the draft SmPC.36 It is highlighted within the 
draft SmPC36 that patients may experience an increase in the size of existing lesion(s) or the 
appearance of a new lesion prior to achieving a response. Therefore, as long as there are 
injectable lesion(s) remaining, T-VEC should continue to be administered for a minimum of 6 
months, unless the patient’s treating physician considers that the patient is not benefitting 
from it or that other treatment is required. It is stated within the draft SmPC36 that T-VEC 
may be reinitiated if new lesions appear following a CR, assuming the physician considers 
that the patient will benefit from treatment. A maximum duration of treatment is not specified 
in the draft SmPC.36 In the OPTiM trial,4 the maximum duration of treatment was 18 months. 
3.3 Comparators 
Comparators currently used in clinical practice 
Although the comparators listed in the NICE scope are ipilimumab, vemurafenib and 
dabrafenib, clinical advice provided to the ERG suggests that currently, in clinical practice, 
for many patients the most appropriate comparator with T-VEC may be pembrolizumab,  
‘wait and watch’,  a regional treatment such as isolated limb perfusion or a procedure such 
as electrochemotherapy.   
Comparators with T-VEC in clinical trials 
There has, to date, only been one Phase III RCT of T-VEC (OPTiM trial4). In this trial, T-VEC 
was compared with GM-CSF, which was administered by subcutaneous injection for 14 
days, followed by 14 days of no injections, in a 28-day cycle. The company describes GM-
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CSF as a potentially immunologically active agent. Indeed, the Food and Drug 
Administration (FDA) notes that, when the OPTiM trial4 was in its design stage, GM-CSF 
was being considered as a possible treatment for melanoma.37 It was noted in a recent 
review of oncolytic viruses as therapeutic cancer vaccines38 that GM-CSF mediates anti-
tumour effects by recruiting natural killer cells and by induction of tumour antigen-specific 
cytotoxic T cells through the action of antigen presenting cells. However, as the company 
states, GM-CSF is not licensed as a treatment for cancer. Rather, the ERG notes, it is 
commonly used as a support medication to accelerate the recovery of white blood cells 
following chemotherapy. Used in this manner, GM-CSF requires fewer injections (at a higher 
dose) than were administered in the OPTiM trial.4   
As highlighted in Section 2.2 of this report, at the time the OPTiM trial4 was planned and 
conducted (recruitment took place between 29 April 2009 and 8 June 2011), approved 
treatment options for patients with metastatic melanoma were largely limited to DTIC and 
interleukin-2, which, as stated by the European Medicines Agency (EMA) in the European 
Public Assessment Report (EPAR),5 are known to have limited clinical effectiveness. Since 
T-VEC contains the GM-CSF gene insert, it was thus considered that this arm would serve 
as an important control to investigate whether GM-CSF alone could be responsible for the 
efficacy observed from treatment with T-VEC. 
Comparators in NICE scope and in company’s decision problem 
Ipilimumab and the BRAF inhibitors, vemurafenib and dabrafenib, are all relevant 
comparators specified in the NICE scope and referenced in the company’s description of the 
decision problem. Importantly, and as noted in Section 2.2 of this report, none of these 
interventions have been studied solely in patients with non-visceral metastatic melanoma. 
Primary comparator in the company’s decision problem 
The company states: “…the primary comparator for the licensed T-VEC population is 
considered to be ipilimumab, although all three comparators [ipilimumab, vemurafenib and 
dabrafenib] are evaluated within the submission (CS, page 48).” Ipilimumab is considered to 
be the primary comparator because, prior to December 2015, ipilimumab was the most 
commonly used treatment for patients with non-visceral metastatic disease. There are two 
main reasons for this: (i) ipilimumab is a treatment option for patients regardless of their 
BRAF mutation status, whereas patients must have BRAF mutation positive melanoma to 
receive a BRAF inhibitor (ii) patient response to ipilimumab is more durable than with BRAF 
inhibitors, albeit with a lower response rate, and so BRAF inhibitors are usually reserved for 
patients requiring a rapid response to disease progression (who would most likely, therefore, 
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have more advanced disease than those with non-visceral metastatic disease). The ERG 
concurs with the company. 
Since neither T-VEC nor GM-CSF have been directly compared to any of the comparators 
specified in the NICE scope, the company considered carrying out an indirect treatment 
comparison. However, the OPTiM trial4 is an isolated trial in that it cannot be linked to 
published trials evaluating the comparators listed in the decision problem as it does not 
share a common comparator with any of these trials. It was not, therefore, possible to 
perform an indirect treatment comparison, and the company had to consider alternative 
methods for providing indirect estimates of the effectiveness of T-VEC comparators. 
Consequently, both the modified Korn model and two-step Korn model were employed by 
the company to compare T-VEC with ipilimumab (see Section 4.3.3 and Section 5.5.1) in the 
patients with non-visceral metastatic disease. Hence evidence was only presented in the CS 
for T-VEC vs GM-CSF (clinical effectiveness) and for T-VEC vs ipilimumab (clinical and cost 
effectiveness evidence).  
The ERG notes that in the OPTiM trial,4 T-VEC was administered both as a first-line and as 
a subsequent line of treatment. However, Section 4.4 of the draft SmPC36 includes the 
warning that “Efficacy data for Imlygic [T-VEC] in the current second or later line treatment 
settings are limited.”   
ERG opinions relating to treatment options 
The ERG considers that clinicians may use T-VEC as both a first-line and a subsequent line 
of treatment if the disease is still largely small volume with little or no distant metastasis.  
The ERG considers pembrolizumab to be the first choice when considering treatment 
options for previously untreated (and treated, if eligible) patients. Pembrolizumab was not, 
however, specified in the NICE scope. This may be because NICE recommended the use of 
pembrolizumab in patients with non-visceral metastatic melanoma after the NICE scope for 
the current appraisal had been finalised.  
The ERG considers that the results of a comparison of T-VEC with ipilimumab are clinically 
meaningful but only for a limited period of time. Until recently, ipilimumab was the treatment 
of choice for the majority of patients with non-visceral metastatic disease; however, there is 
now likely to be a shift towards using pembrolizumab instead of ipilimumab as the first 
choice treatment option in the first- and second-line setting. 
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3.4 Outcomes 
The company states that clinical evidence is reported in the CS for all five outcomes 
specified in the scope: OS, progression-free survival (PFS), tumour response rate, adverse 
events (AEs) of treatment and health-related quality of life (HRQoL). In addition, time to 
treatment failure (TTF) was also reported instead of PFS for the OPTiM trial since patients 
could continue to receive treatment despite showing evidence of disease progression.4 The 
definitions of these endpoints are presented in Section 4.2.2.  
With regard to the reporting of tumour response rates, the ERG notes that these are 
commonly reported as ORRs, a measure of patients who are considered to be either CRs or 
partial responders (PRs) to treatment. These findings are often accompanied by findings 
reporting time to response (response onset) and duration of response. All of these outcomes 
are reported in the CS for the OPTiM trial.4 However, durable response rate (DRR) was the 
primary outcome for the OPTiM trial4 and is also reported in the CS. It is noted in the draft 
EPAR5 that this is a new clinically relevant endpoint. However, it is also noted that DRR is a 
non-validated endpoint and is potentially prone to bias. 
The ERG notes that, in the company model when referring to the OPTiM trial,4 TTF is used 
as a proxy for PFS. In the draft EPAR,5 a separate post-hoc analysis of PFS that differs to 
TTF is provided. Post-hoc analysis refers to those in which the hypotheses being tested are 
not specified before any examination of the data. This post-hoc analysis is based on a 
definition of PFS that is more commonly used in other trials of cancer therapies, namely the 
time from randomisation until first progressive disease per investigator assessment or death, 
whichever was earlier. TTF on the other hand is defined as the time from baseline until the 
first clinically relevant disease progression (PDr) (i.e. progressive disease associated with a 
reduction in performance status [PS]) where there is no response achieved after the PDr. 
Given it was possible for patients to be treated beyond progression in the OPTiM trial,4 the 
ERG considers TTF is an appropriate endpoint in this trial. The ERG does however draw 
attention to the fact that TTF is not defined in the same way as PFS in the pivotal trials of 
ipilimumab,19,22 in these trials the intervention drug was not permitted after progression.19,22  
3.5 Economic analysis 
As specified in the NICE scope, the cost effectiveness of treatments was expressed in terms 
of the incremental cost per QALY gained. Outcomes were assessed over a 30-year time 
horizon (equivalent to a lifetime) and costs were considered from an NHS perspective. 
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3.6 Subgroups 
The company states that no subgroup analyses were considered in its decision problem and 
that none were specified in the NICE scope. The ERG notes that the majority of evidence in 
the CS only includes patients from the pivotal OPTiM trial with stage IIIB to stage IV M1a 
disease. 
3.7 Other considerations 
The company highlights that T-VEC has been recognised by the EMA (in the draft EPAR5) 
as a novel, first-in-class oncolytic immunotherapy treatment. XXXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXX. All currently NICE recommended treatments that are considered 
to be comparators to T-VEC in the NICE scope and company’s decision problem are also 
subject to PAS agreements.11-14  
No equity or End-Of-Life issues were identified by the company. 
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4 CLINICAL EFFECTIVENESS 
4.1 Critique of systematic review methods and synthesis 
4.1.1 Systematic review methods 
A summary of the systematic review methods employed by the company with ERG comment 
is presented in Table 3. Overall, the ERG is satisfied that the review was comprehensive and 
that the eligibility criteria employed were consistent with NICE scope and with the company’s 
decision problem. 
Table 3 Summary and ERG comment on the systematic review methods used by the 
company 
Review method ERG comment 
Searching 
 Company states that one broad search was carried 
out to identify RCTs and non-RCTs  
 Databases searched included Medline, Embase and 
CENTRAL 
 Grey literature was searched for clinical studies and 
conference abstracts 
 
 Where available, appropriate search terms were used; 
however search strategy reported by the company in 
its appendices to the CS  includes a search filter for 
RCTs 
 ERG was unable to replicate company searches since 
search terms were not available for all databases 
searched (or the grey literature searches) and the 
number of results derived from each search term were 
not reported 
Eligibility criteria 
 Two independent assessors assessed study 
eligibility 
 Use of two independent assessor improves quality of 
review 
Data extraction 
 Two independent assessors extracted data 
 A pre-defined extraction form was used 
 Comprehensive data extraction was undertaken 
Quality assessment and risk of bias 
 Descriptive critical appraisal of all included RCTs 
and non-RCTs was undertaken using NICE 
recommended method 
 Unclear if two independent assessors were employed 
 The same tool was used to quality assess RCTs and 
non-RCTs; use of a tool designed specifically to 
assess non-RCTs would have been more appropriate 
CS=company submission; RCT=randomised controlled trial 
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4.1.2 Data synthesis strategy 
A summary of the company’s strategy for data synthesis is presented in Table 4. Overall, the 
ERG is satisfied that appropriate steps were attempted to present a comparison of T-VEC 
with a relevant comparator. 
Table 4 Summary and ERG comment on data synthesis strategy employed by the company 
Data synthesis strategy ERG comment 
Evidence synthesis: RCTs 
 Only one RCT was considered relevant to the 
decision problem (OPTiM trial
4
) and all aspects of 
this trial are reported in detail in the CS 
 Focus of the CS was on the subgroup of patients 
with non-visceral metastatic disease in OPTiM trial
4
 
(T-VEC licensed population) 
 It was not possible to carry out a meta-analysis due 
to lack of relevant studies of T-VEC 
 Company presented comprehensive information 
relating to the OPTiM trial
4 
in the CS 
 ERG considers it appropriate to focus reporting of 
OPTiM trial
4
 results to T-VEC licensed population 
 ERG agrees that it was not possible to carry out a 
meta-analysis 
 Since the OPTiM trial
4
 did not include a relevant 
comparator, a “qualitative synthesis” of RCTs is also 
referred to in the CS  
 A summary of trial characteristics, trial methodology, 
population characteristics, outcome assessment and 
summary of risk of bias (but no results) of included 
trials are presented in the appendices to the CS 
 The “qualitative synthesis” appears to amount to 
studies which were considered for inclusion in the 
systematic review once full papers of titles and 
abstracts were obtained but were then excluded 
 ERG notes it is unusual to extract and present so 
much information about such studies in a systematic 
review but this detail does show that the company has 
made thorough attempts to identify studies which 
include both a relevant comparator to T-VEC and a 
relevant patient population approximating the T-VEC 
licensed population  
 To enable the efficacy of T-VEC to be compared 
with that of the comparators listed in the NICE scope 
the company attempted to undertake NMA of trials 
included in “qualitative synthesis” of RCTs 
 The company states “…all three comparators [i.e. 
ipilimumab, vemurafenib and dabrafenib] are 
evaluated within the submission” (CS, page 48) 
 Alternative approaches were investigated to enable 
an indirect comparison of T-VEC with ipilimumab 
 Appropriately, a table describing the included RCTs 
for attempted NMA is presented in the CS as is a 
network diagram showing how the evidence is broken 
 No trial results are reported anywhere in the CS or 
appendices for vemurafenib or dabrafenib  
 Company adequately described the alternative 
approaches considered to enable an indirect 
comparison of T-VEC with ipilimumab; however some 
of the descriptions used in the Korn analyses were 
incomplete and more information became available to 
the ERG via the clarification process  
Evidence synthesis: non-RCTs 
 A “qualitative synthesis” of non-RCT evidence is 
also referred to in the CS; Since only one non-RCT 
(Study 002/03;
39
 NCT00289016) was considered 
relevant to the decision problem by the company, 
only information about this single non-RCT is 
presented in the CS  
 Non-RCT evidence summary appropriately includes a 
summary of study characteristics, study methodology, 
population characteristics, outcome assessment, 
assessment of risk of bias and study results 
CS=company submission; NMA=network meta-analysis; RCT=randomised controlled trial 
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4.2 Critique, analysis and interpretation of trials of the technology 
4.2.1 Identified studies in the company’s submission 
In total, 59 studies (from 97 records) were included in the company’s “qualitative synthesis” 
of RCTs. Only the OPTiM trial4 included T-VEC as an intervention or comparator. Nine other 
studies17-19,21,22,40-43 were included for consideration in a network meta-analysis (NMA); these 
were trials which included a comparison with ipilimumab, vemurafenib or dabrafenib, i.e. 
comparators relevant to the decision problem. All of the remaining 49 studies in the 
company’s “qualitative synthesis” were considered to be irrelevant to the decision problem.  
It was impossible to complete a network using the data available from the ten RCTs4,17-
19,21,22,40-43 and so a NMA could not be conducted. As noted in Section 3.3, ipilimumab is 
considered to be the primary comparator in the CS. The company considered a number of 
alternative approaches to compare T-VEC with ipilimumab indirectly. The company chose 
the modified Korn model and the two-step Korn model to enable a comparison to be made. 
These included data from the OPTiM trial4 and two trials of ipilimumab: CA184-04417 and 
MDX010-20.19 
In total, 174 studies (from 178 records) and 13 ongoing studies were included in the 
company’s “qualitative synthesis” of non-RCTs. Only one non-RCT (Study 002/0339) studied 
T-VEC monotherapy and was, therefore, considered by the company to be relevant to the 
decision problem. Like the OPTiM trial,4 this study included patients with stage IIIC to stage 
IV M1c disease but, unlike OPTiM,4 this study did not include any patients with stage IIIB 
disease. Results were not presented for patients with stage IIIC to stage IV M1a disease.  
The ERG is satisfied that the company identified all potentially relevant studies (RCTs and 
non-RCTs) and is not aware of any additional studies that should have been included as part 
of the evidence base describing the clinical effectiveness of T-VEC. 
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4.2.2 Statistical approach adopted for the conduct and analysis of OPTiM trial 
In this section, the ERG provides a description and critique of the statistical approach 
adopted to analyse data collected during the OPTiM trial.4 Information relevant to the 
statistical approach taken by the company has been extracted from the clinical study reports 
(CSRs) for the primary analysis44 and the final analysis,45 the trial statistical analysis plan 
(TSAP),46 the trial protocol47 and the CS.  
Trial population 
All pre-specified primary, secondary and tertiary efficacy outcomes were analysed using the 
intention-to-treat (ITT) population, i.e. all patients were analysed according to the treatment 
arm to which they were initially randomised, regardless of which treatment they actually 
received. The safety population included patients who received at least one dose of T-VEC 
or GM-CSF (per-protocol analysis). Both the ITT and safety populations included all patients 
enrolled into the OPTiM trial,4 i.e. patients with stage IIIB to stage IV M1c  disease.  
Efficacy outcomes 
The definitions and methods of analysis for the primary and secondary efficacy outcomes 
from the OPTiM trial4 are listed in Table 5.  
The ERG is satisfied that all outcomes were pre-specified in the TSAP46 and that all 
outcomes were fully reported in the relevant CSR (i.e. primary analysis44 or final analysis45). 
The ERG notes a number of issues in relation to the primary outcome (DRR): 
 DRR is not a commonly used endpoint (neither primary nor secondary) in other trials 
of metastatic melanoma; in the draft EPAR5 it is noted that this is a new clinically 
relevant endpoint. However, it is also noted that it is non-validated endpoint and is 
potentially prone to bias 
 In an FDA briefing document,37 the clinical meaningfulness of a response (and 
therefore DRR) is questioned for patients with already relatively small baseline 
lesions  
 The definition of the primary endpoint allowed a patient to have a durable response 
(DR) even if the patient developed new lesions, relapsed, or progressed after the 6-
month period when the DR was recorded. 
 
Despite these issues, DRR is considered in the draft EPAR5 to be an acceptable endpoint in 
this setting as it captures a relevant clinical effect of the treatment. The ERG’s view concurs 
with that of the EMA. 
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Table 5 Analysis strategy for key efficacy endpoints in the OPTiM trial 
Endpoint  Definition Statistical method 
Primary outcome 
DRR Defined as the percentage of patients with CR or PR lasting ≥6 
continuous months from the time the response was first observed 
and beginning within the first 12 months following treatment 
Analysed using a two-
sided unadjusted Fisher 
exact test 
Secondary outcomes 
OS The time from the date of randomisation to the date of death from 
any cause. Death was the event of interest. OS time was censored 
at the last date the patient was known to be alive when the 
confirmation of death was absent or unknown. Patients were 
censored at the date of randomisation if no additional follow-up data 
was obtained 
Analysed using an 
unadjusted log-rank test. 
A Cox proportional 
hazard model was used 






Best overall response observed across all time points. Disease 
burden at a particular assessment time was defined as the sum of 
the products of the perpendicular diameters of all measurable 
tumours identified at baseline plus the sum of the products of the 
perpendicular diameters of all measurable new lesions that 
appeared since baseline 
Lavin method (using 
actual tumour area 
measurements) was 
used; best tumour 
reduction was compared 




The time from the date of randomisation to the date of the first 
documented evidence of response. This may have extended 
beyond the planned study duration for however long the patient was 
followed. The achievement of response was the event of interest. If 
no response was observed, response onset was censored at the 
last tumour assessment date or at the time of the new anti-cancer 
therapy, whichever was earlier. In the event that there was one or 
more missed or partially missing assessments for response and the 
next assessment showed response, the patient should have been 
scored as response on the first date when complete information was 
available to declare response 
Displayed using a K-M 
life-table and analysed 
with a log rank test 
TTF Calculated from baseline until the first clinically relevant disease 
progression (PDr)  [i.e. progressive disease associated with a 
reduction in performance status)] where there is no response 
achieved after the PDr. PDr is the event of interest. The TTF was 
subject to censoring at the last tumour assessment if the patient had 
not yet experienced PDr. In the event that there was one missed or 
partially missing assessment for PDr and the next assessment 
showed PDr, the patient should have been scored as PDr on the 
visit showing PDr. If there was PDr following two or more missed 
assessments, the patient should have been censored at the time of 
the last tumour assessment before PDr 
Displayed using a K-M 
lifetable and analysed 
with a log rank test 
Duration of 
response 
The longest individual period from entering response (PR or CR) to 
the first documented evidence of the patient no longer meeting the 
criteria for being in response or death, whichever was earlier. The 
duration of response was defined to be zero if no PR or CR was 
ever achieved. This allowed all responders and non-responders to 
be included in the calculations. If the patient was last reported to be 
either a PR or CR, the duration of response was subject to 
censoring at that point 
Displayed using a K-M 
life-table and analysed 
with a log rank test 
Response 
interval 
Defined as the time from the date of randomisation to the date of the 
last documented evidence of response prior to any new anti-cancer 
therapy which may be given. Response interval was zero if no 
response was ever achieved. This allows all randomised patients to 
be included in the analysis but post onset of response was censored 
if the patient is still in response at the last observation, which may 
extend beyond the planned study duration for however long the 
patient is followed 
Displayed using a K-M 
life-table and analysed 
with a log rank test 
CR=complete response; DRR=durable response rate; HR=hazard ratio; K-M=Kaplan-Meier; OS=overall survival; PDr=clinically 
relevant disease progression; PR=partial response; TTF=time to treatment failure 
Source: CS, adapted from Table 4-5 
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Outline of analyses 
It was planned that the primary analysis of DRR would take place when no additional 
patients had the possibility of meeting the criteria for DR. An interim analysis of OS was 
planned after 250 events. The study duration for the OPTiM trial4 was 12 months and 
patients who had successfully completed treatment were eligible to enter a 6-month 
extension study which aimed to assess the long-term safety and efficacy of T-VEC.  
The planned assessment of outcomes is summarised in Table 6. 
Table 6 Outcomes pre-specified to be assessed at each analysis 










DRR, ORR and all response-based endpoints (per 
EAC and investigator) 
Time to treatment failure (per investigator) 
Planned interim analysis of OS and impact of 
response on OS overall 
HRQoL 
Primary OS 




Impact of Response on OS by treatment group 
Systemic effect endpoints (beyond local effects in 
injected lesions) of T-VEC treatment 
Final (descriptive) 
Pre-specified to occur after all patients had 





DRR, ORR and all response-based endpoints (per 
investigator). 
Time to treatment failure (per investigator) 
a 
Interim analyses prior to the primary analysis are not included 
DRR=durable response rate; EAC=Endpoint Assessment Committee; HRQoL= health-related quality of life; ORR, objective 
response rate; OS=overall survival 
Source: Response to the ERG’s clarification letter, Table A-10 
Cox proportional hazard modelling 
The analyses carried out by the company to generate OS, time to first response onset and 
duration of response hazard ratios were conducted using Cox proportional hazards 
modelling. The validity of this method relies on the hazards of the two comparative drugs 
being proportional. The company does not mention carrying out any testing to identify 
whether the assumption of proportional hazards holds. The ERG considers that this lack of 
testing casts doubt on the reliability of the generated hazard ratios. 
ERG assessment of statistical approach  
A summary of the checks made by the ERG in relation to the statistical approach adopted by 
the company to analyse data from the OPTiM trial4 is provided in Table 7. Having carried out 
these checks the ERG is satisfied with the statistical approach employed by the company. 
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Table 7 ERG assessment of statistical approach used to analyse the OPTiM trial data 
Component  Statistical approach ERG comments 
Sample size 
calculation 
Provided in the CS (pages 58 to 
59) 
The ERG considers that the methods used to calculate 
the sample size are correct 
Protocol 
amendments 
Provided in the final analysis CSR 
(Section 8.9) 
The ERG notes that the changes detailed in the 
protocol amendments were unlikely to have been 
driven by the results of the trial and are therefore not a 
cause for concern. All protocol amendments were 
carried out prior to the analysis being conducted 
Missing data 
approach  
Provided in the CS (page 66) In the case of missing or uninterpretable data, the 
company contacted the study investigator to try and 
resolve this data. Missing data were logged in case 
report forms. For the primary endpoint, the EAC was 
permitted to employ last value carry forward imputation 
to account for missing lesion assessments. The ERG is 
satisfied that the company took a suitable approach to 







 Line of therapy (first- vs second- 
line) 
 LDH (≤ULN vs >ULN) 
 Disease stage (stage IIIb/stage 
IIIc vs. stage IV M1a vs stage IV 
M1b vs stage IV M1c) 
 Sex (Male vs female) 
 Age (<50 vs ≥50) 
 HSV-1 status at baseline 
(negative vs positive vs 
unknown 
The ERG is satisfied that all subgroup analyses were 
pre-specified in the TSAP and were fully reported in 
both the primary analysis and final analysis CSRs  
Adverse 
events 
Safety was assessed through 
summaries of all AEs, common 
treatment-emergent AEs, SAEs, 
AEs leading to discontinuation 
and fatal AEs 
The ERG is satisfied that the results of all the AE data 
analyses are provided in both the primary analysis and 
final analysis CSRs 
Health-related 
quality of life 
Functional Assessment of Cancer 
Therapy-Biologic Response 
Modifier (FACT-BRM) 
The ERG is satisfied that the methodology used to 
analyse HRQoL data is appropriate 
AE=adverse event; CS=company submission; CSR=clinical study report; EAC=Endpoint Assessment Committee; 
ERG=evidence review group; HRQoL=health-related quality of life; HSV-1=herpes simplex virus type-1; LDH=lactate 
dehydrogenase; SAE=serious adverse event; ULN= upper limit of normal 
Source: CS, CSRs and ERG comment 
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4.2.3 Characteristics of the OPTiM trial 
The OPTiM trial4 is a Phase III open-label RCT that enabled treatment with T-VEC to be 
compared with GM-CSF in patients with stage IIIB, stage IIIC, and stage IV melanoma that 
was considered to be injectable and not surgically resectable. The OPTiM trial4 was 
conducted at 64 centres across Canada, South Africa, the UK and the United States of 
America. Patients were randomised in a 2:1 ratio to receive either T-VEC (n=295) or GM-
CSF (n=141). Randomisation was stratified according to site of first recurrence, presence of 
liver metastases, disease stage and prior non-adjuvant systemic treatment. The primary 
endpoint of the OPTiM trial4 was DRR. Secondary endpoints included OS, ORR, response 
onset, TTF, duration of response, risk of visceral and/or bone metastasis, evidence of local 
and systemic effects of T-VEC treatment, AEs and HRQoL. 
Patients eligible for the OPTiM trial4 were originally only those who had received one prior 
line of treatment. On 17 November 2009 (around 7 months after the first patient had been 
enrolled), a protocol amendment allowed patients who had received no previous treatment 
for metastatic melanoma to be enrolled.   
All patients enrolled in the OPTiM trial4 had stage IIIB to stage IV disease that was not 
surgically resectable, a common inclusion criteria for trials of melanoma treatments. A less 
common criteria of the OPTiM trial4 was that patients were required to have lactate 
dehydrogenase (LDH) levels ≤1.5 x upper limit of normal. In addition, the disease had to be 
injectable. One of the specific criterion was “…multiple superficial melanoma lesions which in 
aggregate have a total diameter of ≥10mm.” It was noted in the FDA briefing document37 
(page 20) that “…Inclusion of such subjects [with potentially very small lesions] raises 
concerns regarding the reliability of injection, and particularly reliability of measurement, both 
at the baseline and during assessments of response.” The ERG concurs with the view of the 
FDA. 
The volume of T-VEC to be injected into each lesion was dependent on the size of the 
lesion, as described in Table 2 of the draft SmPC.36 This therefore involved much 
investigator discretion in terms of the selection of lesions to be injected, the number of 
lesions to be injected, the total dose administered, the dose administered into each lesion, 
and the frequency of injections. 
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4.2.4 Patient characteristics in the OPTiM trial 
Of the 436 patients that comprise the OPTiM trial4 ITT population, a total of 249 patients 
(57%) had non-visceral metastatic disease (stage IIIB to stage IV M1a), and this specific 
group is the focus of this appraisal. It is stated in the draft EPAR5 that 33 (8%) of the ITT 
population were from the UK.  
The ERG notes that despite the lack of randomisation within the subgroup, with the 
exception of Eastern Cooperative Oncology Group (ECOG) PS, the patient characteristics 
were well balanced for patients with non-visceral metastatic disease. The percentages of 
patients at each stage of disease for T-VEC vs GM-CSF were 13.5% vs 14% for stage IIIB 
disease, 40.5% vs 36% for stage IIIC disease and 46% vs 50% for stage IV M1a disease. 
However, for ECOG PS, 74% in the T-VEC arm and 63% in the GM-CSF arm had ECOG PS 
0. 
Furthermore, the company states that, overall, the baseline characteristics are similar across 
all patients with non-visceral metastatic disease. The ERG agrees with this assessment. The 
proportion of female participants was similar in the ITT population (41.4% and 45.4% in the 
T-VEC and GM-CSF arms, respectively) and in patients with non-visceral metastatic disease 
(43.6% and 45.3% in the T-VEC and GM-CSF arms, respectively). Mean age was also 
similar in the ITT population (63.1 and 62.9 in T-VEC and GM-CSF arms, respectively) and 
in patients with non-visceral metastatic disease (64.5 and 62.5 years in T-VEC and GM-CSF 
arms, respectively).  
In the ITT population, 53.4% of patients in the OPTiM trial4 had received prior treatment for 
metastatic melanoma (the proportion of pre-treated fstatuspatients with non-visceral 
metastatic disease was not reported). The type of treatment received in the trial differs from 
that which would be available for patients with metastatic melanoma in clinical practice 
today. It is therefore unclear if similar findings for pre-treated patients in the OPTiM trial4 
could be replicated in clinical practice in England. 
Overall, despite differences in the types of previous treatments received, the ERG considers 
that the patient population in the OPTiM trial4 is generally similar to the population that is 
likely to be considered for treatment with T-VEC in clinical practice in England.  
4.2.5 Assessment of methodological quality and risk of bias of OPTiM trial 
The company’s assessments of risk of bias presented in the CS (Table 4-11) are 
reproduced, along with ERG comments, in Table 8. The ERG disagrees with the company’s 
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assessment in relation to blinding and drop-outs and also highlights other issues not 
explored by the company’s assessment, many of which were also identified by the EMA5 
and FDA.37 In these reports, the EMA5 and FDA37 highlight issues which may have 
consequences for the results for the ITT population of the OPTiM trial.4  
Table 8 Company’s assessment of risk of bias for the OPTiM trial with ERG comments 




Was randomisation carried out appropriately? Yes Agree 
Was the concealment of treatment allocation 
adequate? 
Yes Agree 
Were the groups similar at the outset of the study in 
terms of prognostic factors?  
No Agree 
Were the care providers, participants and outcome 
assessors blind to treatment allocation? 
N/A Disagree, there was minimal blinding 
and some risk of bias from the 
manner in which response to 
treatment was evaluated 
Were there any unexpected imbalances in dropouts 
between groups? 
No Disagree, a higher proportion of 
patients dropped out of the trial prior 
to receiving treatment in the GM-CSF 
arm than in the T-VEC arm 
Is there any evidence to suggest that the authors 
measured more outcomes than they reported? 
No Agree 
Did the analysis include an intention-to-treat analysis? 
Was this appropriate and were appropriate methods 
used to account for missing data? 
Yes Agree, but note that the evidence in 
the CS for the T-VEC licensed 
population is derived from a subgroup 
of the ITT population 
Other Not explored Issues around DRR:  
 not a validated endpoint 
 subjectivity in terms of assessment 
 missing confirmatory scans for 
response and therefore DRR were 
reported to be the most common 
protocol deviation 
DRR=durable response rate; ITT=intention to treat 
Source: CS, adapted from Table 4-11 
The ERG notes that the OPTiM trial4 was an open-label trial. The lack of blinding in the 
OPTiM trial4 is a concern. Perceived beliefs about the relative efficacy of T-VEC may have 
influenced decision making about whether to stop treatment (particularly in the GM-CSF 
arm) or be given another therapy. Furthermore, clinical assessments of response were 
subjective, susceptible to investigator bias, and could have ultimately influenced the 
determination of stable disease, CR, and PR. Not only could this have affected the 
secondary endpoint of ORR but also the determination of the primary endpoint, DRR. DRR 
is described by the EMA as “a new non-validated endpoint” (draft EPAR,5 page 102) and 
therefore the EMA considered that potential sources of bias may have been introduced 
during the conduct or analyses of the data. The FDA briefing document37 further notes that 
the predominance of patients with only very small baseline lesions raises concern regarding 
errors and inaccuracies in response assessment for lesions. 
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Although the OPTiM trial4 was an open-label trial, data for the primary endpoint, DRR, were 
reviewed and confirmed by an independent, blinded Endpoint Assessment Committee 
(EAC). Central confirmation by the EAC of DR would normally be considered to act as a 
check against bias from a lack of blinding. The FDA briefing document37 reported that in the 
ITT population, the investigators and EAC agreed on approximately 85% of assessments, 
whereas it is noted in the EMA report5 that only one additional DR was identified by the EAC, 
this response occurred in the GM-CSF arm. However, the extent to which the blinded EAC 
minimises bias in the OPTiM trial4 is debateable given that the EAC only evaluated 
information sent by investigators for patients with investigator-determined CR or PR, or 
those who reached 9 months on therapy (also highlighted by the EMA5 and FDA37). As 
summarised in Table 9, not one patient in the GM-CSF arm had a PR or CR for 6 continuous 
months compared with 14.2% in the ITT population and XXXX of patients with non-visceral 
metastatic disease in the T-VEC arm. Hence, it is noted in the FDA briefing document37 that 
proportionately more patients in the GM-CSF arm (87%) than in the T-VEC arm (58%) were 
never evaluated by the EAC. 
In addition, the company noted that TTF may be affected by the open-label nature of the trial 
as outcome assessors may have been influenced by knowledge of which treatment a patient 
had received when judging whether treatment failure had occurred. The ERG agrees, and 
therefore considers that TTF results should be interpreted with caution.  
A concern, in many ways related to the lack of blinding, was the number of drop-outs in the 
GM-CSF arm (Table 11). Most notably, a higher proportion of patients in the GM-CSF arm 
withdrew from the study without ever receiving treatment (XXXXXXXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These patients were considered to be 
non-responders and so their withdrawal could have biased findings in favour of T-VEC. 
Having started treatment, the ERG also notes that those in the GM-CSF arm were also more 
likely to withdraw their consent, which is another potential source of bias and favours T-VEC. 
The FDA briefing document37 reports that the proportion of ITT patients who discontinued 
treatment at 3 months was 56.0% in the GM-CSF arm compared with 29.2% in the T-VEC 
arm. This imbalance in drop-out rates could also have created bias in favour of T-VEC in 
terms of assessment of responses.  
A summary of the reasons for discontinuing treatment and the reasons for discontinuing to 
participate in the trial is presented in Table 9. 
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Table 9 Summary of the reasons for discontinuing treatment and the reasons for 
discontinuing to participate in the OPTiM trial (primary analysis) 
Reason for 
discontinuing 
treatment and from 
study 
stage IIIB–stage IV M1a 
(T-VEC licensed population) 























 Progressive disease XXX XXX 64.7 67.4 
 Adverse event XXX XXX 3.7 2.1 
 Deaths XXX XXX 1.7 2.1 
 Consent withdrawn XXX XXX 3.4 8.5 
 Physician decision XXX XXX 2.0 3.5 
Discontinued from trial 




 Lost to follow up XXX XXX XXX XXX 
 Deaths XXX XXX XXX XXX 
 Consent withdrawn XXX XXX XXX XXX 
 Physician decision XXX XXX XXX XXX 
 Other XXX XXX XXX XXX 
CR=complete response; PR=partial response 
Source: CS, adapted from Figure 4-4 and Table 4-7, CSR (Primary Analysis), adapted from Table 14-1-1 and company’s 
response to clarification letter, adapted from Table A-13 and Figure A-6 
Importantly, the EMA has noted that early treatment discontinuation in the GM-CSF arm 
could have potentially disproportionately affected the OS results in favour of T-VEC.5 
However, the EMA also states that a sensitivity analysis submitted by the company clarified 
that the patients who discontinued early did not affect the observed treatment difference in 
the ITT population for OS (draft EPAR,5 Table 32) or DRR (draft EPAR,5 Table 37).  
The EMA has also highlighted that there was a higher proportion of patients with major 
protocol deviations in the T-VEC arm (12.2%) than in the GM-CSF arm (3.5%).5 Missing 
confirmatory scans were reported to be the most common protocol deviation (6.1% vs 0.7%, 
respectively). However the EMA states that an additional analysis of DR, imputing patients 










Superseded – see 
erratum 
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Despite the concerns raised by the EMA, it concludes: “In general, the study was well 
conducted and no major issues were raised as to the conduct or the validity of the data” 
(draft EPAR,5 page 102). The FDA briefing document37 appeared to be more cautionary in 
tone, particularly as it considered there was uncertainty about the clinical meaningfulness of 
DRR (unlike the EMA who was satisfied that the outcome was clinically meaningful) and 
given there was no clear OS benefit for T-VEC vs GM-CSF in the ITT population (see 
Section 4.2.6).  
Overall, the ERG considers that there are a number of potentially important sources of bias 
in the OPTiM trial.4 Nevertheless, these are not sufficient to question the validity of the 
findings in the subgroup of patients with metastatic non-visceral disease since it is unlikely 
that bias alone could explain the differences between arms (as reported in Section 4.2.6) in 
this subgroup.  
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4.2.6 Results from OPTiM trial 
All pre-specified primary, secondary and tertiary efficacy outcomes from the OPTiM trial4 
have been reported by the company. The key results are summarised in Table 10. In both 
the ITT population and subgroup of patients with non-visceral disease, T-VEC is significantly 
more efficacious than GM-CSF for all key outcomes. 
Table 10 Summary of key efficacy results in the OPTiM trial (final data cut) 













DRR by EAC assessment (%) 25.2 1.2 16.3 2.1 
Unadjusted odds ratio (95% confidence interval) 28.6 (3.9 to 211.5) 8.9 (2.7 to 29.2) 
P-value <0.0001 <0.0001 
ORR by EAC assessment (%) 40.5 2.3 26.4 5.7 
P-value <0.0001 <0.0001 
Median TTF by investigator assessment (months) 13.1 3.3 8.1 2.9 
Hazard ratio (95% confidence interval) 0.28 (0.20 to 0.40) 0.43 (0.33 to 0.56) 
P-value <0.0001 <0.0001 
Median OS (months) 46.8 21.5 23.3 18.9 
Hazard ratio (95% confidence interval) 0.56 (0.40 to 0.79) 0.79 (0.62 to 1.00)  
P-value 0.0008 0.0494 
DRR=duration of response rate; ITT=intention to treat; OS=overall survival; TTF=time to treatment failure 
Source: CS, adapted from Table 4-13, Table 4-16, Table 4-14 and clarification response, Table A-12  (patients with non-
visceral metastatic disease) and appendices to CS, adapted from Table 1-13, Table 1-15, Table 1-17 and Table 1-14 (ITT 
population) 
Subgroup analyses of ITT population 
Subgroup analyses for DRR and OS suggested that the treatment effect of T-VEC may differ 
according to disease stage, prior non-surgical melanoma treatment, line of therapy, 
presence of visceral disease, and (for DRR only) by geographic region. The p-values for the 
tests for interaction for these subgroup analyses are provided in appendices to this ERG 
report (Section 11.1). 
In an exploratory post-hoc analysis of data for patients in the ITT population which was 
presented in the FDA briefing document,37 a larger proportion (30.4%) of patients with a DR 
had only very small lesions (<1cm2) compared to the overall population (10.1%). The FDA 
interpreted this to suggest that patients who had larger lesions were less likely to respond to 
T-VEC, although it also cautioned that the clinical meaningfulness of a response (and 
therefore DRR) is questioned for patients with already relatively small baseline lesions.  
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Subgroup of patients with non-visceral metastatic disease  
In the subgroup of patients with non-visceral metastatic disease, it was noticeable that the 
CR rate was higher in the T-VEC arm than in the GM-CSF arm (16.6% vs 0.0%; p < 0.001; 
primary data cut). Furthermore, results of an analysis presented in the draft EPAR5 show 
that in patients with non-visceral metastatic disease, patients receiving ≥ second-line T-VEC 
also had improved DRR (17% vs 2%) and objective response (28% vs 2%) relative to GM-
CSF. However the p-values for the tests for interaction for these subgroup analyses were not 
provided. 
After treatment failure, a greater proportion of patients in the GM-CSF arm received 
subsequent ipilimumab, vemurafenib, dabrafenib, trametinib or an anti-PD1 antibody (such 
as pembrolizumab) than patients in the T-VEC arm (50% and 41% respectively in T-VEC 
licensed population). Ipilimumab was the most common subsequent treatment (37% of 
patients in both arms). Vemurafenib and anti-PD1 antibo ies (such as pembrolizumab) were 
both more commonly given to patients who failed treatment with GM-CSF than T-VEC: 15% 
vs 9% (vemurafenib) and 5% vs 1% (anti-PD1 antibodies) respectively.  
The annual survival rates for patients in the T-VEC licensed population were consistently 
higher in the T-VEC treatment group compared with the GM-CSF arm. After 3 years, the 
survival rate for patients in the T-VEC treatment group was 54.9% compared with a survival 
rate of 34.6% for patients in the GM-CSF treatment group. Moreover, the survival rate in the 
T-VEC arm appeared to be stable over 4 and 5 years, and the difference in long-term 
survival rates at 4-years between T-VEC patients and GM-CSF patients was more than 20% 
(48.9% vs 27.5%).  
Summary of findings and ERG comment 
The company states that the results from patients with non-visceral metastatic disease are in 
line with the results from the ITT population. The ERG notes that the magnitude of difference 
between arms for all endpoints is much greater in patients with non-visceral metastatic 
disease than in the ITT population. Given the potential risks of bias identified in Section 
4.2.5, the ERG cautions that it is difficult to argue that there is a demonstrable OS benefit for 
T-VEC over GM-CSF in the ITT population. On the other hand, in patients with non-visceral 
metastatic disease, there does seem to be a demonstrable benefit; the difference in efficacy 
endpoints between arms is large and is unlikely to be explained by methodological bias.  
It is further noted that the findings for patients with non-visceral metastatic disease are 
however derived solely from an analysis of an exploratory post-hoc subgroup. Carrying out 
such analyses risks identifying subgroups in which superior drug efficacy occurs only by 
chance. However, the ERG’s primary concern is that the subgroup comprises a mixture of 
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patients with stage III and patients with stage IV disease. This is an issue as the disease 
trajectory for patients with stage III disease is likely to differ from that of patients with stage 




















Confidential until published 
 
Talimogene laherparepvec for treating metastatic melanoma [ID508] 
Single Technology Appraisal: Evidence Review Group Report 
Page 49 of 134 
4.2.7 OPTIM extension study 
Patients who had successfully completed treatment in the 12-month OPTiM trial4 (i.e. if they 
did not have disease progression during the OPTiM trial4 or had a CR but developed new 
lesions within 6 months) were eligible to enter into a 6-month extension study to assess the 
long-term safety and efficacy of T-VEC. A total of 31 patients (28 treated with T-VEC and 3 
treated with GM-CSF) of the 436 patients from the OPTiM trial4 entered the extension study. 
It is not reported how many of these patients had non-visceral disease. 
In this study, patients continued with their randomised treatment allocation for an additional 6 
months until CR, disease progression or unacceptable toxicity. Patients who entered the 
extension trial were included in both the analysis for the primary and final data cut-off. 
Median duration of treatment in the T-VEC and GM-CSF arms was 23.0 weeks (range, 0.1 
to 78.9 weeks) and 10.0 weeks (range, 0.6 to 72.0 weeks), respectively. Median potential 
follow-up (time from random assignment to analysis) was 44.4 months (range, 32.4 to 58.7 
months) at the primary analysis of OS. Including treatment received in the OPTiM trial,4 
median treatment duration was 88 weeks (range: 29 to 177 weeks) for patients in the T-VEC 
arm and 100 weeks for patients in the GM-CSF arm (range: 54 to 120 weeks).  
Results from the extension study are not reported in the CS.  
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4.3 Company’s methods for providing indirect estimates of effect 
As there were no head-to-head RCTs comparing T-VEC with any of the comparators listed 
in the NICE scope, the company considered performing a NMA but found that this was not 
feasible. The company subsequently considered alternative methods to obtain indirect 
estimates of effect, eventually choosing to use two approaches, the modified Korn model 
and the two-step Korn model. Ipilimumab data were obtained from two RCTs19,22 and were 
adjusted to enable comparison with T-VEC survival data from the OPTiM trial.4 In this 
section, the ERG outlines the company’s approach to obtaining indirect estimates of effect. 
4.3.1 Network meta-analysis feasibility assessment 
In order to assess whether it would be possible to perform a NMA, the company considered 
the results of the “qualitative synthesis". The company found that no trials (other than the 
OPTiM trial4) evaluated T-VEC, and no trials evaluated GM-CSF in comparison to any of the 
relevant comparators. Hence, the OPTiM trial4 was found to be an isolated trial, in that it 
cannot be linked to published trials evaluating the comparators listed in the decision problem 
as it does not share a common comparator with any of these trials. Therefore, the company 
decided it was not possible to conduct a NMA. The ERG concurs with the company’s view. 
4.3.2 Network of evidence 
Despite the isolated nature of the OPTiM trial,4 the company decided to construct a broken 
network of Phase III trials in order to present and describe the network of evidence relevant 
to the decision problem. To identify the relevant evidence, the company examined the 59 
studies identified in the “qualitative synthesis” and selected Phase III trials which were 
conducted in the population of interest (adults with stage IIIB to stage IV melanoma), which 
included at least one treatment arm receiving the intervention of interest or a relevant 
comparator (i.e. T-VEC, ipilimumab, vemurafenib or dabrafenib) as a monotherapy, and 
which reported data for either OS or PFS (TTF and not PFS data was utilised from the 
OPTiM trial4). Table 11 provides a summary of the ten studies that met these criteria and 
Figure 1 shows the resulting broken network.  
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Table 11 List of studies included in the network of evidence 
# in 
Figure 1 
Trial name and 
primary reference 
Trial design Trial drugs (n per arm) Dabrafenib GM-CSF Ipilimumab T-VEC Vemurafenib 
1 CA184-024  
Robert et al 2011
22
 
Phase III, DB 
RCT 
Ipilimumab + DTIC (n=250) 
DTIC (n=252) 
-- -- yes -- -- 
2 BRIM-3  







-- -- -- -- yes 
3 Check-Mate 067 
Larkin et al 2015
41
 
Phase III, DB 
RCT 
Nivolumab 3mg/kg (n=316) 
Nivolumab 1mg/kg + ipilimumab 
3mg/kg (n=314) 
Ipilimumab 3mg/kg (n=315) 
-- -- yes -- -- 
4 MDX01020 
Hodi et al et al 2010
19
 
Phase III, DB 
RCT 
Ipilimumab + gp100 (n=403) 
Ipilimumab (n=137) 
gp100 (n=136) 
-- -- yes -- -- 
5 KEYNOTE-006  





Pembrolizumab 10mg/kg (n=279) 
Pembrolizumab 3mg/kg (n=277) 
Ipilimumab 3mg/kg (n=278) 
-- -- yes -- -- 
6 COMBI-V  
Robert et al 2015
43
 
Phase III, OL 
RCT 
Dabrafenib + trametinib (n=352) 
Vemurafenib (n=241) 
-- -- -- -- yes 
7 COMBI-D 
Long et al 2014
42
 
Phase III, DB 
RCT 
Dabrafenib + trametinib (n=211) 
Dabrafenib (n=212) 
yes -- -- -- -- 
8 BREAK-3  
Hauschild et al 2012
18
 




yes -- -- -- -- 
9 coBRIM 





Vemurafenib + cobimetinib 
(n=248) 
Vemurafenib (n=247) 
-- -- -- -- yes 
10 OPTiM trial  





T-VEC (n=295)  
GM-CSF (n=141) 
 yes  yes  
DB=double blind; DTIC=dacarbazine; OL=open label; RCT=randomised controlled trial 
*The company cites the primary reference for the OPTiM trial to be a 2014 conference abstract by Kaufman et al
48
   
Source: CS, adapted from Table 4-21 
Confidential until published 
 
Talimogene laherparepvec for treating metastatic melanoma [ID508] 
Single Technology Appraisal: Evidence Review Group Report 
Page 52 of 134 
 
Figure 1 Network of evidence relevant to the decision problem 
Note: Numbers correspond to # in Table 11 of this ERG report 
Cobi=cobimetinib; dab=dabrafenib; DTIC=dacarbazine; GM-CSF=granulocyte macrophage colony-stimulating factor; 
gp100=glycoproteind100; nivo=nivolumab; ipi=ipilimumab; pem=pembrolizumab; tram=trametinib 
Source: CS, Figure 4-11 
The proportion of patients in the non-visceral metastatic disease subgroup varied widely 
between trials, ranging from 57% in the OPTiM trial,4 to much lower percentages in the 
relevant comparator arms of the trials: ipilimumab (11%19 to 17%22), vemurafenib (18%17 to 
23%40), and dabrafenib (16%42 to 20%18). Most patients treated with ipilimumab, 
vemurafenib and dabrafenib had later stage metastatic disease (stage IV M1b to stage IV 
M1c). The company states that, as stage of disease is a known treatment effect modifier, the 
substantial differences between the proportions of patients at each stage within the trials 
introduce heterogeneity into the network, and therefore the RCTs are not comparable, even 
if a connected network were formed. The ERG concurs with this assessment. 
The ERG further notes that the proportion of patients with injectable melanoma in these 
studies is unknown. Therefore the characteristics of patients with non-visceral metastatic 
disease in these trials may differ from those in the OPTiM trial.4  
4.3.3 Assessment of alternative methods for comparative effectiveness 
The company considered alternatives to a NMA to allow survival data from the T-VEC arm of 
the OPTiM trial4 to be compared with survival data from other relevant RCTs. The main 
challenge was that the patient populations differed greatly across the RCTs identified as part 
of the relevant (broken) network of evidence (see Section 4.3.2 of ERG report). The relevant 
evidence for T-VEC comes from patients with non-visceral metastatic disease in the OPTiM 
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trial.4 However, in the trials which evaluated the comparator treatments, results for this 
particular subgroup of patients were never reported; some reports did include subgroup 
analyses of patients by stage of disease, however, these groups did not categorise patients 
as having non-visceral metastatic disease defined as stage IIIB to stage IV M1a disease.  
Since individual patient data were only available from the OPTiM trial,4 only methods that 
attempted to adjust reported trial-level data for the comparator trials could be considered. 
The company considered six such methods for comparative effectiveness; a summary of the 
methodology and the company’s evaluation of each method are provided in Table 12. 
As the relevant data for T-VEC are derived from patients with non-visceral metastatic 
disease in the OPTiM trial4 and the data available from the comparator trials are derived 
from whole trial populations which include patients with more advanced disease, it was 
necessary to account for differences in prognostic factors for OS and PFS (or TTF) between 
these populations. However, it was also important to consider whether there may be 
potential interactions between treatment and subgroups. The company claims that T-VEC is 
likely to have a greater treatment effect in patients with non-visceral metastatic melanoma 
than in the wider population of patients with all stages of metastatic disease. The ERG 
agrees that the OPTiM trial4 evidence does appear to support this claim and agrees that this 
observation could be taken into consideration when choosing the most appropriate indirect 
comparison method. As shown in Table 12, the company rejected the matching-adjusted 
indirect comparison, simulated treatment comparison, and model-based meta-analysis 
methods as they fail to account for interactions between treatment and subgroups. Instead, 
the modified Korn model was employed as it captures prognostic differences between the 
trial populations in the comparator trials and in the subgroup of patients with non-visceral 
metastatic disease in the OPTiM trial,4 and also allows for the interaction between T-VEC 
and patients with non-visceral metastatic disease. Since the modified Korn model does not 
allow for an interaction between comparators and the subgroup of patients with non-visceral 
metastatic disease, the company developed the two-step Korn model, even though it was 
uncertain whether an interaction between the comparator treatment and this subgroup of 
patients existed. 
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Table 12 Summary of the alternative indirect comparison methods considered and the company’s evaluation of these methods 






IPD from trials of treatment A are matched to summary baseline characteristics from 
trials of treatment B. Survival outcomes for treatment A are adjusted (using an approach 
similar to propensity score weighting) so that the survival data for treatment A reflects 
survival if treatment A had been given to treatment B’s patient population 
Not suitable 
Does not allow for interactions between treatment and 






Similar to MAIC (uses IPD data for treatment A, and summary data for treatment B). 
STC creates a predictive equation for the survival outcome using treatment A IPD, in 
order to obtain survival data for treatment A as if it had been given to the patient 
population for treatment B 
Not suitable 
Does not allow for interactions between treatment and 
population with metastatic non-visceral disease 
American Joint Committee 





Published, long-term survival data by stage of melanoma from the AJCC used to adjust 
survival outcomes based on disease stage for each trial 
Not suitable 
Only adjusts for disease stage and no other variables, 






Predicts OS using pooled data from 42 trials of 2100 melanoma patients, making 
adjustments for gender, ECOG PS, presence of visceral metastases, and presence of 
brain metastases
51
. Can be used to adjust OS and PFS from comparator trials based on 
patient characteristics from the intervention trial, so adjusted OS/PFS represent 
expected survival if patients in the comparator trials had a similar distribution of patient 
characteristics to those in the intervention trial 
Suitable with modification  
A viable alternative method, but less appropriate than 
the modified Korn model, which includes an important 
fifth prognostic factor, elevated LDH levels 
Model-based meta-analysis (MBMA) can be used to implement the Korn model. MBMA 
uses a multivariable hierarchical survival model developed using the Korn algorithm as 
a reference 
Not suitable 
Does not allow for interactions between treatment and 
population with metastatic non-visceral disease 
Modified Korn model 
 
First developed by Bristol‑Myers Squibb for the NICE appraisal of ipilimumab for 
previously untreated metastatic malignant melanoma,
11
 the modified Korn model 
includes the original Korn prognostic factors, with the addition of elevated LDH levels as 
the fifth prognostic factor. Elevated LDH levels have been found to be an important 




Due to the presence of important treatment-subgroup 
interactions, and the inclusion of elevated LDH levels 
as an important prognostic factor, the modified Korn 
model was chosen to be a suitable approach 
Two-step Korn prediction 
model 
 
Developed by the company; includes an adjustment for the fact that the data entered for 
ipilimumab are for the whole trial populations, whereas for T-VEC the data are from the 
stage IIIB to stage IV M1a disease subgroup. The method assumes there is an 
interaction between the treatment effect of ipilimumab and the earlier stage disease 
subgroup.  
Suitable 
More conservative than the modified Korn model as it 
assumes ipilimumab would be more effective in a 
population with metastatic non-visceral disease than 
in the overall patient populations of the ipilimumab 
trials 
AJCC=American Joint Committee on Cancer; Bristol‑Myers Squibb=Bristol Myers Squibb; ECOG PS=Eastern Cooperative Oncology Group performance status; IPD=individual patient data; 
LDH=lactate dehydrogenase; MAIC=matching-adjusted indirect comparison; MBMA=model-based meta-analysis; OS=overall survival; PFS=progression-free survival; STC=simulated treatment 
comparison 
Confidential until published 
Talimogene laherparepvec for treating metastatic melanoma [ID508] 
Single Technology Appraisal: Evidence Review Group Report 









Superseded – see 
erratum 
The company did not attempt to employ the modified Korn model or the two-step Korn model 
to adjust the survival curves of patients receiving BRAF inhibitors. The reason given for this 
was that the trials included in the meta-analysis which forms the basis for the original Korn51 
model did not differentiate patients by BRAF status. The ERG concurs with the company.  
The results of the two-step Korn model are more conservative than the results from 
implementing the modified Korn model as the two-step approach assumes that ipilimumab is 
more effective in patients with non-visceral metastatic melanoma than in the wider 
population of patients with metastatic melanoma (predominantly later stage disease). Hence, 
the latter is considered to generate “best case” findings and the former “worst case” findings. 
More information about the Korn models is presented in the appendices to this ERG report 
(Section 11.2).  
In summary, the trial results for T-VEC are: median OS: 46.8 months; mean OS: 36.9 
months; median TTF: 13.1 months; mean TTF not reached; TTF is considered by the 
company to be a proxy for PFS. For ipilimumab, the adjusted results, as presented in the 
company’s response to the ERG’s clarification letter, are: 
 Modified Korn model results for ipilimumab:   
o median OS increases from 10.9 months to 21.3 months (95% prediction 
interval: 14.6 months to upper interval not reached) 
o mean OS increases from 19.5 to 29.2 months (95% prediction interval: 23.8 
months to 34.6 months) 
o median PFS increases from 2.8 months to 5.3 months 
o mean PFS increases from 8.0 to 15.2 months. 
 Two-step Korn model results for ipilimumab:  
o median OS increases from 10.9 months to median not reached (95% 
prediction interval: 27.0 months to upper interval not reached) 
o mean OS increases from 18.0 to 32.3 months (95% prediction interval: 28.1 
months to 35.8 months) 
o median PFS increases from 2.8 months to 17.6 months 
o mean PFS increases from 7.4 to 18.6 months. 
Given the lack of clinical effectiveness evidence available, the ERG considers that the 
company was correct to attempt to apply alternative approaches for the comparison of T-
VEC with ipilimumab. However, for reasons described in Section 5.5.1, the ERG does not 
consider that the use of either of the Korn models was appropriate. Therefore, the ERG does 
not consider the findings reported by the company when utilising the modified Korn model or 
the two-step Korn model to be either reliable or robust. 
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4.4 Safety 
AE data are available for patients treated with T-VEC; these data have been previously 
reported for the OPTiM trial overall safety population (patients with stage IIB to stage IV M1c 
disease) in the published paper4 and in the draft EPAR.5 In the CS, the company reports 
only AEs for patients with non-visceral metastatic disease. Data for both populations are 
summarised by the ERG in Table 13 and a summary of the specific types of AEs and serious 
AEs (SAEs) is presented in the appendices of the ERG report (Section 11.3, Table 50). 
Table 13 Summary of safety profiles of T-VEC and GM-CSF in the OPTiM trial 














All cause and any Grade treatment emergent AE 99 93 99 95 
All cause treatment emergent Grade 3 to 5 AEs 33 23 XX† XX† 
All cause and any Grade treatment emergent SAE 20 13 26 13 
All cause treatment emergent Grade 3 to 5 SAEs NR NR XX† XX† 
Treatment-related AEs 93 79 93 80 
Treatment-related Grade 3 to 5 AEs 14 5 XX† XX† 
Treatment-related SAE 6 0 7 0 
Treatment emergent AE leading to discontinuation 9 7 10 6 
Fatal AEs on study 1 0 3 2 
AE=adverse event; NR=not reported; SAE=serious adverse event 
Source: CS, adapted from Table 4-32 and *draft EPAR,
5
 Table 46 except † taken from CSR, Table 12-2 
The ERG concurs with the company that treatment emergent AEs, SAEs and treatment-
related AEs were higher in the T-VEC arm than in the GM-CSF arm. In patients with non-
visceral metastatic disease, AEs leading to treatment discontinuation were reported to be 
similar between arms and there was only one fatal AE, in the T-VEC arm, but this was not 
related to treatment. The ERG notes that treatment discontinuation rates due to AEs were 
marginally higher in the T-VEC arm than in the GM-CSF arm in the overall safety population. 
Adverse events of special interest (AEOSIs) have also been identified by the company, and 
feature in the risk management plan (RMP), agreed with the EMA,5 as being important 
safety concerns. These AEOSIs were not fully reported in the CS. The ERG has 
summarised the AEOSI data in Table 14; these events include flu-like symptoms, injection 
site reactions and cellulitis. The draft EPAR5 states that the majority (70% to 90%) of the flu-
like symptoms were reported to resolve within 72 hours. These events were also reported 
more frequently within the period of the first six treatments, particularly in patients who were 
HSV-1 negative at baseline, due to the intratumoral injection route of administration of T-
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VEC. None of the serious cellulitis events resulted in study treatment discontinuation but 
study treatment was delayed as a result of cellulitis for one subject. 
Table 14 Subject incidence of adverse events of special interest in the overall safety 
population of the OPTiM trial 
Type of AEOSI Patients with each type of AE (%) 
T-VEC (n=292) GM-CSF (n=127)* 
AEOSI SAEOSI AEOSI SAEOSI 
Immune mediated events (autoimmune disorders) 2 ≤1 2 0 
Cellulitis at the injection site 6 2 2 ≤1 
Flu-like symptoms 90 3 65 0 
Herpes simplex virus infections 6 0 2 0 
Hypersensitivity 18 0 20 0 
Injection site reactions 42 0 50 0 
Vitiligo 5 0 2 0 
Impaired wound healing at the injection site 6 0 2 ≤1 
Other neoplastic events (malignant/unspecified tumours) 6 3 2 ≤1 
Plasmacytoma ≤1 ≤1 0 0 
AEOSI=adverse event of special interest; SAEOSI=serious adverse event of special interest 
Source: draft EPAR,
5
 adapted from Table 49  
To enable a crude comparison of T-VEC with ipilimumab, vemurafenib and dabrafenib, rates 
of dose discontinuations and/or modifications identified with these other agents are reported 
in the CS (pages 108 to 109 and Table 4-38). Similar data, supplemented by data from the 
pivotal pembrolizumab and T-VEC trials,4,21 are summarised by the ERG in Table 15. These 
data show that T-VEC compares favourably in terms of safety when compared to other 
recommended treatments for metastatic melanoma. 
It is highlighted in the draft EPAR5 that data on long-term exposure to T-VEC are currently 
limited. Hence, a registry study is ongoing to monitor the long-term safety of patients who 
have received T-VEC as part of the RMP agreed between the company and the EMA5 and a 
final study report is expected in July 2023. 
Since T-VEC is an oncolytic virus, it is expected to have biological properties that are similar 
to wild type HSV-1 with regard to viral shedding. There is the potential for transmission of 
infection from patients to close contacts or carers. The conduct of a Phase II multicentre, 
single-arm trial to evaluate the biodistribution and shedding of T-VEC in patients with non-
visceral metastatic disease is included in the RMP detailed in the draft EPAR.5 The primary 
analysis CSR for this study is anticipated to be released in August 2016 and the final 
analysis CSR is anticipated to be available in February 2017. 
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Table 15 Adverse events reported during pivotal trials with ipilimumab, vemurafenib, 
dabrafenib, pembrolizumab and T-VEC 
Trial/ 
treatment 
Frequency of any treatment emergent and/or 
treatment-related AEs, dose discontinuations 








Grade 3 or 4 treatment-related AEs 




AEs were mostly immune-related 
which may involve the 
gastrointestinal, liver, skin, 
nervous, endocrine, ocular, or 






Grade 3 to 5 AEs 
SAEs  
AEs leading to treatment discontinuation 






Most frequently occurring Grade 
3 or 4 AEs (%):  
Cutaneous SCC 














Grade 3 to 5 AEs 
SAEs 
Treatment-related SAEs 
AEs leading to treatment discontinuation 
AEs leading to dose reduction 







Most frequently occurring Grade 
3 to 5 AEs (%):  
Back pain  
Hyperglycaemia  
Pyrexia  











Grade 3 to 5 AEs 
Grade 3 to 5 treatment-related AEs 
SAEs 
Treatment-related SAEs 






Most frequently occurring Grade 













Grade 3 to 5 AEs 
Grade 3 to 5 treatment-related AEs 
SAEs 
Treatment-related SAEs 






Most frequently occurring Grade 














Grade 3 to 5 AEs 
Grade 3 to 5 treatment-related AEs 
SAEs 
Treatment-related SAEs 






Most frequently occurring Grade 
3 to 5 AEs (%): 
Fatigue 
Injection-site pain  
2 
1 
AE=adverse event; AEOSI=adverse event of special interest; CS=company submission; GGT= Gamma-glutamyl transferase;  
LFT=liver function tests; SCC=squamous-cell carcinoma 
*T-VEC licensed population only 





taken from ERG report submitted during the dabrafenib STA
53
 and from the company’s submission (Merck) for pembrolizumab 
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4.5 Health-related quality of life  
Health-related quality of life data were only reported from the OPTiM trial4 using the 
Functional Assessment of Cancer Therapy - Biologic Response Modifier (FACT-BRM) 
questionnaire. This questionnaire has a total of 40 items that are posed under six subscales:  
1. Physical well-being 
2. Social/family well-being  
3. Emotional well-being 
4. Functional well-being  
5. Additional concerns-physical  
6. Additional concerns-mental 
 
Analyses were conducted to evaluate patient-level improvement in each of the above 
subdomains, as well as in three individual items: 
7. Overall quality of life [QoL]  
8. Pain 
9. Ability to work 
 
In addition, the company describes:  
10. Trial Outcome Index (TOI) score defined as the sum of subscales 1, 4, 5 and 6  
11. Total BRM score (which appears to be the total score from all 40 questions). 
 
The company reports that more patients treated with T-VEC than GM-CSF experienced 
improvements in HRQoL when they were assessed using these 11 measures. Between 
group differences reached statistical significance for six of the 11 measures: emotional well-
being, functional well-being, social/family well-being, overall QoL, pain, and ability to work 
(CS, Figure 4-9). However, as recognised by the company, a substantial percentage of 
patients in the GM-CSF arm did not fully complete the questionnaires (CS, Table 4-19: by 
cycle 8 the response level from patients in the T-VEC arm was 56%, compared with 16% in 
GM-CSF arm) this is likely to be related to the differences between treatment arms in rates 
of treatment discontinuation, disease progression and death. The ERG therefore considers 
that HRQoL findings (reproduced in Figure 2) should be interpreted with caution. 
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Scores from unscheduled visits were not included 
A subject is considered evaluable for a domain if baseline score is not the best score and has at least one post-baseline score 
TOI and total improvements are defined as >=5-point score increase from baseline with a >=1 cycle duration 
QoL, pain and work improvements are defined as >=1-point score increase from baseline with a >=1 cycle duration 
Other improvements are defined as >=2-point score increase from baseline with a >=1 cycle duration 
Abbreviations: CI, confidence interval; GM-CSF, granulocyte–macrophage colony-stimulating factor; ITT, intent-to-treat; QoL, 
overall quality of life 
Figure 2 Improvement Rates of Patient Report Outcome by Treatment of T-VEC and GM-
CSF stage IIIB/C, stage IV M1a ITT Subjects Evaluable for Domain Improvement 
Source: CS, Figure 4-9 
 
 
4.6 Evidence from non-RCTs 
Evidence from one Phase II non-RCT (Study 002/0339) is also presented in the CS. Unlike 
the OPTiM trial,4 this study did not include patients with stage IIIB melanoma. In total, 23 
patients had stage IIIC to stage IV M1a disease. Patient characteristics also differed to the 
characteristics of patients enrolled in OPTiM trial4 in many other respects. The ERG 
therefore considers its findings are of limited relevance to the decision problem. The 
company, on the other hand, considers Study 002/0339 provides supportive evidence of 
effectiveness. Information about this study, including study and participant characteristics 
and study results, is summarised by the ERG in the appendices (Section 11.4). 
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4.7 Conclusions of the clinical effectiveness section 
The majority of evidence for the clinical effectiveness of T-VEC is derived from the OPTiM 
trial,4 a relatively large (n=463), open-label, multi-centre, international Phase III trial which 
included patients from the UK (n=33 [8%]). ITT population (patients with stage IIIB to stage 
IV M1c disease) results show statistically significant improvements in favour of T-VEC vs 
GM-CSF for DRR, TTF (a proxy for PFS in this trial) and ORR but not for OS (although the 
OS gain was close to being statistically significant).  
Findings from the OPTiM trial4 were reported for patients with non-visceral metastatic 
melanoma (patients with stage IIIB to stage IV M1a disease); these patients are the focus of 
this appraisal as these are the patients for whom T-VEC will be licensed. Statistically 
significant improvements in DRR, TTF, ORR and OS were reported for patients treated with 
T-VEC compared with those treated with GM-CSF. The magnitude of the effect in the 
licensed population is much greater for all outcomes than in the ITT population. These 
findings were derived from an exploratory post-hoc analysis of 279 patients.  
The ERG has concerns that the population considered in this STA comprises a mixture of 
patients with stage III and stag  IV M1a disease as it is likely that the disease trajectory of 
patients with stage III disease differs from that of patients with stage IV disease. The ERG 
also considers that there are a number of potentially important sources of bias in the OPTiM 
trial4 due to limited blinding, a higher proportion of drop-outs in the GM-CSF arm (particularly 
in the first few months of the trial), and the use of DRR as the primary endpoint. However, 
the ERG does not consider that the potential sources of bias explain the improvements in 
efficacy in the T-VEC arm compared with the GM-CSF arm reported for patients with non-
visceral disease.  
An area of uncertainty that has been raised by the FDA37 relates to the size of lesions. The 
results of an FDA post-hoc analysis suggest that patients who had very small lesions 
(<1cm2) were more likely to respond to T-VEC than the overall population (30.4% vs 10.1% 
respectively).37 
In both the overall trial population and the subgroup of patients with non-visceral metastatic 
melanoma, there were more treatment emergent AEs, SAEs and treatment-related AEs in 
the T-VEC arm of the OPTiM trial4 than in the GM-CSF arm. The types of AEs included flu-
like symptoms (very common), injection site reactions (very common) and cellulitis (common 
and potentially serious). Careful wound care is important to minimise risk of infection, 
particularly if tissue necrosis results in open wounds. In terms of the types of AEs observed, 
T-VEC compares favourably in terms of safety to other recommended treatments 
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(pembrolizumab, ipilimumab, vemurafenib and dabrafenib) for metastatic melanoma. 
Although not reported in the OPTiM trial,4 there is a potential risk for  transmission of T-VEC 
and  life-long latency with possible symptomatic herpetic infection due to reactivation. Long-
term safety of T-VEC has not yet been established. 
The ERG considers that the HRQoL findings from the OPTiM trial4 should be interpreted with 
caution since a substantial percentage of patients in the GM-CSF arm did not fully complete 
the questionnaires. Furthermore, the findings comparing HRQoL for patients treated with T-
VEC with those treated with GM-CSF are arguably of limited value since GM-CSF is not a 
relevant comparator in clinical practice. The same could be argued to be true for all findings 
of relative effectiveness for all other reported outcomes in the OPTiM trial.4 
Pembrolizumab was not listed as a relevant comparator in either the NICE scope or the 
company’s decision problem since both documents were produced when pembrolizumab 
was neither recommended by NICE nor used in clinical practice. However, the ERG 
considers that pembrolizumab is now likely to be the most appropriate comparator for 
patients with non-visceral metastatic melanoma in clinical practice.  
Whilst, the ERG considers that a comparison with ipilimumab is clinically meaningful, it was 
not possible to conduct a NMA as the OPTiM trial4 was found to be an isolated trial which 
could not be linked to any relevant published trials. Therefore, the company employed two 
alternative methods in an attempt to compare the efficacy of T-VEC with that of ipilimumab: 
the modified Korn model and the two-step Korn model. The ERG does not consider that 
either of the Korn models produces robust or reliable results. Hence, the relative clinical 
effectiveness of T-VEC vs ipilimumab is unknown. T-VEC does, however, appear to have a 
better safety profile than ipilimumab (and indeed, pembrolizumab). 
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5 COST EFFECTIVENESS 
5.1 Introduction 
This section provides a structured critique of the economic evidence submitted by the 
company in support of the use of T-VEC for treating patients with non-visceral metastatic 
melanoma. The two key components of the economic evidence presented in the CS are (i) a 
systematic review of the relevant literature and (ii) a report of the company’s de novo 
economic evaluation. The company provided an electronic copy of their economic model, 
which was developed in Microsoft Excel. 
5.2 The company’s review of cost effectiveness evidence 
5.2.1 Objective of cost effectiveness review  
The company undertook a search to identify studies reporting the cost effectiveness of T-
VEC, compared with other therapies, for treating patients with non-visceral metastatic 
melanoma. Details of the search strategies employed by the company are included in 
Appendix 1.2 of the CS.  
5.2.2 Eligibility criteria used in study selection 
The application of the inclusion/exclusion criteria was a two-step process. First, the 
inclusion/exclusion criteria detailed in Table 16 were applied to the identified studies. The 
studies that were not rejected were then assessed for relevance. The company considered a 
study to be relevant if it included a comparator listed in the final NICE scope and had content 
that was applicable to the NICE reference case. 
5.2.3 Included and excluded studies 
The searches identified 10,667 titles. After the first eligibility assessment phase, 51 studies 
were considered to meet the inclusion criteria. However, only 11 (of the 51) studies met the 
relevance criteria. The identified studies comprised five NICE STAs,11-15 four Scottish 
Medicines Consortium appraisals,55-58 and two cost utility analyses.59,60 
5.2.4 Findings from cost effectiveness review 
Summary details relating to the 11 studies considered relevant are reported in the CS (Table 
5-2).  
5.2.5 Conclusions of the cost effectiveness review  
None of the identified studies considered the cost effectiveness of T-VEC and therefore the 
findings from the review are of limited relevance to this STA. 
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Table 16 Economic evaluation search inclusion/exclusion criteria 
HTA=health technology assessment; ICER=incremental cost effectiveness ratio; QALY=quality adjusted life year; UK=United 
Kingdom   
Source: CS, Table 5-1 
 
5.2.6 ERG critique of the company’s literature review 
The ERG is satisfied with the company’s search strategy and stated inclusion/exclusion 
criteria and is confident that the company did not miss any relevant published papers.  
Parameter Inclusion criteria Exclusion criteria 
Population Adults (≥18 years of age) with any stage 
melanoma who are receiving treatment for 
the first time or have received prior 
treatment  
 Studies including patients with non-
cutaneous (e.g., ocular/uveal) 
melanoma and/or active cerebral or 
bone metastases. 
 Studies of mixed cancer populations not 




Not applicable Not applicable 
Outcomes  Economic model methods  
 Incremental costs and QALYs 
 Other efficacy measures with associated 
costs 
 Incremental ICER outputs 
Not applicable 
Study Design  Cost-effectiveness analyses 
 Cost-utility analyses 
 Cost-benefit analyses 
 Cost-minimisation analyses 










Date restrictions Conference proceedings 2013 - present Not applicable 
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5.3 ERG’s summary of company’s submitted economic evaluation 
5.3.1 Model structure 
The company has developed a de novo economic model to predict and compare the long-
term costs and health outcomes associated with using T-VEC and ipilimumab to treat 
patients with non-visceral metastatic melanoma (stage IIIB to stage IV M1a disease). A 
schematic of the company’s economic model is provided in the CS and is reproduced in 
Figure 3. It is a partitioned survival model comprising three mutually exclusive health states: 
non-progressive disease (comprising CR, PR and SD), progressive disease (PD) and death.  
All patients enter the model in the non-progressive state and receive treatment with either T-
VEC or ipilimumab. At the beginning of each time period patients can either remain in the 
same health state or progress to a worse health state; that is, patients in the non-progressive 
state can move to either the progressive disease health state or to death, whilst patients in 
the progressive disease state can only move to death. 
Estimates of OS for patients treated with T-VEC are based on survival data from the OPTiM 
trial.4 Estimates of PFS for patients treated with T-VEC are based on TTF data from the 
OPTiM trial.4 Estimates of OS and PFS for patients treated with ipilimumab have been 
generated using published data.19,22,61-64 The proportion of patients in the post-progression 
state is calculated as the difference between OS and PFS at each time point. 
 
Figure 3 Schematic of company model 
Source: CS, Figure 5-2 
Patients receiving T-VEC were categorised into each health state based on the clinical 
definitions used in the OPTiM trial,4 which are described in Table 17. The non-progressive 
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disease state is considered equivalent to PFS in the model, and TTF data are used as a 
proxy for PFS; thus the T-VEC non-progressive disease state is represented in the model by 
TTF data from the OPTiM trial.4 
Table 17 Health state definitions used in the OPTiM trial 








PR ≥50% reduction from baseline in the sum of the surface area of all 
measurable tumours 
SD Neither sufficient overall tumour shrinkage to qualify for response 
(CR or PR) nor sufficient tumour increase to qualify for PD 
Progressive 
disease 
PD >25% increase in the sum of the surface areas of all measurable 
tumours, or a single lesion increase of >25% (over the smallest 
measurement achieved for the single lesion), or the appearance of 
a new lesion 
Death Death from any cause - 
CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease 
Source: CS, Table 5-4 
Patients in the ipilimumab arm are categorised into each health state based on the clinical 
definitions used in the pivotal clinical trials of ipilimumab (CA184-04422 and MDX010-2019).  
Published PFS data from these trials19,22 are assumed to be equivalent to the non-
progressive disease state in the OPTiM trial.4 
Upon disease progression, patients in both arms of the model are assumed to receive no 
further systemic treatment and, instead, receive best supportive care (BSC). BSC is defined 
in the CS as non-curative health care received by patients in the period between disease 
progression and administration of palliative care. Patients who die are assumed to have 
received palliative care for up to 3 months before death, and terminal care immediately prior 
to death. 
The model includes five phases of disease management which are independent of active 
treatment. These are intended to address the differences in the quality of life, decrements in 
utility associated with AEs and the disease management costs associated with transitioning 
through the three health states: 
 On-treatment pre-progression (routine treatment): the health care received while in 
the non-PD state 
 On-treatment disease progression: the health care package received when switching 
to BSC because of disease progression  
 BSC: the non-curative health care received in the period between disease 
progression and administration of palliative care 
 Palliative care: the health care received up to 3 months before death 
 Terminal care: the health care received immediately prior to death. 
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The model has been developed in Microsoft Excel and employs a cycle length of 1 week 
(with half-cycle correction). The time horizon is 30 years and health effects are measured in 
quality adjusted life years (QALYs). The perspective is that of the NHS and cost and 
outcomes are discounted at an annual rate of 3.5%. 
Variants of the company model structure have been used previously in the modelling of 
advanced melanoma for previous STAs (Vemurafenib for treating locally advanced or 
metastatic BRAF mutation‑positive malignant melanoma [TA269],13 Ipilimumab for 
previously untreated advanced [unresectable or metastatic] melanoma [TA319],11 
Dabrafenib for treating unresectable or metastatic BRAF mutation positive melanoma 
[TA321]14). 
5.3.2 Population 
The population considered in the economic evaluation includes patients with unresectable 
regionally or distantly metastatic melanoma with no bone, brain, lung or other visceral 
disease (i.e. patients with stage IIIB to stage IV M1a disease) that may or may not have 
been previously treated.  
The baseline patient characteristics used in the economic model are estimated using 
weighted averages from both arms (T-VEC and GM-CSF) of the OPTiM trial4 and are 
presented in Table 18.  
Table 18 Model population baseline patient characteristics 
Characteristic All lines: stage IIIB 
to stage  IV M1a 
PSA distribution Source 
Mean age, years 64 Fixed 
OPTiM
4
 Proportion male, % 56 87.77 to 93.93 (gamma) 
Mean weight, kg 86
 
74.68 to 83.17 (gamma) 
PSA=Probabilistic sensitivity analysis 
Source: CS, Table 5-3 
 
5.3.3 Intervention and comparator 
T-VEC 
The recommended dosing schedule for T-VEC comprises an initial dose of up to 4mL at a 
concentration of 106 PFU/mL followed by subsequent doses of up to 4mL every 2 weeks at a 
concentration of 108 PFU/mL. Treatment with T-VEC is implemented in the model in line with 
the mean dose and treatment duration for the subgroup in OPTiM trial4 who had stage IIIB to 
stage IV M1a disease. The mean dosage and treatment values do not include the 
accelerated dosing schedule allowed in the OPTiM trial protocol.65 
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Ipilimumab 
The licensed dosing regimen for ipilimumab is 3mg/kg administered intravenously over a 90-
minute period and given every 3 weeks for a total of four doses.66 However, the company 
implemented ipilimumab treatment in the model in line with the mean dosage and treatment 
duration observed in the CA184-02419 trial and reported in TA319,11 which was slightly 
shorter than the currently recommended regimen and which the company states represents 
a conservative estimate which favours treatment with ipilimumab. 
The mean dosage and treatment duration values used in the model are shown in Table 19. 
Table 19 Mean dosing and treatment duration for patients receiving T-VEC and ipilimumab 
Treatment Dosage (including wastage) Mean duration of 
treatment 
Source 
T-VEC Cycle 1 (21 days): 2.86 vials of 10
6
 pfu/mL  









Ipilimumab 52.20mL every 3 weeks (1.22 x 10mL vials and 
1.00 x 40mL vial) 









*All reported doses in the base case assume drug wastage 
Source: CS, Table 5-18 
Discontinuation rules 
No clinical discontinuation rules were implemented. 
5.3.4 Perspective, time horizon and discounting 
The economic evaluation is undertaken from the perspective of the NHS. The time horizon is 
set at 30 years and, in line with the NICE Methods Guide to Technology Appraisal,67 both 
costs and outcomes are discounted at 3.5%. 
5.3.5 Treatment effectiveness and extrapolation 
Progression-free survival 
The company states that the mode of action of T-VEC can lead to response happening post-
progression, which renders inappropriate a standard definition of PFS. The company 
therefore use TTF data as a proxy for PFS. The TTF was defined as time from the first dose 
of study treatment until death or the development of the first clinically significant progression 
per investigator for which no objective response was subsequently achieved. Clinically 
significant progressive disease was defined as a progressive disease that is associated with 
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a decline in PS and/or that the patient requires alternative therapy in the opinion of the 
investigator.  
In the company’s base case, PFS for patients receiving T-VEC was modelled using a 
generalised gamma curve fitted to the OPTiM trial4 TTF K-M data from week 0 to week 184 
(at which point no more K-M TTF data were available). Hazards from the ipilimumab PFS 
arm were then applied to project PFS to 30 years. 
The company base case for PFS associated with treatment with ipilimumab was based on 
published PFS K-M data from two trials.19,22 The data from each trial were adjusted (to 
account for differences in the baseline characteristics between patients included in the T-
VEC arm of the OPTiM trial4 and patients included in the two ipilimumab trials19,22) using 
either the modified Korn model or the two-step Korn model. The modified data were then 
pooled and a generalised gamma curve was fitted to these data to project PFS to 30 years. 
Overall survival 
For patients treated with T-VEC, OPTiM trial4 K-M OS data were used directly for the first 
177 weeks. An exponential curve was then used to represent survival from week 178 to 
week 269 (at which point no further K-M data were available). From week 270 to 10 years, 
the company applied mortality rates calculated using combined data from the AJCC registry1 
and UK life tables.68 UK life table mortality rates alone were applied from year 10 until 30 
years.  
OS for patients treated with ipilimumab was modelled using a similar multi-part extrapolation; 
however, cut points were implemented at different times to those used to model OS for 
patients treated with T-VEC. The OS projection for patients treated with ipilimumab was 
based on published K-M data from two trials,19,22 which were adapted using either the 
modified Korn model or the two-step Korn model (to account for differences in the baseline 
characteristics between patients included in the T-VEC arm of the OPTiM trial4 and patients 
included in the two ipilimumab trials19,22) and then pooled. These modified (and pooled) K-M 
data were used directly for the first 129 weeks, after which an exponential curve was used to 
represent survival until 239 weeks. Mortality rates calculated from AJCC registry data1 and 
UK life tables68 data were applied from week 240 to 10 years and then UK life table mortality 
rates alone were used until 30 years.  
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5.3.6 Health-related quality of life 
The FACT-BRM questionnaire was used in the OPTiM trial4 to assess patient HRQoL. 
However, the FACT-BRM is not a preference-based measure of HRQoL and does not 
conform to the NICE reference case. The company did not undertake mapping of the FACT-
BRM. Instead, the company used utility values from NICE TA32114 in the economic model. 
Utilities used in the base case are based on progression status, and patients with non-
progressive disease are assumed to have the same HRQoL regardless of their response to 
treatment (CR, PR or SD). Within the model it is assumed that progression is a predictor of 
HRQoL and so patients with PD are assigned a lower utility value than those with non-
progressive disease. 
Table 20 Summary of utility values used in the company's base case 
State 









PD 0.68 (0.084) 0.52 to 0.85 
CR=complete response; PD=progressive disease; PR=partial response, SD=stable disease 
Source: CS, Table 5-12 
The model also includes disutilities associated with grade ≥3 AEs (see Table 21). These 
values were obtained from a proprietary study commissioned by Amgen Limited.69  
Table 21 Disutility values used in the company model 
Adverse event 
Mean utility value 
(standard error) 
95% confidence interval Source 




Cellulitis 0.12 (0.005) 0.111 to 0.129 
Colitis 0.26 (0.010) 0.241 to 0.280 
Constipation 0.14 (0.005) 0.130 to 0.151 
Diarrhea 0.11 (0.004) 0.102 to 0.118 
Dyspnea 0.11 (0.004) 0.102 to 0.118 
Fatigue 0.05 (0.002) 0.046 to 0.054 
Headache 0.16 (0.006) 0.148 to 0.172 
Nausea 0.26 (0.010) 0.241 to 0.280 
Vomiting 0.26 (0.010) 0.241 to 0.280 
Source: CS, Table 5-12 
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5.3.7 Resources and costs 
Drug costs 
The anticipated list price for T-VEC at both the initial 106 PFU/mL and subsequent 108 
PFU/mL concentrations is £1,445 per 1mL vial. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXx. 
The ipilimumab acquisition costs used in the model are based on the NHS list price, 
although the company acknowledges that a confidential PAS is available for ipilimumab in 
the NHS.  
Drug acquisition costs and the mean acquisition costs per patient for both treatments are 
shown in Table 22. 
Table 22 Treatment dosing schedule 


















 x 1mL 









 PFU/mL  
x 1mL 
£1,445* Subsequent cycles 
(every 14 days):  
XXX vials 
Ipilimumab 
10mL (50mg) £3,750 52.20 mL every 3 
weeks  
(1.22 x 10mL vials 
and 1 x 40mL vial) 






40mL (200mg) £15,000 
*Anticipated list price 




T-VEC is administered via intralesional injection into cutaneous, subcutaneous, and/or nodal 
lesions that are visible, palpable, or detectable by ultrasound guidance. The company 
anticipates that administration of T-VEC will take place in a limited number of centres 
specialising in the treatment of skin cancers and that it will be administered in an outpatient 
setting in a designated side room (day case). 
The company was unable to identify any Health Resource Group (HRG) codes specific to T-
VEC, nor any other chemotherapy treatments administered in a similar fashion. It, therefore, 
assumed that the cost of administering T-VEC would be equivalent to that of ipilimumab 
(HRG code SB13Z).71 The company states that this assumption is supported by its own 
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study72  which was carried out to explore the administration cost of T-VEC. Further details of 
the Amgen Limited study are given in Appendix 1.8 of the CS. 
Table 23 NHS reference costs 
NHS=National Health Service 
Source: CS, Table 5-20 
Health state unit costs and resource use 
The company’s systematic review of the economic literature identified only one study (the 
MELODY study73,74) that formally reported resource utilisation for melanoma in terms of 
inpatient, outpatient and hospice care requirements for a UK-specific cohort. The company 
notes that although the MELODY study73,74 has been used in previous appraisals (TA31911 
and TA35715) it is of limited relevance as it was carried out some years ago, and predates 
current melanoma treatments and UK clinical practice. Instead the company carried out its 
own resource utilisation study75 to collect costs throughout the treatment pathway for 
advanced melanoma. This study identified four treatment phases: active systemic treatment 
(pre-progression); disease progression; BSC/palliative care; and terminal care. Health 
resource utilisation (HRU) elements were identified for each phase, and estimates of the 
magnitude and frequency of their use in clinical practice were obtained through a UK Delphi 
panel, comprising seven oncologists. These costs were then applied in the model in five 
phases as BSC and palliative care costs were considered separately. 
All data were obtained from NHS reference costs,71 the Personal Social Services Research 
Unit (PSSRU),76 and NICE TA268.12 A one-off cost of £6,105 for terminal care was based on 
data published by the King’s Fund.77 All unit costs were inflated to 2013-2014 values using a 
PSSRU76 published inflation index. A summary of the HRU estimates for each phase is 
shown in Table 24. Full details of the monthly HRU estimates for each phase are presented 





Description Source Unit price 
Deliver more complex parenteral chemotherapy at first 
attendance- day case 
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Table 24 Summary of resource use costs 
Health state Cost Frequency 
Non-progressive disease 
Routine treatment £86.52 Per cycle 
Progressive disease 
On progression £1,198.50 One-off 
Best supportive care £91.24 Per cycle 
Palliative care £192.03 Per cycle 
Terminal care £6,105.00 One-off 
Source: CS, Table 5-21 
Adverse event costs and resource use 
The company model includes Grade 3 or 4 AEs experienced by at least 2% of patients 
receiving any of the treatment options. These AEs were assumed to occur once and persist 
for 1 day. The costs were mainly derived from NICE TA31911 and NICE TA269,13 and were 
inflated to 2013/14 values. These costs are consistent with those reported in TA357 
(Pembrolizumab for treating advanced melanoma after disease progression with 
ipilimumab).15 The values used in the model are summarised in Table 25. 
Table 25 Adverse event costs applied in the model 
AEs Value Source 
Anaemia £376.61 Cost assumed to be the same as for fatigue in NICE TA319 
Cellulitis £137.31 Cost assumed to be the same as for rash in NICE TA269 and 
inflated to 2014 cost 
Colitis £1,011.21 NICE TA319 inflated to 2014 costs 
Constipation £0 Cost assumed to be £0 
Diarrhoea £491.26 NICE TA319 inflated to 2014 costs 
Dyspnoea £0 NICE TA319; cost assumed to be £0 
Fatigue £200.79 NICE TA319 inflated to 2014 costs 
Headache £171.86 Cost assumed to be the same as for pain in NICE TA357  
Nausea £213.49 Cost assumed to be the same as for diarrhoea in NICE TA319 
Vomiting £213.49 Cost assumed to be the same as for diarrhoea in NICE TA319 
Source: CS, Table 5-23 
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5.3.8 Cost effectiveness results 
The company presents two sets of base case results for the comparison of T-VEC with 
ipilimumab. These differ in the approach used to project the efficacy of ipilimumab: the 
modified Korn model or the two-step Korn model. All results have been generated using list 
prices. Predicted (per patient) base case costs are presented in Table 26. 
Table 26 Summary of predicted resource use by category of cost 
Item 
Treatment Difference 





Modified Korn model 
Treatment costs XXXXXX £68,038 XXXXXX XXXXXX XXXXXX 
Administration 
costs 
£5,092 £1,311 £3,780 £3,780 18.73% 
Routine care 
costs 
£17,083 £10,789 £6,294 £6,294 31.2% 
On progression 
costs  
£1,013 £1,080 -£67 £67 0.3% 
BSC/palliative 
care costs 
£12,885 £11,897 £989 £989 4.9% 
Terminal care 
costs 
£4,580 £4,986 -£406 £406 2.0% 
Adverse events £3 £118 –£115 £115 0.57% 
Total XXXXXX £98,219 XXXXXX XXXXXX XXXXXX 
Two-step Korn model 
Treatment costs XXXXXX £68,038 XXXXXX XXXXXX XXXXXX 
Administration 
costs 
£5,092 £1,311 £3,780 £3,780 18.43% 
Routine care 
costs 
£18,198 £12,239 £5,959 £5,959 29.0% 
On progression 
costs  
£993 £997 -£4 £4 0.0% 
BSC/palliative 
care costs 
£10,647 £8,635 £2,013 £2,013 9.8% 
Terminal care 
costs 
£4,580 £4,696 -£116 £116 0.6% 
Adverse events £3 £118 –£115 £115 0.56% 
Total XXXXXX £96,035 XXXXXX XXXXXX XXXXXX 
Source: Company model 
The incremental cost effectiveness ratios (ICERs) generated by the company model are 
presented in Table 27. 
Confidential until published 
Talimogene laherparepvec for treating metastatic melanoma [ID508] 
Single Technology Appraisal: Evidence Review Group Report 
Page 75 of 134 
Table 27 Company base case cost effectiveness results using the modified Korn model and 
two-step Korn model to project survival for patients treated with ipilimumab 












Modified Korn model 
Ipilimumab £98,219 4.90 3.57 - - - - 
T-VEC £100,166 6.66 4.91 £1,947 1.76 1.34 £1,458 
Two-Step Korn model 
Ipilimumab £96,035 6.16 4.61 - - - - 
T-VEC £99,024 6.66 4.95 £2,989 0.50 0.35 £8,654 
ICER=incremental cost effectiveness ratio; Inc=incremental; LYG=life years gained; QALYs=quality adjusted life years 
Source: CS, Table 5-25 
 
When the modified Korn model is used to project the efficacy of ipilimumab the model results 
show that treatment with T-VEC leads to a lifetime increase in cost to the NHS of £1,947 per 
patient and delivers an additional 1.34 quality adjusted life years (QALYs) per patient. The 
resultant ICER for this comparison is £1,458 per QALY gained.  
When the two-step Korn model is used to project the efficacy of ipilimumab the model results 
show that treatment with T-VEC leads to a lifetime increase in cost to the NHS of £2,989 per 
patient and delivers an additional 0.35 QALYs per patient. The resultant ICER for this 
comparison is £8,654 per QALY gained.  
The company recognises that a confidential PAS (comprising a simple discount) means that 
the real cost of ipilimumab to the NHS is less than the list price. As the details of this PAS 
are not publicly available, the company calculated ICERs per QALY gained for a range of 
simple discounts (0% to100%) for ipilimumab. In the analyses that used the modified Korn 
model (or two-step Korn model) to model the efficacy of ipilimumab, the ICER remained 
below a threshold of £30,000 per QALY gained when a discount of 55% (or 10%) or less 
was assumed.  
5.3.9 Sensitivity analyses 
Deterministic sensitivity analyses 
The company carried out a range of deterministic sensitivity analyses based around six 
variables: duration of treatment; response rates; administration costs; discount rates; health 
state utility values; and costs of terminal care. Variations in ICERs per QALY gained were 
generated by increasing and decreasing the parameter values by 20%. The ICERs per 
QALY gained for the ten most influential parameters following the modified Korn model and 
two-step Korn model are shown in Table 28 and Table 29 respectively. 
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Table 28 Ten most influential deterministic sensitivity analyses (modified Korn model) 
Variable 
ICER per QALY gained 
Range 20% decrease in 
base case value 
20% increase in 
base case value 
Ipilimumab duration of treatment £11,754 -£8,810 £20,564 
Ipilimumab price £11,647 -£8,732 £20,379 
T-VEC duration of treatment -£8,443 £11,359 £19,802 
T-VEC price: main dose -£6,850 £9,765 £16,615 
T-VEC response rate: SD £41 £2,874 £2,833 
Ipilimumab response rate: PD £2,385 £531 £1,854 
T-VEC administration cost per cycle £742 £2,174 £1,432 
T-VEC price: first dose £853 £2,063 £1,210 
Discount rate: costs £1,971 £986 £985 
T-VEC response rate: PR £1,015 £1,901 £887 
ICER=incremental cost effectiveness ratio; PD=progressed disease; SD=stable disease; PR=partial response 
Source: Company model 
 
Table 29 Ten most influential deterministic sensitivity analyses (two-step Korn model) 
Variable 
ICER per QALY gained 
Range 20% decrease in 
base case value 
20% increase in 
base case value 
Ipilimumab duration of treatment £48,470 -£31,050 £79,520 
Ipilimumab  price £48,056 -£30,747 £78,803 
T-VEC duration of treatment -£29,630 £46,939 £76,570 
T-VEC price: main dose -£23,469 £40,778 £64,247 
T-VEC response rate: SD £2,565 £14,744 £12,179 
Ipilimumab response rate: SD £11,513 £5,796 £5,717 
T-VEC administration cost per cycle £5,885 £11,424 £5,539 
HSUV: PR £6,827 £11,817 £4,990 
Ipilimumab response rate: PD £11,144 £6,165 £4,978 
T-VEC price: first dose £6,315 £10,994 £4,679 
ICER=incremental cost effectiveness ratio; PD=progressed disease; SD=stable disease; PR=partial response; 
HSUV=health state utility value 
Source: Company model 
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Scenario analyses 
A wide range of scenario analyses was undertaken by the company to assess the structural 
and methodological assumptions implemented in the model. No scenarios had an impact 
greater than +/-£5,000 on the base case ICERs per QALY gained when using the modified 
Korn model. However, two scenarios had an impact of over £5,000 when using the two-step 
Korn model. These two scenarios were related to the inclusion of an accelerated dosing 
schedule for patients treated with T-VEC and to including zero costs for routine treatment for 
patients with CR. Results from these scenarios are shown in Table 30. 
Table 30 Scenario analyses that change the ICER per QALY gained by at least £5,000 
CR=complete response; ICER=incremental cost effectiveness ratio; QALY=quality adjusted life year 
Source: CS, adapted from Table 5-32 
Probabilistic sensitivity analyses 
The company undertook two probabilistic sensitivity analyses (PSAs) to generate ICERs per 
QALY gained. One used the modified Korn model to model the efficacy of ipilimumab and 
the other used the two-step Korn model. The PSAs were carried out using 1,000 iterations of 


















Base case result: £1,458 - £8,654 - 




















Total number of 













Mean number of 
injections post 
first injection:  
XXX 
 
Total number of 
vials:  XXX 
£4,124 +£2,666 £18,964 +£10,310 







Costs of routine 
treatment with 
CR are £86.52 for 
both T-VEC and 
ipilimumab 
Costs of routine 
treatment with 
CR assumed to 
be zero for both  
T-VEC and 
ipilimumab 
£56 -£1,402 £2,958 -£5,696 
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the cost effectiveness model. The cost effectiveness planes for these comparisons are 
shown in Figure 4 and Figure 6 respectively, whilst the cost effectiveness acceptability 
curves (CEACs) are shown in Figure 5 and Figure 7 respectively. 
When the modified Korn model was used to model the efficacy of treatment with ipilimumab 
the mean probabilistic ICER for T-VEC vs ipilimumab was £1,680 per QALY gained. This 
value is £222 greater than the deterministic ICER for this comparison. The CEAC shows that 
the chance of treatment with T-VEC being cost effective at a threshold of £20,000 (or 
£30,000) per QALY gained is 98.39% (or 99.7%).  
 
Figure 4 Cost effectiveness plane - modified Korn model 
Source: Company model 
 
Figure 5 Cost effectiveness acceptability curve - modified Korn model (willingness-to-pay 
threshold £20,000)  
Source: CS, Figure 5-42 
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When the two-step Korn model was used to model the efficacy of treatment with ipilimumab 
the mean probabilistic ICER for treatment with T-VEC vs ipilimumab was XXXXXX per QALY 
gained, which is XXXXXX less than the deterministic ICER. This reflects the inherent 
uncertainty in the calculation of the two-step Korn model. The CEAC shows that the chance 
of treatment with T-VEC being cost effective at a threshold of £20,000 (or £30,000) per 
QALY gained is 80.02% (or 81.83%).  
 
Figure 6 Cost effectiveness plane (two-step Korn model) 
Source: Company model 
 
Figure 7 Cost effectiveness acceptability curve (two-step Korn model) 
Source: CS, Figure 5-43 
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Table 31 and Table 32 show that the mean PSA and deterministic ICERs per QALY gained 
when the two different Korn models were used to model the efficacy of ipilimumab treatment. 
The PSA ICER generated when the modified Korn model was used is positive and similar to 
the associated deterministic ICER. However, when the two-step Korn model was used the 
mean PSA ICER is negative and substantially different from the deterministic ICER, which 
reflects the uncertainty in the estimate. 
Table 31 Deterministic and PSA ICER results (modified Korn model) 








Deterministic results  
T-VEC £100,166 4.91 
£1,947 1.34 £1,458 
Ipilimumab £98,219 3.57 
Probabilistic sensitivity analysis results 
T-VEC £101,212 4.79 
£2,083 1.24 £1,680* 
Ipilimumab £99,129 3.56 
QALY=quality adjusted life years 
*ERG calculated value from incremental cost and QALY values given in CS, as ICER given in CS was calculated 
incorrectly 
Source: CS table 5-31 and company model 
Table 32 Deterministic and PSA ICER results (two-step Korn model) 






Deterministic results  
T-VEC £99,024 4.95 
£2,989 0.35 £8,654 
Ipilimumab £96,035 4.61 
Probabilistic sensitivity analysis results 
T-VEC £100,450 4.82 
-£3,091 0.24 -£12,879* 
Ipilimumab £103,541 4.58 
QALY=quality adjusted life years 
*ERG calculated value from incremental cost and QALY values given in CS, as ICER given in CS was calculated 
incorrectly 
Source: CS table 5-31 and company model 
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5.3.10 Model validation and face validity check 
Clinical benefit 
The company compared the model’s predicted outcomes for patients treated with T-VEC, 
both short- and long-term, with the reported outcomes from the OPTiM trial4 and found them 
to be comparable. The company notes that the ipilimumab survival outputs estimated by the 
model (which are based on the modified Korn model and two-step Korn model) differ from 
clinical trial19,22 results. 
Model validation 
The company states that the general model structure is consistent with metastatic melanoma 
models (TA321,14 TA319,11 TA26913) that have previously been accepted by NICE as part of 
STAs and that assumptions relating to current treatment options were supported by key 
opinion leaders practicing in the UK. The company reports that it used the input of these 
clinicians and health economic experts to inform the methods for survival analyses, dosing 
and application of AEs. The opinions provided by these experts were also used to inform the 
decision to use the modified Korn model and two-step Korn model to model survival for 
patients treated with ipilimumab.  
The company reports that quality-control procedures for verification of input data and coding 
were performed by staff not involved in the model development. A checklist was used to 
verify the results, which were found to be consistent. Furthermore the input data were found 
to be robust to extreme values. 
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erratum 
5.4 ERG’s critique of the submitted economic evaluation 
5.4.1 NICE reference case checklist  
Table 33 NICE Reference case checklist completed by ERG 
Attribute Reference case 
Does the de novo economic evaluation 
match the reference case? 
Decision problem The scope developed by NICE Partial. The economic evaluation considers a 
subgroup of that issued in the final NICE scope in 
line with the anticipated licence. The decision 
problem addressed in the submission is adults with 
unresectable melanoma that is regionally or 
distantly metastatic with no bone, brain, lung or 
other visceral disease (disease stage IIIB–stage 
IV M1a) 
Comparator(s) As listed in the scope 
developed by NICE 
Partial. The company considers that BRAF inhibitors 
are unlikely to be treatment options for the stage IIIB 
to stage IV M1a population and that ipilimumab is 
the primary comparator 
Perspective on costs NHS and PSS Partial. The model only includes NHS costs. 




All direct health effects, 
whether for patients or, when 
relevant, carers 
Patient related direct health effects are considered. 
No impact on carers has been considered in the 
model 
Form of economic 
evaluation 
Cost–utility analysis with fully 
incremental analysis 
Yes 
Time horizon Long enough to reflect all 
important differences in costs 
or outcomes between the 
technologies being compared 




Based on systematic review No – no connected evidence network is possible. A 
synthesised comparator was developed from three 
arms of two ipilimumab trials with adjustments to 
match baseline patient characteristics 
Outcome measure Health effects should be 
expressed in QALYs. The EQ-
5D is the preferred measure of 
HRQoL in adults 
Yes – health effects are expressed in QALYs, using 
utility estimates from other NICE appraisals which 
used the EQ-5D instrument 
Source of data for 
measurement of 
HRQoL 
Reported directly by patients 
and/or carers 
Yes, HRQoL data were collected as part of the 
OPTiM trial
4
 but these were not suitable for utility 
estimation 
Source of preference 
data for valuation of 
changes in HRQoL  
Representative sample of the 
UK population 
Yes 
Discount rate The same annual rate for both 
costs and effects (currently 
3.5%) 
Benefits and costs have been discounted at the 
3.5% rate 
Equity  An additional QALY has the 
same weight regardless of the 
other characteristics of the 
individuals receiving the health 
benefit 
All QALYs estimated by the economic model have 
the same weight 
Evidence on 
resource use and 
costs 
Costs should relate to NHS and 
PSS resources and should be 
valued using the prices relevant 
to the NHS and PSS 
Yes, partially - NHS costs, valued at relevant prices, 
have been used. PSS costs are not included in the 
model 
EQ-5D=EuroQol-5 dimension; PPS=personal social services; QALY=quality adjusted life year 
 
Confidential until published 
Talimogene laherparepvec for treating metastatic melanoma [ID508] 
Single Technology Appraisal: Evidence Review Group Report 
Page 83 of 134 
5.4.2 Drummond checklist  





Was a well-defined question posed in 
answerable form? 
No The question was well-defined but could not be 
answered with the available trial data nor via 
standard methods of evidence synthesis 
Was a comprehensive description of the 
competing alternatives given? 
Yes - 
Was the effectiveness of the programme 
or services established? 
Partially No direct RCT evidence or standard indirect 
evidence was available to compare the 
intervention to the selected comparator treatment 
Were all the important and relevant costs 
and consequences for each alternative 
identified? 
Yes - 
Were costs and consequences 
measured accurately in appropriate 
physical units? 
Yes - 
Were the cost and consequences valued 
credibly? 
Yes - 
Were costs and consequences adjusted 
for differential timing? 
Yes - 
Was an incremental analysis of costs 
and consequences of alternatives 
performed? 
Yes - 
Was allowance made for uncertainty in 
the estimates of costs and 
consequences? 
Yes Sensitivity and scenario analyses were reported 
Did the presentation and discussion of 
study results include all issues of 
concern to users? 
Partially Weaknesses in the methods used to synthesise a 
notional comparator were not fully explored 
RCT=randomised controlled trial 
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5.5 Critique of cost effectiveness analyses 
5.5.1 Reliability of the comparator used in the company model 
The comparator employed in the company model as the basis for assessing the incremental 
cost utility of T-VEC is not the comparator employed in the OPTiM trial4 (in this trial T-VEC 
was compared with GM-CSF). The comparator in the company model was synthesised from 
data describing the ipilimumab treatment arms of two clinical trials.19,22 The reliability of this 
synthesised comparator depends upon six assumptions and are each considered in detail in 
this section: 
a) Ipilimumab is the most appropriate comparator for T-VEC in the specified patient 
population (non-visceral metastatic melanoma) 
NICE has very recently recommended pembrolizumab for both first-line and second-line15 
treatment of patients with metastatic malignant melanoma. As discussed in Section 2.2 and 
Section 3.3 of this report, this means that clinicians’ first choice systemic treatment is 
expected to shift away from ipilimumab and towards pembrolizumab. Thus the outcome of 
this STA, which is necessarily focussed on ipilimumab as the prime comparator, is likely only 
to be most relevant to usual clinical practice in England for a limited period of time. 
b) Data from three arms of two published clinical trials19,22 provides a valid 
approximation to survival time profiles for patients treated with ipilimumab. 
Furthermore, this pooled dataset can be compared with the survival data 
collected during the OPTiM trial4 for patients treated with T-VEC  
The data pooled by the company in the development of a dataset for an ipilimumab 
comparator were derived from the ipilimumab plus DTIC arm of a trial that included only 
patients with previously untreated metastatic melanoma,22 and also from the two ipilimumab 
arms (ipilimumab plus gp100, and ipilimumab monotherapy) of a trial that included only 
patients with previously treated metastatic melanoma.19 This approach assumes that DTIC 
and gp100 are both ineffective, and that survival patterns are equivalent for patients treated 
with ipilimumab as first-line systemic therapy and patients for whom ipilimumab is 
administered subsequent to other treatment(s). The method of pooling used by the company 
involves calculating the combined mortality risk for separate arbitrary time periods across all 
of the trial arms being combined. This involves the assumption that censoring occurs at a 
constant rate within each time period for each of the data sets pooled and provides a reliable 
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approximation to full pooling. However, where possible, pooling should be carried out based 
on the K-M estimates using recorded patient event times. 
c) The Korn proportional hazard model is an appropriate method for adjusting 
ipilimumab survival trends for differences in baseline patient characteristics 
between the ipilimumab trial data and the T-VEC data from the OPTiM trial4  
The Korn model51 was originally developed to help clinical researchers design new clinical 
trials of potentially promising treatments for patients with metastatic melanoma. Survival data 
were gathered from 70 individual trial arms from 42 separate Phase II trials relating to 
patients with stage IV disease in which the substances tested were deemed to be clinically 
ineffective. The Korn model was calibrated against these data, including only patients with 
stage IV disease. The ERG considers that this model is not appropriate for correcting the 
most important difference in prognostic factors between patients in the OPTiM trial4 and 
patients in the ipilimumab trials.19,22 In the OPTiM trial 54.7% of T-VEC patients had stage 
IIIB, stage IIIC or stage IV M1a disease compared with less than 20% in the ipilimumab 
trials.19,22 In addition, the Korn data are dominated by the most seriously affected patient 
groups (stage IV M1b and stage IV M1c) rather than by stage IV M1a patients who are the 
only stage IV patients featured in the target subgroup of the OPTiM trial4 for this appraisal. In 
previous NICE appraisals of ipilimumab (TA26812 and TA31911), it was argued that that the 
use of the Korn model was appropriate as the trial populations consisted overwhelmingly of 
stage IV patients. However, this is not the case in this STA as the recommended treatment 
subgroup of the OPTiM trial4 is restricted to patients with stage IIIB, stage IIIC and stage IV 
M1a disease. 
d) The modified Korn model is superior to the original published Korn model 
The unpublished modified Korn model was developed by the manufacturer of ipilimumab as 
an alternative to the original Korn model for use in the recent NICE appraisal of ipilimumab 
for patients with previously untreated metastatic melanoma (TA31911). There is no 
information in the public domain relating to the methods employed to modify the original 
model or to the data used to calibrate the modified model. However, it is reasonable to 
assume that the same, or similar, patient data were involved, and that therefore the 
problems already described (point c) regarding the use of the original Korn model are also 
valid for the modified version. 
The modified Korn model includes five rather than four adjustment factors, adding elevated 
LDH whilst substituting a single ECOG variable (0 vs >0) in place of two ECOG variables 
Confidential until published 
Talimogene laherparepvec for treating metastatic melanoma [ID508] 
Single Technology Appraisal: Evidence Review Group Report 
Page 86 of 134 
previously used (0 vs 1 vs 2+), alongside gender, visceral metastases and brain metastases. 
This alteration has the effect of placing a high weight on LDH status, but reducing the 
influence of gender, visceral metastases and ECOG PS. In the derivation of the AJCC 2009 
melanoma staging classification,1 elevated LDH was only considered relevant to patients 
with stage IV disease for whom it was found to be equivalent in effect to the most severe 
form of metastatic melanoma (non-pulmonary visceral stage IV M1c), so that any patient 
with distant metastases and elevated LDH is automatically assigned to the stage IV M1c 
category. 
The company base case scenario only includes patients with stage IIIB, stage IIIC and IV 
M1a, so the new elevated LDH factor in the modified Korn model is irrelevant for this 
population. However, its calibration (based only on stage IV patients) has reduced the 
coefficients for the gender, ECOG and visceral metastases variables in the original equation. 
Thus the use of the modified Korn model introduces even greater uncertainty, and probable 
bias, than the original Korn model. The ERG therefore considers that the company’s 
adjusted ipilimumab survival curves that employ the modified Korn model lack credibility. 
e) An additional ‘two-step’ adjustment may also be necessary and appropriate 
A further complication is presented by the possibility that the effectiveness of ipilimumab in 
the main trials19,22 may vary significantly by stage of disease, so that a simple average effect 
over all trial patients may not adequately represent the true effectiveness of ipilimumab in a 
population similar to that enrolled in the OPTiM trial.4 The company has attempted to correct 
for this additional case-mix imbalance by using a further application of the modified Korn 
model, resulting in a range of possible OS ipilimumab trends above and below the profile 
obtained by using the modified Korn model alone. Of course, the problems previously 
described are thereby confounded further, so that a very wide range of possible ipilimumab 
results is considered by the company to be feasible (and therefore a correspondingly wide 
range of incremental life years and QALYs have been generated). 
f) PFS comparator data may be synthesised using the same modified Korn model as 
for OS 
It is stated in the CS (page 89): 
“In the absence of a Korn equation for PFS and the high correlation likely between PFS and 
OS, the same adjustments were applied to PFS.” 
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However it is not the case that the multivariate model results reported in the Korn 
publication51 are not available for PFS. In Table 2 of the published paper,51 a full description 
is provided of a similar multivariate model for adjusting PFS data. The distributional model 
features three significant variables used to adjust for differences in baseline characteristics 
(PS 0/1/2+, gender and age). This PFS model is clearly quite different from the equivalent 
Korn OS model, the OS model in the modified Korn model and the two-step OS Korn model. 
In particular, it is noteworthy that where the same factors are present in both the Korn OS 
and PFS models, the estimated coefficient values are substantially lower in the PFS model 
than in the OS model. 
The ERG therefore concludes that the company’s use of the same OS modified Korn model 
for both OS and PFS is inappropriate and is likely to lead to misrepresentation of estimated 
PFS trends for ipilimumab and substantial additional uncertainty in estimated model 
outcomes, which in turn will affect the balance between survival time spent in the PFS and 
progressed health states. 
ERG summary 
The company is to be complemented for their thorough approach to the problem of defining 
a credible ipilimumab comparator from the available trial data. However, the difficulties 
associated with pooling data from very different clinical trials, and then applying multiple 
case-mix corrections in an effort to standardise published outcomes to the very different T-
VEC population in the OPTiM trial,4 serve only to demonstrate the very substantial 
uncertainty that attaches to the methods used and therefore to the outcome estimates 
obtained. The ERG concludes that the derived ipilimumab survival trends cannot be credited 
with any degree of reliability, and are an inadequate basis for estimating the cost 
effectiveness of T-VEC in the specified patient population, i.e. patients with non-visceral 
metastatic melanoma. 
Confidential until published 
Talimogene laherparepvec for treating metastatic melanoma [ID508] 
Single Technology Appraisal: Evidence Review Group Report 
Page 88 of 134 
5.5.2 Lifetime survival projection for patients treated with T-VEC in the OPTiM 
trial 
Within the company model different methods are applied sequentially to estimate OS over a 
period of 30 years from randomisation into the OPTiM trial.4 The four phases, which are also 
displayed in Figure 8 are as follows: 
- Phase 1a (weeks 1-177): direct use of results from K-M analysis of the OPTiM trial4 data 
- Phase 1b (weeks 178-269): estimated OS based on an exponential projection model 
developed by the company (no details are provided in the CS) 
- Phase 2 (weeks 270-520): estimated OS based on survival trends calculated from case-
mix adjusted published analyses of a patient registry used in the development of the 
AJCC staging classification system1  
- Phase 3 (weeks 521-1560): estimated OS based on applying age/sex adjusted life table 
mortality rates. 
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Figure 8 Company long-term T-VEC OS projection compared to ERG simple exponential alternative projection 
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It is generally appropriate to use K-M analysis results directly in a model prior to use of 
projection methods. However, in this case, it appears that the final analysis of the trial data 
(CS, Figure 4-6) has not been used in the model, which includes only OS data from the 
earlier, less mature, data cut. The ERG has carried out a curve-fitting exercise to a re-
analysis of the final data cut which was requested during the clarification process. The ERG 
has found that a 2-part exponential model (Figure 9) closely follows the trial OS data from 9 
months until the last recorded death (47 months).  
It is noteworthy that the company model exponential trend (Phase 1b in Figure 8) deviates 
markedly from the final recorded trial data and leads to a clear separation from the 
exponential trend identified by the ERG. This results in a much more advantageous OS 
estimate for T-VEC compared to the long-term projection resulting from the fitted ERG curve 
(Figure 9). 
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erratum 
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In Phase 2, the company model uses a trend derived from published results of the analyses 
of patient registry data on which the AJCC staging classification1 was based, with the 
addition of UK life table information68 (though the exact nature of this adjustment has not 
been described in the CS). There are several difficulties with this method: 
- The AJCC survival trends1 only provide results for a maximum of 10 years from the date 
of diagnosis for patients with stage I to stage III disease, and from the recorded time of 
first distant metastases for patients with stage IV disease. Assuming that the submitted 
model uses a case-mix adjusted combination of AJCC1 trends for stage IIIB, stage IIIC 
and stage IV M1a melanoma, the estimates used in the company model will mix patients 
at very different times in their disease career, starting from 0 to more than 20 years after 
first diagnosis. The relevance of such mixed AJCC1 adjusted mortality estimates to the 
period up to 10 years from randomisation is highly questionable. 
- The data on which the AJCC1 analysis was performed were gathered prior to the current 
era of novel immunological treatments; these newer treatments have significantly altered 
the prospects for many patients. The AJCC1 trends therefore probably represent a 
reasonable approximation to the prognosis of patients with access to only minimally 
effective treatments. The application of these data to extend the survival data in the 
OPTiM trial4 implies that T-VEC has little or no continuing benefit after 5 years. 
- The junction between Phase 1b and Phase 2 in the company model features a sudden 
increase in the mortality rate after exactly 270 weeks (62.1 months). However, there 
does not appear to be any clinical justification to support such a sudden change in the 
long-term mortality rate. 
- For Phase 3, UK life table mortality rates68 without adjustment, other than for age and 
sex, are applied within the company model. This implies that the remaining cohort of 
long-term survivors is at the same mortality risk as the general population. In effect, this 
means that the malignant melanoma suffered by all surviving patients is suddenly cured 
10 years after entering the trial. The ERG is not aware of any evidence supporting such 
a claim. 
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ERG exploratory OS projections 
The ERG has explored two approaches to the estimation of long-term OS for patients 
receiving T-VEC: 
- Simple exponential modelling of the OPTiM trial4 final data cut for T-VEC to 30 
years (as shown in Figures 8 and 9). 
- Modelling trends in PFS and post-progression survival (PPS) separately before 
combining the results to obtain an estimate for the mean OS. 
 
Firstly, K-M analysis results for PPS in the OPTiM trial4 (provided in response to an ERG 
clarification request) were reviewed and found to indicate that there is no basis for 
considering that after patients have suffered disease progression their future survival 
prognosis will be affected by prior treatment allocation. Therefore, the PPS data from both 
trial arms were pooled and re-analysed, resulting in a simple exponential (constant risk) 
model applicable to all progressed patients, with an expected mean PPS of 24.7 months. 
ERG exploratory PFS projections 
Analysis of the TTF data (as a proxy for PFS) from the final data cut from the OPTiM trial4 
revealed that a 2-phase exponential model accurately represented the trial data and 
provided an appropriate basis for projecting PFS in the T-VEC arm. In order to combine PFS 
and PPS it is necessary to exclude the portion of patients whose progression event was fatal 
(estimated as 4.8%) from the projected PPS component of the combined OS estimate. 
Impact of ERG projections on the company’s ICER 
The importance of the problems identified by the ERG in relation to the company’s approach 
to estimation of long-term survival in the T-VEC arm of the OPTiM trial4 is most clearly seen 
in Figure 8 by considering the difference between the area under the survival curve in the 
company model after 30 years (108.5 months), the exploratory ERG OS exponential 
projection (73 months), and also the ERG PFS+PPS projection (68 months). The ERG’s 
projections suggest that the company estimate for the mean OS of patients treated with T-
VEC may be overstated by 49% to 59%. This will have a substantial effect on the model 
estimates of QALYs gained from treatment with T-VEC compared to any comparator, 
leading to sizeable increases in the size of estimated ICERs. 
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5.5.3 Issues related to ERG clarification questions 
The responses provided to the ERG in respect of issues of concern with the company’s cost 
effectiveness analysis are considered in this section. 
Censoring of time to event data from the OPTiM clinical trial 
The company provided the results of the requested re-analysis of OPTiM trial4 data for OS, 
PFS (TTF) and PPS (ERG clarification question B-1), together with helpful graphical 
comparisons of K-M results for each outcome. These demonstrate that the censoring 
method has little effect on the survival time pattern for OS and PPS, which is to be expected 
as death is a ‘hard outcome’ and is generally reported rapidly. However, the PFS (TTF) 
results are markedly different indicating that informative censoring consistently understates 
PFS in each patient subgroup (Figures B-7, B-8 and B9 of the company response to ERG 
clarification questions). This is important for the decision model as it alters the balance of 
patients’ projected time in PFS vs PPS, since PPS is calculated in the model as the 
difference between OS and PFS. 
Adjustment anomaly in PFS estimation 
The ERG identified an apparent anomaly in the CS (Figures 5-30 and 5-32), which appeared 
to show an unexpected alteration in the PFS profile of patients treated with T-VEC when the 
modified Korn model adjustment was active in the company model (ERG clarification 
question B-2). In response, the company explained that this change is not the direct effect of 
applying the modified Korn model adjustment (as it at first appeared to the ERG), but is due 
to the way subsequent registry data results were applied to both arms of the model, 
overriding the parametric model trends employed in the first phase of the model, which were 
found to be clinically implausible. 
The ERG is grateful for the explanation of this anomaly, and acknowledges that the logic 
alteration is conservative. However, the ERG remains concerned that it can be seen as a 
strong indicator that the methods used to fit a parametric model to the trial PFS data are 
unreliable (clinically implausible), and that the correct approach would be to employ a more 
robust method for carrying out this analysis. The ERG PFS projective model described in 
Section 5.4.2 is a suitable alternative. 
Time from diagnosis 
The mean time from diagnosis to randomisation in the OPTiM trial4 is greater than 3 years 
(Table B-5 of the company clarification response) with a standard deviation greater than 3 
years. This is comparable with MDX010-2019 in which the median time from diagnosis was 
3.1 years, with a range from 0 to 38.9 years.12 This confirms that the use of AJCC registry 
trends68 up to 10 years from diagnosis (stage IIIB and stage IIIC patients) is inappropriate 
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when a substantial proportion of patients in one (MDX010-2019) of the two trials19,22 that were 
pooled were already beyond the longevity limit of the AJCC data. This issue may also be 
true for the other ipilimumab trial (CA184-04422). 
Ipilimumab acquisition cost per dose received 
Ipilimumab treatment doses are calculated by patient body weight. The company provided 
mean body weight statistics for male and female patients who were randomised in the 
OPTiM trial4 in response to an ERG clarification request. 
A comparison with results reported from a survey of cancer patients in the UK78 suggests 
that the North American population enrolled in the OPTiM trial4 is generally heavier than the 
population typically treated in England and Wales. The UK study78 showed that, across all 
types of adult cancer, the mean body weight in UK centres was 68.1kg for females and 
77.1kg for males, whereas in the OPTiM trial4 mean weight was 79.8kg for females, and 
91.1kg for males. 
Re-estimating the average cost per patient of treating English patients with ipilimumab, using 
separate male and female calculations results in a reduction in the drug acquisition cost of 
ipilimumab by 6.7%. 
5.5.4 Other model issues 
Discounting 
The company model applies discounting to costs and outcomes on a continuous (weekly) 
basis, rather than annually in line with NHS budgeting and accounting years. This has the 
effect of reducing treatment acquisition and administration costs during the first year for both 
T-VEC and ipilimumab, as well as reducing the QALYs associated with both treatments. In 
particular, for those patients who continue on T-VEC treatment beyond 12 months, treatment 
costs are reduced from week 3 of year 1 instead of from the start of year 2. 
Health state utility values 
In the company’s base case analysis, health state utility values are taken from the NICE 
appraisal of dabrafenib (TA32114) in preference to the values obtained by the company from 
a commissioned study75 (CS, Appendix 1.7). It is the ERG’s considered opinion that the 
values obtained from the commissioned study have greater face validity than those used in 
the base case analysis. In particular, the TA32114 values poorly differentiate between distinct 
health states: there is no difference between values assigned to CR, PR and SD. Applying 
the commissioned study utility estimates reduces the number of incremental QALYs gained 
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by a small amount with a corresponding increase in the size of the estimated ICER per 
QALY gained. 
Continuity correction 
The company employs a half-cycle correction in their decision model for the estimation of 
outcomes and some costs. This method is recognised to be inaccurate except in particular 
circumstances. The ERG has applied the more generally applicable mid-cycle correction to 
the affected model outcomes. This results in a small decrease in the estimated incremental 
life years and QALYs gained, and a small increase in the estimated incremental costs per 
patient, so that the estimated ICER per QALY gained increases by a small amount. 
Terminal disutility 
The company model does not differentiate the estimated HRQoL applicable to patients in the 
PD state (which can last for an extended period) from the condition of patients in terminal 
care (usually considered as the last 2 weeks of life). Applying the utility value estimated in 
the commissioned utility study75 (CS, Appendix 1.7) for the BSC state to the last 2 weeks of 
life results in a very small increase in the incremental QALYs gained from use of T-VEC, with 
a corresponding small reduction in the size of the estimated ICER per QALY gained. 
Probabilistic ICER calculation error 
An error has been identified in the method used by the company to calculate the probabilistic 
ICER per QALY gained. In the last stage of processing the PSA data, the ICER has been 
calculated as the simple average of 10,000 simulated ICERs, instead of as the ratio of the 
combined average of 10,000 incremental costs to the combined average of 10,000 
incremental QALYs. This causes a bias in the value of the probabilistic ICER, so that the 
base case reported by the company (£1,647 per QALY gained) should in fact be £1,680 per 
QALY gained. This has no impact on the size of the estimated deterministic ICER.  
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5.6 Exploratory and sensitivity analyses undertaken by the ERG 
In view of the serious problems identified by the ERG relating to the construction of an 
ipilimumab comparator for use in the company model, the ERG does not consider that any 
estimates of the cost effectiveness of T-VEC compared with ipilimumab in patients with non-
visceral metastatic disease are reliable. Using different assumptions, widely differing 
estimated ICERs can be obtained, from T-VEC appearing to be dominant compared with 
ipilimumab (better outcomes at lower cost) to T-VEC appearing to be dominated by 
ipilimumab (poorer outcomes at higher cost), so that quoting any specific unreliable ICERs 
would be potentially misleading. 
However, it is possible to offer a broad indication of the relative significance of the issues 
identified by the ERG: 
- The company base case analysis uses the list price for ipilimumab and the proposed 
list price for T-VEC. Thus the current PAS price for ipilimumab is not applied. 
Results from the company model suggest that the estimated cost effectiveness of T-
VEC is substantially worsened when using the reduced ipilimumab PAS price. 
- Taken separately, the ERG approach to estimating OS and PFS have contrary 
effects on estimated cost effectiveness: the revised OS estimate appears to improve 
the position of T-VEC, whereas the revised PFS estimate worsens it. 
- All of the other issues identified when considered individually have a very small 
impact on the position of T-VEC, generally increasing the size of the estimated ICER 
per QALY gained. 
- When the PAS for ipilimumab is applied alongside the ERG’s OS and PFS estimates, 
the ICER per QALY gained is very severely increased to a value far beyond the 
range normally considered acceptable. 
- The cost effectiveness of T-VEC compared to ipilimumab varies from dominating 
(more effective at less cost in the modified Korn model) to being dominated (less 
effective at greater cost in the two-step Korn model). 
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5.7 Conclusions of the cost effectiveness section 
In the absence of direct trial evidence for a clinically appropriate comparator, estimation of 
the relative cost effectiveness of T-VEC vs current clinical practice is rendered extremely 
difficult. The company’s proposal for a constructed comparator, based on the pooling of data 
from two ipilimumab trials19,22 adjusted for baseline characteristics and using a proportional 
hazard model derived from a patient population that is very different from the anticipated T-
VEC licensed population, is considered by the ERG to be ill-conceived and unreliable as the 
basis for determining cost effectiveness. Moreover, due to the high degree of volatility 
exhibited in model-generated quantitative estimates of cost effectiveness when ERG 
amendments are implemented, the ERG does not consider that it is appropriate to present 
detailed alternative ICERs for this questionable comparison. 
The ERG has also identified serious problems relating to the long-term projection of survival. 
These relate to the selective use of registry data and life table estimates. The company 
appeals to precedents from previous appraisals in melanoma to justify their approach to 
projecting survival. However, the ERG considers that the populations studied previously 
differ substantially from the target population proposed for T-VEC and from the population on 
which the Korn model51 was bas d, so that the appeal to such precedents is not appropriate. 
Had the OPTiM trial4 included an alternative treatment arm involving a recognised alternative 
treatment (e.g. DTIC), then indirect evidence synthesis may have been appropriate. 
Unfortunately, it is not possible to determine whether GM-CSF constitutes an active or 
inactive comparator for T-VEC, so the data from the comparator arm of the OPTiM trial4 can 
play no part in assessing the extent to which T-VEC benefits patients with non-visceral 
metastatic disease compared to current practice. 
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6 IMPACT ON THE ICER OF ADDITIONAL CLINICAL AND 
ECONOMIC ANALYSES UNDERTAKEN BY THE ERG 
As concluded in Section 5.7, due to the issues associated with T-VEC data and the method 
employed to construct a synthesised ipilimumab comparator, the ERG does not consider 
that it is appropriate to present detailed alternative ICERs for T-VEC vs ipilimumab. 
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7 END OF LIFE 
The company has not made a case for T-VEC to be considered under NICE’s End-of-Life 
criteria.  
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8 DISCUSSION 
Evidence from the OPTiM trial 
T-VEC is expected to be licensed for the treatment of patients with unresectable melanoma 
that is regionally or distantly metastatic (stage IIIB, stage IIIC and stage IV M1a) with no 
bone, brain, lung or other visceral disease. In practice, the melanoma must also be 
injectable. Evidence for the efficacy of T-VEC treatment in this population has been obtained 
from a post-hoc analysis of data from patients with non-visceral metastatic disease who took 
part in the OPTiM trial4. 
The ERG considers that the efficacy results for the OPTiM trial4 ITT population (a broader 
patient population that also includes patients with stage IV M1b and stage IV M1c disease), 
all of which favour T-VEC, may be subject to bias. This is because the trial lacked blinding, 
employed limited central assessment and the proportion of patients dropping out of the GM-
CSF arm was higher than that associated with the T-VEC arm. All of these limitations also 
apply to the analyses carried out on data collected from the subgroup of patients with non-
visceral metastatic melanoma, with the additional concern that these analyses were not pre-
specified. The ERG notes that, for this non-visceral metastatic disease subgroup, the 
differences in treatment effect between the two trial arms, for all efficacy outcomes, were 
large. This suggests that, despite the identified limitations, for these patients, the conclusion 
that T-VEC is a more efficacious treatment option than GM-CSF may be credible. However, 
the ERG has concerns relating to the validity of this subgroup as it comprises both patients 
with stage III and stage IV disease. This is of concern as it is likely that the disease trajectory 
of patients differs by stage of disease which means this is not a relatively homogeneous 
patient group. 
In summary, results from the OPTiM trial4 show that T-VEC is clinically superior to GM-CSF. 
However, GM-CSF is not used in the NHS to treat patients with melanoma and, therefore, 
for the purposes of this STA, is not considered to be a relevant comparator 
Applicability of the OPTiM trial results to clinical practice 
The ERG considers that the characteristics of patients included in the OPTiM tria,4 with non-
visceral metastatic disease, are generally similar to the patient population likely to be 
considered for treatment with T-VEC in clinical practice in England. In this respect, the 
results from the OPTiM trial4 are generalisable to patients seen in clinical practice in 
England. 
Results from the OPTiM trial4 show that, for patients treated with T-VEC, measures of ORR, 
DRR and TTF were better in the subgroup of patients with non-visceral metastatic disease 
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than in the whole trial arm: 40.5% vs 26.4%, 25.2% vs 16.3% and 13.1 months vs 8.1 
months respectively. In addition, the results of an analysis conducted by the FDA,37 of data 
from the subgroup of patients with non-visceral metastatic disease, suggest that patients 
who had very small lesions (<1cm2) were more likely to respond to T-VEC than the overall 
population: 30.4% vs 10.1% respectively. It is, therefore, possible that lesion size is also 
related to clinical effectiveness. 
Survival results from the OPTiM trial4 show that, for patients treated with T-VEC, OS benefit 
is extended further in the subgroup of patients with non-visceral metastatic melanoma than it 
is in the whole trial arm: 46.8 months vs 23.3 months respectively.  
Results from the OPTiM trial4 also suggest that T-VEC is a relatively safe treatment option. 
The most common AEs were flu-like symptoms. Patients experienced relatively few 
treatment-related Grade 3 to 5 AEs, treatment related SAEs or AEs leading to treatment 
discontinuation. However, evidence describing the effects of long-term exposure to T-VEC is 
currently limited, as is the extent of the risk of infection transmission from patients to close 
contacts or carers (T-VEC is expected to have biological properties that are similar to wild 
type HSV-1 with regard to viral shedding). The safety profile of T-VEC is considered to 
compare favourably to the safety profiles of other currently available treatment options.  
Comparison of T-VEC with relevant treatment options  
The relevant comparators specified in the NICE scope and included in the company’s 
decision problem were ipilimumab, vemurafenib and dabrafenib. Ipilimumab was considered 
by the company to be the primary comparator. In late 2015, NICE recommended that 
pembrolizumab should be made available for the treatment of NHS patients with malignant 
melanoma (both those previously treated,15 and those who had not been previously 
treated,16 with ipilimumab). The ERG’s expert clinical advisor has suggested that clinicians 
may now shift from prescribing ipilimumab to prescribing pembrolizumab, making the latter 
the most appropriate alternative treatment for the majority of patients for whom treatment 
with T-VEC is being proposed. The ERG recognises, however, that pembrolizumab was not 
recommended by NICE at the time when the company produced its submission.  
The only published trial results describing the efficacy of any treatment for patients with non-
visceral metastatic melanoma are those from the OPTiM trial;4 in this trial, these patients 
constituted 57% of the overall trial population. Relevant trials17-22 assessing the efficacy of 
other currently recommended treatments by NICE,11-16 only include relative few patients with 
non-visceral metastatic disease, fewerthan 20% of included patients. No subgroup analyses 
were conducted for this specific patient population in any of these trials. 
Confidential until published 
Talimogene laherparepvec for treating metastatic melanoma [ID508] 
Single Technology Appraisal: Evidence Review Group Report 
Page 102 of 134 
As there was insufficient trial evidence to allow the efficacy of T-VEC to be compared with 
any of the comparators listed in the NICE scope, the company, after exploring a number of 
alternative methods, determined that the best approach was to generate a synthesised 
ipilimumab comparator using either the modified Korn model or the two-step Korn model. 
However, the ERG also considers that neither the modified Korn model nor the two-step 
Korn model enables a robust ipilimumab comparator to be created.  
Currently, for a small proportion of patients with metastatic non-visceral melanoma seen in 
NHS clinical practice, a ‘wait and watch’ policy (in which no treatment is offered) is 
employed. Such a policy is likely to be favoured for the treatment of patients for whom the 
potential side-effects from immunotherapy outweigh the potential benefits from treatment. 
The ERG is not aware of any relevant trials of a ‘wait and watch’ policy. It may be that the 
results from the GM-CSF  arm of the OPTiM trial4 are similar to those expected from a ‘wait 
and watch’ policy as GM-CSF is not thought to be an active cancer treatment. However, 
although GM-CSF is not a recognised cancer treatment it is, nevertheless, not the same as 
‘no treatment’. For a minority of patients in the OPTiM trial,4 improved outcomes were 
observed for some patients treated with GM-CSF. Furthermore, some Grade 1 and 2 AEs 
were associated with GM-CSF treatment, most notably fatigue and injection-site erythema. A 
‘wait and watch’ policy would not be expected to result in improved outcomes, nor would 
such an approach be expected to result in AEs. 
Expert advice to the ERG has highlighted that there is a very small group of patients with 
injectable non-visceral metastatic melanoma for whom treatment with an immunotherapy is 
not appropriate. This group includes patients with auto-immune diseases, such as 
rheumatoid arthritis, and those with inflammatory diseases, such as ulcerative colitis. 
Furthermore, the ERG has received clinical advice which suggests that for many patients in 
clinical practice, the most appropriate comparators to T-VEC are either isolated limb 
perfusion or electrochemotherapy, rather than an immunotherapy or a BRAF inhibitor.  
Patient experience of injectable treatments is not discussed in the CS. The ERG is not 
confident that all patients with injectable melanoma will be accepting of this type of treatment 
every 2 weeks over a long period of time. 
Appropriate line of treatment for T-VEC 
The OPTiM trial4 included a mix of patients treated in the first-line setting and those receiving 
T-VEC as a later line of treatment. Results for this mixed cohort are presented in the CS and 
the company model does not differentiate by line of treatment. It is, however, stated in the 
draft EPAR5 that the efficacy of T-VEC can only be considered established in the first-line 
setting. In the FDA briefing document37 it is suggested that the overall risk-benefit profile of 
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T-VEC shows most benefit to patients receiving first-line treatment. Furthermore, within the 
draft SmPC,36 there is a caution that the efficacy data supporting the use of T-VEC in second 
or later line treatment settings are limited.  
The lack of confidence in the efficacy of T-VEC as a second (or later) line of treatment is 
largely due to the fact that, during the period when the OPTiM trial4 was conducted, first-line 
treatment options for patients were different from those available to such patients today. This 
means that the patients in the OPTiM trial4 who received T-VEC as a second- (or  later) line 
of treatment will be different from the patients receiving T-VEC as a second- (or later) line of 
treatment in clinical practice today. In addition, it is reported in the draft EPAR5 that there is a 
strong correlation between line of therapy and disease stage; line of therapy was not 
retained as an independent predictor for DR in a multivariate analysis considering disease 
stage. 
Treatment with T-VEC can be continued even if there is some evidence of disease 
progression, with a minimum of 6 months of treatment being recommended. The EMA5 
raised concern that, for some patients, next-line treatment may commence later than if an 
alternative to T-VEC had been administered at the time of disease progression. The ERG 
considers that, because injectable melanoma entails lesions that can be clearly seen by the 
treating clinician, unnecessary treatment delays are unlikely since, if there is evidence of 
rapid progression, clinicians would not delay next-line treatment in clinical practice.   
Company’s cost effectiveness estimates 
The ERG does not consider that the cost effectiveness results presented by the company 
are reliable. The reasons that support this conclusion relate primarily to the clinical evidence 
employed within the model and the methods used in the company model to project survival. 
There are four main clinical issues that cast doubt on the reliability of the company’s cost 
effectiveness results. The first issue is whether ipilimumab is the most appropriate 
comparator to include in the company’s baseline cost effectiveness analysis. The second 
and third issues relate to factors that affect patients’ disease trajectory, namely (a) that the 
subgroup of patients with injectable non-visceral metastatic disease includes both patients 
with stage III and those with stage IV disease, and (b) that this subgroup includes both 
patients receiving T-VEC as a first-line treatment and those receiving it as a later line of 
treatment. The fourth issue is that the relative clinical effectiveness of T-VEC compared with 
any treatment currently used in clinical practice is unknown. 
The methods employed within cost effectiveness models to project survival (PFS and OS) 
have a major influence on the magnitude of cost effectiveness results. The ERG considers 
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that the methods employed by the company to project OS for patients receiving T-VEC lack 
face validity. In addition, although the ERG commends the company on its endeavours to 
construct comparator data to enable the cost effectiveness of T-VEC to be compared with 
that of ipilimumab, the ERG does not consider that this synthesised comparator is sufficiently 
reliable to support a valid assessment.  
The high degree of uncertainty associated with the model results is of particular concern to 
the ERG. When cost effectiveness estimates are generated using the company’s 
synthesised ipilimumab comparators and the ERG’s preferred OS and PFS projections for T-
VEC (based on data from the OPTiM trial4), the cost effectiveness of T-VEC compared with 
ipilimumab varies from dominating (more effective at less cost in the modified Korn model) to 
being dominated (less effective at greater cost in the two-step Korn model). 
Due to the issues relating to the clinical data, the absence of a credible comparator and the 
methods used by the company to project patient survival, the ERG does not consider that it 
is appropriate to present detailed alternative ICERs. However, results from exploratory 
analyses carried out by the ERG indicate that the 30-year mean survival for patients treated 
with T-VEC in the company model may be overstated by 49% to 59%, indicating the high 
level of uncertainty associated with the submitted cost effectiveness estimates. 
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9 OVERALL CONCLUSIONS 
Results from the OPTiM trial4 suggest that treatment with T-VEC is of superior efficacy to 
GM-CSF for a number of outcomes, including OS, in patients with injectable unresectable 
melanoma that is regionally or distantly metastatic (stage IIIB, stage IIIC and stage IV M1a) 
with no bone, brain, lung or other visceral disease. However, GM-CSF is not used in the 
NHS to treat patients with melanoma and, therefore, for the purposes of this STA, is not 
considered to be a relevant comparator. It has not been possible to obtain data that would 
allow the efficacy of T-VEC to be compared with any of the comparators currently used in 
NHS clinical practice to be undertaken with confidence.  
The company has presented results that show the relative cost effectiveness of treatment 
with T-VEC compared with ipilimumab. However, the ERG considers that the company’s 
synthesised comparator (created to represent the effectiveness of ipilimumab treatment) is 
ill-conceived and provides an unreliable basis for determining cost effectiveness. In addition, 
the ERG considers that serious issues relating to the methods employed in the company 
model to project long-term survival further reduce the reliability of the company’s cost 
effectiveness results.  
9.1 Implications for research 
There has recently been a rapid increase in the number of drugs licensed (and 
recommended by NICE) to treat patients with malignant melanoma. Currently, the two most 
relevant comparators to T-VEC are pembrolizumab and ipilimumab. However, there is 
insufficient evidence available to allow a comparison of the efficacy of T-VEC to be made 
with either of these two drugs. Analyses, using data collected from patients with stage IIIB to 
stage IV M1a disease, included in both completed, ongoing and future trials assessing the 
efficacy of pembrolizumab and ipilimumab, would add to the evidence base. These analyses 
would be subject to limitations, namely that they would be an exploratory post-hoc subgroup 
comprising a mix of patients with stage III and stage IV disease and be undertaken in a small 
proportion of patients included in the trials. Thus the benefits of randomisation may be lost. 
Furthermore, not all patients would have injectable disease (the company estimates 73% of 
patients with stage IIIB to stage IV M1a have injectable disease). The analyses should 
include assessment of OS, PFS (and, where available, TTF) and ORR.  
Data supporting the long-term safety of T-VEC treatment, including the potential for viral 
shedding, is currently lacking. This issue has, however, been addressed in the RMP agreed 
between the company and the EMA,5 and post-marketing studies are being conducted to 
address this issue. 
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11 APPENDICES 
11.1 Treatment by subgroup interaction tests in OPTiM trial 
Table 35 Treatment by subgroup interaction tests for DRR and OS in OPTiM trial (ITT 
population) 
Subgroup DRR - primary analysis 
(N=295 T-VEC, 
 N=141 GM-CSF) 























Disease stage (IVRS) 
(stage IIIb / stage IIIc, stage IV M1a 
/ M1b, stage IV M1c ) 
<0.0001 0.7500 0.1907 0.7500 
Disease stage (CRF) 
(stage IIIb / stage IIIc, stage IV M1a, 
stage IV M1b, stage IV M1c) 
<0.0001 0.8204 0.0719 0.7331 
Disease stage (CRF) 
(early [stage IIIb / stage IIIc / stage 
IV M1a],         late [stage IV M1b / 
stage IV M1c]) 
<0.0001 0.5000 0.0101 0.3550 
Site of first recurrence (visceral, in 
transit or distant skin, lymph node) 
NE NE 0.0034 0.1571 
Presence of liver metastasis 
(yes, no) 
0.5341 0.5000 0.5868 0.5000 
Prior non-surgical melanoma 
treatment (prior treatment other than 
adjuvant therapy with recurrence > 1 
year from primary diagnosis, prior 
treatment other than adjuvant 
therapy with recurrence <1 year 
from primary diagnosis, no prior 
treatment other than adjuvant 
therapy) 
0.0006 0.7500 0.0059 0.4459 
Line of therapy (first-line, second-
line or greater) 
0.0002 0.5000 0.0012 0.2318 
LDH (≤ ULN, >ULN, unknown) NE NE 0.4038 0.5000 
Visceral disease (CRF) (yes, no) <0.0001 0.5000 0.0377 0.3793 
ECOG (0, 1, unknown) 0.5485 0.5000 0.1472 0.5000 
Sex (male, female) 0.9751 0.5000 0.9883 0.5000 
Age (<50, ≥50) 0.1997 0.5000 0.5088 0.5000 
Geographic region (US, rest of 
world) 
0.0012 0.5000 0.4228 0.4992 
HSV-1 status at baseline (negative, 
positive, unknown) 
0.9258 0.5000 0.7539 0.5000 
BRAF status at baseline (mutation, 
wild-type, unknown) 
0.5993 0.5000 0.3888 0.3872 
a 
Gail and Simon test 
BRAF=v-raf murine sarcoma viral oncogene homolog B; CRF=case report form; DRR=durable response rate, ECOG=Eastern 
Cooperative Oncology Group; GM-CSF=granulocyte macrophage colony-stimulating factor; HSV-1=herpes simplex virus type-
1; IVRS=Interactive Voice Response System; LDH=Lactate dehydrogenase; NE=not estimable; OS=overall survival; T-
VEC=talimogene laherparepvec; ULN=upper limit of normal 
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11.2 Additional information on the modified Korn model and the two-step 
Korn model 
The aim of applying the modified Korn model and the two-step Korn model was to derive an 
adjusted K-M curve for ipilimumab in relation to the K-M curves for T-VEC. The KM curves 
for T-VEC are those for OS and TTF (a proxy for PFS in this trial) in the T-VEC licensed 
population of OPTiM trial.4  The K-M curves for ipilimumab OS and PFS are compared with 
these respective T-VEC K-M curves by applying data from the relevant ipilimumab trials into 
the modified Korn model and the two-step Korn model.  
As outcomes were not specifically reported for patients with metastatic non-visceral disease 
in the ipilimumab trials,19,22 the company had to estimate survival of ipilimumab patients in 
this subgroup. The modified Korn model attempts to do this by adjusting data for the patients 
treated with ipilimumab in the ipilimumab trials19,22 by taking the five prognostic factors into 
consideration, i.e. the baseline data for these prognostic factors are entered into an 
equation. 
As suggested by the name given to the two-step Korn model, there were two steps to this 
approach: 
1. Adjust data for the comparator arms in the ipilimumab trials (i.e. gp100 and DTIC) by 
taking the same five prognostic factors into consideration as in the modified Korn 
model  
2. Adjust the comparator arm data further by applying a hazard ratio (derived from one19 
of the two ipilimumab trials19,22) for ipilimumab vs the comparator in the subgroups of 
patients with metastatic non-visceral disease to estimate survival outcomes for 
ipilimumab in a population broadly equivalent to the T-VEC licensed population; this 
is in order to assume that that there is an interaction between ipilimumab and 
patients with non-visceral metastatic melanoma. 
 
The company specified that studies to be used in the application of the Korn methodology 
had to be Phase III RCTs, which evaluated either T-VEC or ipilimumab (which the company 
states to be the primary comparator), and which reported OS data. From the ten RCTs4,17-
19,21,22,40-43 identified for the NMA, three RCTs4,19,22 were identified which met the company’s 
inclusion criteria (Table 36). 
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Superseded – see 
erratum 
Table 36 List of studies included in the evidence base for the modified Korn and two-step 
Korn models 
Study Treatments Patient population 
OPTiM trial
4
*  T-VEC   
GM-CSF 
Previously treated and untreated patients 
with stage IIIC to stage IV M1c disease 
MDX010-20
19
  Ipilimumab monotherapy   
ipilimumab in combination with gp100  
gp100 
Previously treated patients with stage III or 
stage IV disease 
CA184-024
22
  Ipilimumab + DTIC   
DTIC monotherapy 
Previously untreated with stage III or stage 
IV disease 
Bristol‑Myers Squibb=Bristol Myers Squibb; DTIC=dacarbazine; GM-CSF= granulocyte-macrophage colony-stimulating factor 
*The company cites the primary reference for the OPTiM trial to be a 2014 conference abstract by Kaufman et al
48
   
Source: CS, adapted from Table 4-22 
 
11.2.1 The modified Korn model 
The model originally reported by Korn51 can be used to predict OS for melanoma patients 
using four prognostic characteristics; gender, ECOG PS, presence of visceral metastases, 
and presence of brain metastases. The coefficients for the effects of these variables on 
relative risk were obtained using prediction models based on individual patient data from 42 





The proportion of patients with each specified characteristic are inputted into the equation in 
order to give the log(HR) for each treatment group.  
However, the company decided that a modified Korn model, which would take elevated LDH 
levels into consideration as a prognostic factor, was more appropriate to adjust the data as 
elevated LDH levels has been found to be an important independent prognostic factor in 
metastatic melanoma.52 Bristol‑Myers Squibb developed such a model in their recent 
submission to NICE for the use of ipilimumab in previously untreated metastatic malignant 




Confidential until published 
Talimogene laherparepvec for treating metastatic melanoma [ID508] 
Single Technology Appraisal: Evidence Review Group Report 
Page 115 of 134 
The company used the modified Korn-adjusted model to adjust OS and PFS for ipilimumab, 
so that the adjusted survival data represent survival for ipilimumab treated patients as if they 
had the patient characteristics of the T-VEC-licensed population. Although the Korn 
algorithm was developed for OS data, the company justify their use of the Korn algorithm for 
adjusting PFS data by stating that high correlation is likely to occur between PFS and OS.  
The ERG also notes that where the company present PFS data for T-VEC from OPTiM trial,4  
they are actually presenting TTF, which was a secondary outcome of the OPTiM trial4 (see 
Table 5 for definition). In the company’s response to the ERG clarification letter, the 
company state that due to the mode of action of T-VEC, whereby responses may occur post-
progression, PFS would not be a meaningful endpoint for the OPTiM trial4 study.  
Method 
1. The company calculated log(HR)s for each of the T-VEC and ipilimumab trial arms, by 
inputting each treatment arm’s baseline distribution values into Equation 2. The difference in 
log(HR)s for the T-VEC licensed population for OPTiM trial4 and for the ITT population for 
the ipilimumab trials reflects the size of the difference in outcomes due to differences in 
patient populations.  
2. An adjustment factor was estimated, which would could then be used to adjust the worse 
prognosis of patients in the ipilimumab trials to the baseline characteristics of the T-VEC 
licensed population in the OPTiM trial.4  The lower the adjustment factor, the greater the 
upward adjustment in ipilimumab survival.  




The calculated HRs and adjustment factors are presented in Table 37.  
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Table 37 Model coefficients and adjustment factors for OS and PFS: modified Korn model 
Study Treatment 
(population) 




 T-VEC  
(stage IIIB to stage 
IV M1a) 
Log(HR) = -0.154XGender=0.44 -0.400XECOG=0.74 








stage III to stage IV) 
Log(HR) = -0.154XGender=0.41 -0.400XECOG=0.53 







untreated stage III 
to stage IV)* 
Log(HR) = -0.154XGender=0.39 -0.400XECOG=0.71 
-0.285Xvisceral=0.17 -0.306XBrain=0.99                             
-0.782XLDH=0.63 
0.31 0.60 
*In the Bristol‑Myers Squibb NICE submission for ipilimumab in previously untreated patients, an OS was derived for 
monotherapy ipilimumab at 3mg/kg for the previously untreated study population. The adjustment factor calculated in this 
analysis was applied to the derived OS data 
HR=hazard ratio; NA=not applicable; OS=overall survival; PFS=progression free survival 
Note: Time to treatment failure used as proxy for PFS for patients treated with T-VEC  in OPTiM trial
4
 
Source: CS, adapted from Table 4-24 
 
 
3. Adjusted OS and PFS for ipilimumab were estimated by adjusting Kaplan-Meier curves 




4. A 95% prediction about the adjusted OS estimates was calculated using standard errors 
provided in TA319 to calculate a 95% confidence interval for the HR.  
5. As two curves were generated for ipilimumab, these were pooled using the modified 
Mantel-Haenszel method. 
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11.2.2 Two-step Korn model 
The two step Korn model assumes that there is an interaction between ipilimumab and a 
population broadly equivalent to the T-VEC licensed population. In other words, this method 
assumes that the treatment effect of ipilimumab would be greater in a population broadly 
equivalent to the T-VEC licensed population than in the ITT population of the ipilimumab 
trials.  
As outcomes were not specifically reported for a population broadly equivalent to the T-VEC 
licensed population in the ipilimumab trials, the company had to estimate survival of 
ipilimumab patients in this subgroup. The company’s approach was to adjust data for the 
comparators in the ipilimumab trials (i.e. gp100 and DTIC) using the modified Korn model, 
which would take five prognostic factors into consideration, and then adjust the comparator 
arm data again by applying a HR (from one of the ipilimumab trials) for ipilimumab vs the 
comparator in a population broadly equivalent to the T-VEC licensed population to estimate 
survival outcomes for ipilimumab in a population broadly equivalent to the T-VEC licensed 
population.  
Table 38 Hazard ratios reported in ipilimumab trials  
Trial ITT population 
type 
ITT population 










  Previously treated 
patients 
0.64 
(0.49 to 0.84) 
 
M0, M1a and M1b 
combined 
0.47 









(0.59 to 0.87)  
M0 and M1a* 0.83* 
(not estimated) 
* HR calculated based on the weighted average of HRs for M0 and M1a reported in CA184-024
22
   
CI=confidence interval; HR=hazard ratio; ITT=intention-to-treat 
Source: CS, adapted from Table 4-25  
 
Although the ipilimumab trials did not report data for the exact TVEC licensed population 
(stage IIIB to stage IV M1a, non-visceral metastatic disease subgroup) the company 
obtained HRs for ipilimumab vs the relevant comparator (i.e. gp100 or DTIC) in earlier stage 
disease subgroups as shown in Table 38. The HR obtained from the ipilimumab trial in 
previously treated patients was for the subgroup of M0, M1a and Mb stage patients. For the 
ipilimumab trial in previously untreated patients, the HR was obtained by calculating the 
weighted average of HRs for M0 stage and M1a stage subgroups. The company used the 
more conservative HR (0.47), assuming that ipilimumab would have a larger interaction 
effect in the T-VEC licensed population. The company notes that the HRs for the earlier 
disease stage subgroups are based on very small numbers; less than 20% of patients 
belonged to this subgroup in these trials. The company highlights that these small numbers 
render the estimate of interaction highly uncertain. 
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Method 
1. The company calculated log(HR)s using the Korn equation (as before) for the T-VEC, 
gp100 and DTIC trial arms. The difference in log(HR)s for the T-VEC licensed population 
and ipilimumab trials ITT population reflects the size of the difference in outcomes due to 
differences in patient populations. 
2. The company calculated the adjustment factor, which would could then be used to adjust 
the worse prognosis of patients in the gp100 and DTIC trial arms to the baseline 
characteristics of the T-VEC licensed population in the OPTiM trial.4   




The calculated HRs are presented in Table 39. 
Table 39 Model coefficients and adjustment factors for OS and PFS: two-step Korn model 
Study Treatment 
(population) 




 T-VEC  
(stage IIIB to stage 
IV M1a) 
Log(HR) = -0.154XGender=0.44 -0.400XECOG=0.74 








stage III to stage IV) 
Log(HR) = -0.154XGender=0.41 -0.400XECOG=0.53 







untreated stage III 
to stage IV) 
Log(HR) = -0.154XGender=0.39 -0.400XECOG=0.71 
-0.285Xvisceral=0.17 -0.306XBrain=0.99                   
-0.782XLDH=0.63 
0.31 0.60 
DTIC=dacarbazine; HR=hazard ratio; NA=not applicable; OS=overall survival; PFS=progression free survival 
Note: Time to treatment failure used as proxy for PFS for patients treated with T-VEC  in OPTiM trial
4
 
Source: CS, adapted from Table 4-26 
 
3. The company adjusted survival curves for gp100 and DTIC using the calculated 
adjustment factor, as shown in Equation 4, to reflect survival as if the gp100 and DTIC 
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4. The reported HR (0.47) for ipilimumab vs gp100 stage IIIB to stage IV M1a disease 
subgroup was applied to adjust gp100 outcomes to reflect outcomes for ipilimumab in this 
population. The company assume that the HR for ipilimumab compared to gp100 is fully 
adjusted and applies across different populations.  
5. The company pool the two curves using the modified Mantel-Haenszel method to 
generate the estimated OS of ipilimumab. 
11.2.3 Participant characteristics of studies included in application of both Korn 
models 
The baseline characteristics of the participants in the T-VEC and ipilimumab trials are 
provided in Table 11. There were differences in terms of ECOG PS, LDH levels, and stage 
of metastases across trials, emphasising the importance of performing adjustments which 
take these prognostic factors into consideration. The company highlights that the T-VEC 
licensed population did not have visceral metastases (due to the earlier stage of disease 
within these patients), whereas 11% and 17% of patients in the two ipilimumab arms of the 
MDX010-2019 and CA184-02422 trials had no visceral disease. 
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Table 40 Comparison of patient baseline characteristics from OPTiM trial and ipilimumab 
trials MDX010-20 and CA184-024 
Patient characteristic OPTiM trial
4
  
stage IIIB to 





















Age Median: 63.0 Median: 63.1 Mean: 56.8 Mean: 57.5 
Gender (%)     
Male  56 59 59 61 
Female 44 41 41 39 
ECOG performance status (%)     
0 74 71 53 71 
>=1 26 28 47 29 
Unknown 1 1 0 0 
No visceral disease (%)* 100 55 11 17 
Stage of disease (%)†     
 III 55 30 1 2 
 IV M1a 46 25 10 15 
 IV M1b NA 22 16 26 
 IV M1c NA 23 73 57 
Unknown 0 <1   
Brain metastases (%)     
No 100 99 89 99 
Yes 0 1 11 1 
LDH (%)     
≤ULN 95 90 61 63 
>ULN 1 5 39 37 
Unknown 4 5 0 0 
ECOG=Eastern cooperative oncology group; ITT=intention to treat; LDH=Lactate dehydrogenese; NA=not applicable; 
ULN=upper limit of normal 
*Visceral disease defined as inclusion of stage IIIB to stage IV M1a and exclusion of stage IV M1b to stage IV M1c 
† Values are rounded up to the nearest whole number and so may exceed 100% 
Source: CS, adapted from Table 4-23 
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11.2.4 Risk of bias of included studies in application of both Korn models 
The company’s assessments of risk of bias for the OPTiM trial4 have been reported in 
Section 4.2.5 (Table 8). The company’s assessment of risk of bias for the ipilimumab trials 
presented in Appendix 1.4 of the CS (Table 1-26) is summarised in Table 41. As is evident, 
the ERG disagrees with the company that there is evidence to suggest that the authors 
measured more outcomes than they reported in these trials. From an examination of only the 
published papers for MDX010-2019 and CA184-024,22 the ERG does not believe there is any 
such evidence.   
Table 41 Company’s assessment of risk of bias for ipilimumab trials with ERG comments 
Risk of bias criteria 
Company assessment ERG comment 
MDX010-20 CA184-024 
Was randomisation carried out 
appropriately? 
Yes Yes Agree 
Was the concealment of treatment allocation 
adequate? 
Unclear Yes Agree 
Were the groups similar at the outset of the 
study in terms of prognostic factors?  
Yes Yes Agree 
Were the care providers, participants and 
outcome assessors blind to treatment 
allocation? 
Yes Yes Agree 
Were there any unexpected imbalances in 
dropouts between groups? 
No No Agree 
Is there any evidence to suggest that the 
authors measured more outcomes than they 
reported? 
Yes Yes Disagree 
Did the analysis include an intention-to-treat 
analysis? Was this appropriate and were 
appropriate methods used to account for 
missing data? 
Yes Yes Agree 
Source: CS, appendix 1.4, adapted from Table 1-26 
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11.2.5 Results from the modified Korn model 
The adjusted OS data from the modified Korn model are provided in Figure 10. The affect on 
the ipilimumab data is to increases median OS from 10.8 months to 21.3 months. This 
compares with a median OS for T-VEC of 46.8 months. Mean (calculated by finding the area 
under the curve [AUC]) and median OS results are tabulated in Table 42. 
 
Figure 10 Modified Korn model OS curve for ipilimumab in patients with stage IIIB to stage 
IV M1a disease 
OS=overall survival; ipi=ipilimumab; T-VEC=talimogene laherparepvec 
Source: CS, Figure 4-12 
 
Table 42 Modified Korn model median and mean OS for ipilimumab in patients with stage 
IIIB to stage IV M1a disease 
Median or mean Unadjusted OS Modified Korn 
Median   
   T-VEC 46.8 – 
   Ipilimumab pooled 10.9 21.3 
Mean (AUC)
a
   
   T-VEC 36.9 – 
   Ipilimumab pooled 19.5 29.2 
a
 Calculated using the shorter available time period (55 months). 
AUC=area under the curve; OS=overall survival; T-VEC=talimogene laherparepvec 
Source: Response to the ERG clarification letter, Table A-2 
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The adjusted PFS data using the modified Korn model are provided in Figure 11. The effect 
on the ipilimumab data is to increase median PFS from 2.8 months to 5.3 months. This 
compares with a median TTF (proxy for PFS) for T-VEC of 13.1 months. Mean (AUC) and 
median PFS results are tabulated in Table 43. 
 
Figure 11 Modified Korn adjusted PFS curve for ipilimumab in patients with stage IIIB to 
stage IV M1a disease 
Ipi=ipilimumab; PFS=progression free survival; T-VEC=talimogene laherparepvec 
Source: CS, Figure 4-13 
 
Table 43 Modified Korn model median and mean PFS for ipilimumab in patients with stage 
IIIB to stage IV M1a disease 
Median or mean Unadjusted OS Modified Korn 
Median   
   T-VEC 13.1 – 
   Ipilimumab pooled 2.8 5.3 
Mean (AUC)
a
   
   T-VEC 20.6 – 
   Ipilimumab pooled 8.0 15.2 
a
 Calculated using the shorter available time period (43 months). 
AUC=area under the curve; PFS=progression-free survival; T-VEC=talimogene laherparepvec 
Note: Time to treatment failure used as proxy for PFS for patients treated with T-VEC  in OPTiM trial
4
 
Source: Response to the ERG clarification letter, Table A-3 
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The company also provided the 95% prediction interval about the adjusted ipilimumab curve, 
displaying the upper and lower limits for the adjusted ipilimumab curve, as shown in Figure 
12. An upper limit for the median OS of ipilimumab was not reached, as the OS rate for the 
upper limit curve does not fall below 50%. The upper limit for ipilimumab OS suggests that T-
VEC is initially more effective than ipilimumab, but in later years, the curves cross and that 
patients on ipilimumab may experience better OS rates than those on T-VEC. However, this 
would only be the case if ipilimumab OS is close to the upper limit of the estimated 
ipilimumab survival. The lower limit curve suggests that ipilimumab median survival may be 
as low as 14.6 months, in comparison to 46.8 months with T-VEC. Mean (AUC) and median 
OS results are tabulated in Table 44. 
 
Figure 12 95% prediction interval around the modified Korn adjustment for ipilimumab OS 
Ipi=ipilimumab; ITT=intention-to-treat; OS=overall survival; T-VEC=talimogene laherparepvec 
Source: CS, Figure 4-14 
 
Table 44 Prediction interval (95%) around the modified Korn adjustment for Ipilmumab OS 
Median or mean Unadjusted OS Modified Korn 
Median   
   T-VEC 46.8 – 
   Ipilimumab pooled 
– Not reached (upper limit) 
14.6 (lower limit) 
Mean (AUC)
a
   
   T-VEC 36.9 – 
   Ipilimumab pooled – 
34.6 (upper limit) 
23.8 (lower limit) 
a
 Calculated using the shorter available time period (55 months). 
AUC=area under the curve; OS=overall survival; T-VEC=talimogene laherparepvec 
Source: Response to the ERG clarification letter, Table A-4 
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11.2.6 Results from applying the two-step Korn model 
The adjusted OS data from the two-step Korn model are provided in Figure 13. The Korn 
adjustment to the ipilimumab data generates a survival curve which is comparable to that of 
T-VEC. Median OS was not reached for adjusted ipilimumab, as survival rates do not fall 
below 50%. The curves suggest that T-VEC is initially more effective than ipilimumab, but in 
later years, patients on ipilimumab may experience better OS rates than those on T-VEC. 
Overall, the results suggest that  OS is comparable between T-VEC and ipilimumab even 
after applying the conservative two-step Korn model. Mean (AUC) and median OS results 
are tabulated in Table 45.  
 
Figure 13 Two-step Korn model OS curve for ipilimumab in patients with stage IIIB to stage 
IV M1a disease 
 
Table 45 Two-step Korn model median and mean OS for ipilimumab in patients with stage 
IIIB to stage IV M1a disease 
Median or mean Unadjusted OS Two-step Korn 
Median   
   T-VEC 46.8 – 
   Ipilimumab pooled 10.9 Not reached 
Mean (AUC)
a
   
   T-VEC 33.5 – 
   Ipilimumab pooled 18.0 32.3 
a
 Calculated using the shorter available time period (48 months). 
AUC=area under the curve; OS=overall survival; T-VEC=talimogene laherparepvec 
Source: Response to the ERG clarification letter, Table A-5 
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The company also provided a figure with 95% prediction intervals around the two-step Korn 
model OS estimate for ipilimumab in their response to the ERG clarification questions which 
is provided in Figure 14. The 95% prediction interval was constructed based on the 
estimated standard errors for coefficients in the modified Korn equation. The uncertainty 
associated with the hazard ratio of 0.47 was not incorporated.  
 
Figure 14 Two-step Korn model OS curve for ipilimumab in patients with stage IIIB to stage 
IV M1a disease 
Ipi=ipilimumab; OS=overall survival; T-VEC=talimogene laherparepvec. 
Source: Response to the ERG’s clarification letter, Figure A-2 
 
Table 46 Two-step Korn adjusted median and mean OS for ipilimumab in patients with stage 
IIIB to stage IV M1a disease 
Median or mean Unadjusted OS Two-step Korn 
Median   
   T-VEC 46.8 – 
   Ipilimumab pooled – 
 
Not reached (upper limit) 
27.0 (lower limit) 
Mean (AUC)
a
   
   T-VEC 33.5 – 
   Ipilimumab pooled – 
 
35.8 (upper limit) 
28.1 (lower limit) 
a
 Calculated using the shorter available time period (48 months) 
AUC=area under the curve; OS=overall survival; T-VEC=talimogene laherparepvec 
Source: Response to the ERG’s clarification letter, Table A-7 
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The adjusted PFS data from the two-step Korn model are provided in Figure 15. Median 
PFS was found to be greater for the adjusted ipilimumab data (17.6 months) than for T-VEC 
(13.1 months). Mean (AUC) and median PFS results are tabulated in Table 47. 
 
Figure 15 Two-step Korn model PFS curve for ipilimumab in patients with stage IIIB stage IV 
M1a disease 
Ipi=ipilimumab; ITT=intention-to-treat; PFS=progression free survival; T-VEC=talimogene laherparepvec 
Source: CS, Figure 4-16 
Table 47 Two-step Korn model median and mean PFS for ipilimumab in patients with stage 
IIIB to stage IV M1a disease 
Median or mean Unadjusted OS Two-step Korn 
Median   
   T-VEC 13.1 – 
   Ipilimumab pooled 2.8 17.6 
Mean (AUC)
a
   
   T-VEC 18.2 – 
   Ipilimumab pooled 7.4 18.6 
a
 Calculated using the shorter available time period (35 months). 
AUC, area under the curve; PFS, progression-free survival; T-VEC, talimogene laherparepvec  
Source: Response to the ERG clarification letter, Table A-6 
Ipi=ipilimumab; ITT=intention-to-treat; OS=overall survival; T-VEC=talimogene laherparepvec 
Note: Time to treatment failure used as proxy for PFS for patients treated with T-VEC in OPTiM trial
4
 
Source: Response to the ERG’s clarification letter, Table A-6 
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11.2.7 Additional analysis requested by the ERG: inclusion of additional 
studies into modified Korn model 
It was unclear to the ERG as to why the company did not include data from CheckMate 067 
(a Phase III trial of nivolumab alone or combined with ipilimumab vs ipilimumab alone) and 
KEYNOTE 006 trials (a comparison of two different dosing schedules of pembrolizumab with 
ipilimumab alone) to obtain Korn-adjusted estimates of ipilimumab survival. The ERG 
therefore requested the company clarify this and perform additional analyses, if possible. 
In the company’s response to the ERG’s clarification letter, the company confirmed that 
Checkmate 067 did not report OS data, and so it was not possible to include this study. The 
company also stated that KEYNOTE 006 was not included as OS data were immature data 
from an interim analysis.  
Since OS data were reported in KEYNOTE 006, the company did nevertheless present the 
findings from the modified Korn model by including the data from the trial. These findings are 
presented in Figure 16 to Figure 17. In summary, the company noted that the impact of 
including data from KEYNOTE 006 is small: the mean OS for ipilimumab is increased from 
29.2 to 30.6 months, compared with 36.9 months for T-VEC. The mean PFS for ipilimumab 
is decreased from 15.2 to 14.4 months, compared with 20.6 months for T-VEC. These 
results were in accordance with those from the analysis which excluded KEYNOTE 006 data 
(Table 48 and Table 49). 
The company stated it was not possible to implement the two-step Korn model by 
incorporating data from KEYNOTE 006 as the first step of the two-step Korn model requires 
RCTs with a non-active control group (to represent BSC); the company considers DTIC and 
gp100 to be non-active controls. As KEYNOTE 006 compared ipilimumab to the active 
comparator pembrolizumab, it was not possible to include KEYNOTE 006 data in the two 
step Korn model.  
The ERG notes that the company assessed Checkmate 067 and KEYNOTE 006 to be at low 
risk of bias. Both studies performed ITT analyses, although the concealment of treatment 
allocation was judged to be unclear for both trials. Randomisation was carried out 
appropriately for KEYNOTE 006, however was judged unclear for Checkmate 067. Both 
studies blinded the care providers, participants and outcome assessors to treatment 
allocation. The ERG agrees with the company’s risk of bias assessment for these two 
studies. 
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Figure 16 OS curves including KEYNOTE 006 trial using modified Korn model 
Ipi=ipilimumab; ITT=intent to treat; OS=overall survival 
Source: Response to the ERG’s clarification letter, Figure A-4 
 
































19.5 21.2 29.2 30.6 36.9 
a
 Calculated using the shorter available time period (55 months) 
AUC=area under the curve; OS=overall survival 
Source: Response to ERG’s clarification letter, Table A-8 
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Figure 17 PFS curves including KEYNOTE 006 trial using modified Korn model 
Ipi=ipilimumab; ITT=intent to treat; PFS=progression-free survival 
Source: Response to the ERG’s clarification letter, Figure A-5 
 
































8.0 7.8 15.2 14.4 20.6 
a
 Calculated using the shorter available time period (43 months). 
AUC=area under the curve; PFS=progression-free survival 
Source: Response to ERG’s clarification letter, Table A-9 
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11.3  Additional adverse events reported in the OPTiM trial 
Table 50 summarises specific types of AEs reported in the OPTiM trial.4 The most common 
treatment-related AEs associated with T-VEC are reported to be flu-like symptoms (fatigue, 
chills, pyrexia and “influenza-like illness”). Pruritis, injection-site erythema and injection site 
reaction were the only treatment-related AEs more common amongst patients treated with 
GM-CSF than with T-VEC in the licensed T-VEC population. Most of the AEs were also mild 
to moderate in severity. Grade 3 to 5 treatment-related AEs were uncommon in the T-VEC 
arm; in the licensed T-VEC population only fatigue and injection-site pain occurred at a 
frequency ≥1%. No Grade 3 or 5 treatment-related AEs were reported with GM-CSF. 
Table 50 Summary of treatment-related AEs reported in the T-VEC licensed population of 
the OPTiM trial 
Specific AE type Patients with each type of AE (%) 








or 4  
Chills 49 0 4 0 
Fatigue 45 2 32 0 
Pyrexia 38 0 8 0 
Influenza like illness 34 ≤1 9 0 
Injection-site pain 28 1 7 0 
Nausea 25 ≤1 12 0 
Myalgia 17 ≤1 5 0 
Pain 15 ≤1 9 0 
Vomiting 13 ≤1 5 0 
Headache 13 ≤1 8 0 
Arthralgia 13 ≤1 5 0 
Diarrhoea 10 0 5 0 
Pruritus 7 0 12 0 
Injection-site erythema 6 0 20 0 
Injection site reaction 4 0 12 0 
AE=adverse event; 
Source: CS, adapted from Table 4-34  
 
The most common treatment-emergent SAEs (other than disease progression), as reported 
in the FDA briefing document37 and draft EPAR5 were cellulitis and pyrexia. These SAEs 
were reported in the overall safety population. Equivalent data were not reported in the CS 
for patients in the T-VEC licensed population. 
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The FDA briefing document37 also highlights that six months after the last dose of therapy, 
preceded by three months of unsuccessful medical interventions a wound became resistant 
to medical therapy and required a below-the-knee amputation for a non-healing, infected 
wound in the left foot. Due to several confounders (e.g., treatment of the limb with radiation), 
the relationship of this event to T-VEC is however unclear. As this AE is not reported in the 
CS, it is also unclear whether this patient belonged to the T-VEC licensed population. 
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11.4 Non-RCT evidence 
11.4.1 Trial characteristics of non-RCT evidence 
The company presented evidence from one non-randomised single-arm multicentre Phase II 
study (Study 002/03;39 NCT00289016) of T-VEC. This study was conducted in the UK and 
US and included 50 patients with stage IIIC to stage IV melanoma who were not eligible for 
curative surgery and who had one or more tumours accessible for direct injection.   
Duration of follow-up was up was cited to be 47 weeks (CS, Table 4-28) but the median 
follow-up during the study was reported to be longer than this, 18 months (range, 11 to 36 
months) (CS, page 99). Median duration in the study was reported to be 13.2 months (range 
1 to 39 months) (CS, Table 4-30). 
11.4.2 Patient characteristics of non-RCT evidence 
In total, 23 patients had stage IIIC to stage IV M1a disease. Patient characteristics differed to 
the characteristics of patients enrolled in OPTiM trial:4  the OPTiM trial4 included 
proportionately more males, patients with ECOG PS 0, patients with elevated LDH levels 
and first-line patients than in the non-RCT. This study therefore appears to be less 
representative of patients likely to be considered for T-VEC in clinical practice than patients 
in the OPTiM trial.4 The ERG therefore considers Study 002/0339 to be of limited relevance to 
the company’s decision problem 
11.4.3 Assessment of methodological quality and risk of bias of non-RCT 
evidence 
As noted in Section 4.1.1 (Table 3) the company did not use the most appropriate tool for 
assessing the methodological quality or risk of bias of Study 002/03.39 Given the ERG 
considers that Study 002/0339 is of limited relevance to the company’s decision problem, the 
ERG has not conducted its own assessment. 
11.4.4 Efficacy findings from non-RCT evidence 
No results were reported for patients in the T-VEC licensed population. However, the 
following findings were reported for the overall study population: 
 ORR was 26% (n=13); although not reported in the CS, this was highest for patients 
with stage IIIC disease (40%, n=4) as opposed to only 15% for patients with the most 
severe stage IV M1c  disease 
 Median OS was ≥ 16 months  
 1-year OS rate was 58%; although not reported in the CS, 1-year OS for patients with 
the most severe stage IV M1c  disease was 40% (data not reported for stage III 
disease) 
 2-year OS rate was 52%. 
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11.4.5 Safety findings from non-RCT evidence 
In total, 85% of patients had T-VEC related AEs. Six (12%) patients experienced pain that 
was potentially related to the underlying disease. There were 21 (42%) severe AEs, all of 
which were considered unrelated to T-VEC therapy. Fatigue/malaise (8%) and dyspnoea 
(8%) were the most common Grade 3 AEs; there were no Grade 4 or Grade 5 AEs. 
11.4.6 Comparison of findings from non-RCT to findings from RCT 
The ERG makes the following observations with regard to the findings from Study 002/03:39 
 The ORR of 26% was similar to that observed in the ITT population in the OPTiM 
trial4 (26%) but lower than in the T-VEC licensed population (41%) 
 1-year OS rate (58%) was lower than that estimated from the OPTiM trial4 ITT 
population (74%) and T-VEC licensed population (87%) 
 2-year OS rate (52%) was similar to that estimated from the OPTiM trial4 ITT 
population (50%) but lower than T-VEC licensed population (64%) 
 Rates of specific AEs appeared to be higher in the non-RCT but this included only a 
small sample of patients. 
 
